6-May-11	13-May-11	20-May-11	27-May-11	3-Jun-11	10-Jun-11	17-Jun-11	24-Jun-11	1-Jul-11
3.3%	2.9%	2.7%	2.2%	2.4%	2.0%	1.9%	1.8%	1.9%
12.8%	10.4%	10.7%	9.2%	8.6%	9.1%	8.5%	8.2%	8.4%
1.9%	1.5%	1.5%	1.2%	1.3%	1.1%	1.2%	1.0%	0.9%
4.8%	4.5%	3.3%	3.3%	3.1%	2.9%	3.1%	2.8%	2.5%
1.9%	1.4%	1.3%	1.2%	1.0%	1.0%	1.0%	0.9%	0.7%
4.3%	3.1%	3.0%	2.7%	2.8%	2.2%	2.1%	2.0%	2.0%
1.9%	1.5%	1.3%	1.1%	1.2%	1.0%	0.9%	0.8%	0.9%
2.8%	2.3%	2.1%	1.8%	1.8%	1.7%	1.6%	1.5%	1.4%
96.7%	97.1%	97.3%	97.8%	97.6%	98.0%	98.1%	98.2%	98.1%
87.2%	89.6%	89.3%	90.8%	91.4%	90.9%	91.5%	91.8%	91.6%
98.1%	98.5%	98.5%	98.8%	98.7%	98.9%	98.8%	99.0%	99.1%
95.2%	95.5%	96.7%	96.7%	96.9%	97.1%	96.9%	97.2%	97.5%
98.1%	98.6%	98.7%	98.8%	99.0%	99.0%	99.0%	99.1%	99.3%
95.7%	96.9%	97.0%	97.3%	97.2%	97.8%	97.9%	98.0%	98.0%
98.1%	98.5%	98.7%	98.9%	98.8%	99.0%	99.1%	99.2%	99.1%
97.203%	97.694%	97.879%	98.159%	98.174%	98.348%	98.373%	98.511%	98.585%

8-Jul-11	15-Jul-11	22-Jul-11	29-Jul-11	5-Aug-11	12-Aug-11	19-Aug-11	26-Aug-11	2-Sep-11	9-Sep-11
1.6%	1.7%	1.9%	1.8%	1.6%	1.5%	1.5%	1.3%	1.4%	1.3%
7.3%	6.9%	6.2%	7.0%	6.2%	5.9%	7.0%	6.1%	5.6%	5.5%
1.0%	0.9%	0.8%	0.8%	0.8%	0.7%	0.7%	0.6%	0.6%	0.6%
2.8%	2.3%	1.9%	1.9%	2.1%	2.0%	1.7%	1.5%	1.6%	1.9%
0.9%	0.7%	0.8%	0.7%	0.7%	0.6%	0.5%	0.6%	0.5%	0.5%
1.9%	1.6%	1.9%	1.7%	1.9%	1.7%	1.6%	1.6%	1.4%	1.5%
0.7%	0.6%	0.7%	0.7%	0.7%	0.6%	0.6%	0.7%	0.6%	0.6%
1.4%	1.3%	1.3%	1.3%	1.2%	1.1%	1.1%	1.0%	1.0%	1.0%
98.4%	98.3%	98.1%	98.2%	98.4%	98.5%	98.5%	98.7%	98.6%	98.7%
92.7%	93.1%	93.8%	93.0%	93.8%	94.1%	93.0%	93.9%	94.4%	94.5%
99.0%	99.1%	99.2%	99.2%	99.2%	99.3%	99.3%	99.4%	99.4%	99.4%
97.2%	97.7%	98.1%	98.1%	97.9%	98.0%	98.3%	98.5%	98.4%	98.1%
99.1%	99.3%	99.2%	99.3%	99.3%	99.4%	99.5%	99.4%	99.5%	99.5%
98.1%	98.4%	98.1%	98.3%	98.1%	98.3%	98.4%	98.4%	98.6%	98.5%
99.3%	99.4%	99.3%	99.3%	99.3%	99.4%	99.4%	99.3%	99.4%	99.4%
98.581%	98.711%	98.727%	98.744%	98.790%	98.872%	98.901%	98.968%	99.035%	98.988%

16-Sep-11	23-Sep-11	30-Sep-11	7-Oct-11	14-Oct-11	21-Oct-11	28-Oct-11	4-Nov-11	11-Nov-11
1.1%	1.1%	1.0%	0.7%	0.8%	0.8%	0.9%	0.7%	0.7%
4.6%	4.2%	3.9%	4.5%	3.1%	3.5%	3.4%	3.8%	3.8%
0.5%	0.5%	0.5%	0.5%	0.4%	0.4%	0.4%	0.4%	0.5%
1.7%	1.3%	1.4%	1.5%	1.1%	1.2%	1.1%	1.3%	1.0%
0.5%	0.5%	0.5%	0.3%	0.3%	0.4%	0.4%	0.5%	0.4%
1.2%	1.1%	1.2%	1.0%	0.9%	1.3%	1.0%	0.9%	0.9%
0.5%	0.5%	0.4%	0.5%	0.5%	0.4%	0.4%	0.4%	0.4%
0.9%	0.8%	0.8%	0.7%	0.7%	0.7%	0.7%	0.7%	0.7%
98.9%	98.9%	99.0%	99.3%	99.2%	99.2%	99.1%	99.3%	99.3%
95.4%	95.8%	96.1%	95.5%	96.9%	96.5%	96.6%	96.2%	96.2%
99.5%	99.5%	99.5%	99.5%	99.6%	99.6%	99.6%	99.6%	99.5%
98.3%	98.7%	98.6%	98.5%	98.9%	98.8%	98.9%	98.7%	99.0%
99.5%	99.5%	99.5%	99.7%	99.7%	99.6%	99.6%	99.5%	99.6%
98.8%	98.9%	98.8%	99.0%	99.1%	98.7%	99.0%	99.1%	99.1%
99.5%	99.5%	99.6%	99.5%	99.5%	99.6%	99.6%	99.6%	99.6%
99.134%	99.190%	99.201%	99.288%	99.349%	99.280%	99.324%	99.335%	99.336%

18-Nov-11	25-Nov-11	2-Dec-11	9-Dec-11	16-Dec-11	23-Dec-11	30-Dec-11	6-Jan-12	13-Jan-12
0.8%	0.8%	0.7%	0.8%	0.7%	0.8%	0.6%	0.5%	0.7%
3.3%	3.3%	3.0%	2.2%	3.3%	2.2%	2.7%	2.6%	2.5%
0.4%	0.5%	0.4%	0.5%	0.4%	0.4%	0.4%	0.4%	0.4%
1.1%	1.2%	1.2%	1.1%	1.1%	1.1%	1.0%	1.1%	1.0%
0.3%	0.4%	0.4%	0.4%	0.4%	0.4%	0.3%	0.3%	0.3%
1.0%	0.8%	0.8%	0.8%	0.8%	0.8%	0.9%	0.9%	1.0%
0.4%	0.4%	0.4%	0.4%	0.4%	0.4%	0.2%	0.4%	0.4%
0.7%	0.7%	0.6%	0.6%	0.6%	0.6%	0.5%	0.6%	0.6%
99.2%	99.2%	99.3%	99.2%	99.3%	99.2%	99.4%	99.5%	99.3%
96.7%	96.7%	97.0%	97.8%	96.7%	97.8%	97.3%	97.4%	97.5%
99.6%	99.5%	99.6%	99.5%	99.6%	99.6%	99.6%	99.6%	99.6%
98.9%	98.8%	98.8%	98.9%	98.9%	98.9%	99.0%	98.9%	99.0%
99.7%	99.6%	99.6%	99.6%	99.6%	99.6%	99.7%	99.7%	99.7%
99.0%	99.2%	99.2%	99.2%	99.2%	99.2%	99.1%	99.1%	99.0%
99.6%	99.6%	99.6%	99.6%	99.6%	99.6%	99.8%	99.6%	99.6%
99.342%	99.332%	99.384%	99.386%	99.386%	99.373%	99.458%	99.419%	99.419%

20-Jan-12	27-Jan-12	3-Feb-12	10-Feb-12	17-Feb-12	24-Feb-12	2-Mar-12	9-Mar-12	16-Mar-12
0.7%	0.6%	0.7%	0.6%	0.4%	0.5%	0.5%	0.4%	0.3%
2.4%	2.8%	3.0%	2.4%	2.6%	2.9%	2.0%	2.6%	2.0%
0.4%	0.4%	0.5%	0.3%	0.3%	0.3%	0.2%	0.2%	0.3%
1.2%	1.1%	1.0%	0.9%	0.8%	0.8%	0.6%	0.9%	0.8%
0.3%	0.4%	0.3%	0.3%	0.3%	0.3%	0.2%	0.3%	0.2%
0.9%	0.9%	0.8%	1.0%	0.6%	0.7%	0.4%	0.6%	0.6%
0.3%	0.3%	0.3%	0.4%	0.3%	0.2%	0.2%	0.3%	0.3%
0.6%	0.6%	0.6%	0.5%	0.5%	0.4%	0.4%	0.4%	0.4%
99.3%	99.4%	99.3%	99.4%	99.6%	99.5%	99.5%	99.6%	99.7%
97.6%	97.2%	97.0%	97.6%	97.4%	97.1%	98.0%	97.4%	98.0%
99.6%	99.6%	99.5%	99.7%	99.7%	99.7%	99.8%	99.8%	99.7%
98.8%	98.9%	99.0%	99.1%	99.2%	99.2%	99.4%	99.1%	99.2%
99.7%	99.6%	99.7%	99.7%	99.7%	99.7%	99.8%	99.7%	99.8%
99.1%	99.1%	99.2%	99.0%	99.4%	99.3%	99.6%	99.4%	99.4%
99.7%	99.7%	99.7%	99.6%	99.7%	99.8%	99.8%	99.7%	99.7%
99.410%	99.413%	99.416%	99.457%	99.546%	99.552%	99.627%	99.585%	99.600%

23-Mar-12	30-Mar-12	6-Apr-12	13-Apr-12	20-Apr-12	27-Apr-12	4-May-12	11-May-12	18-May-12
0.5%	0.3%	0.3%	0.3%	0.4%	0.4%	0.3%	0.3%	0.3%
1.9%	1.6%	2.0%	1.4%	1.7%	1.4%	1.6%	1.5%	2.1%
0.2%	0.2%	0.2%	0.3%	0.2%	0.2%	0.1%	0.2%	0.2%
0.6%	0.7%	0.7%	0.6%	0.5%	0.5%	0.6%	0.5%	0.5%
0.2%	0.2%	0.2%	0.2%	0.1%	0.2%	0.2%	0.2%	0.2%
0.6%	0.5%	0.5%	0.5%	0.6%	0.4%	0.6%	0.4%	0.4%
0.2%	0.2%	0.3%	0.2%	0.2%	0.1%	0.2%	0.2%	0.2%
0.4%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%	0.3%
99.5%	99.7%	99.7%	99.7%	99.6%	99.6%	99.7%	99.7%	99.7%
98.1%	98.4%	98.0%	98.6%	98.3%	98.6%	98.4%	98.5%	97.9%
99.8%	99.8%	99.8%	99.7%	99.8%	99.8%	99.9%	99.8%	99.8%
99.4%	99.3%	99.3%	99.4%	99.5%	99.5%	99.4%	99.5%	99.5%
99.8%	99.8%	99.8%	99.8%	99.9%	99.8%	99.8%	99.8%	99.8%
99.4%	99.5%	99.5%	99.5%	99.4%	99.6%	99.4%	99.6%	99.6%
99.8%	99.8%	99.7%	99.8%	99.8%	99.9%	99.8%	99.8%	99.8%
99.637%	99.661%	99.659%	99.656%	99.670%	99.713%	99.686%	99.688%	99.690%

25-May-12	1-Jun-12	8-Jun-12	15-Jun-12	22-Jun-12	29-Jun-12	6-Jul-12	13-Jul-12	20-Jul-12	27-Jul-12
0.2%	0.3%	0.3%	0.3%	0.3%	0.2%	0.2%	0.3%	0.3%	0.2%
1.3%	1.9%	1.9%	1.7%	1.4%	1.0%	1.2%	1.3%	1.5%	0.9%
0.2%	0.2%	0.2%	0.1%	0.1%	0.2%	0.1%	0.1%	0.1%	0.1%
0.8%	0.6%	0.4%	0.4%	0.6%	0.4%	0.4%	0.3%	0.4%	0.5%
0.2%	0.2%	0.2%	0.2%	0.2%	0.2%	0.1%	0.2%	0.1%	0.1%
0.4%	0.5%	0.4%	0.4%	0.5%	0.4%	0.4%	0.3%	0.5%	0.3%
0.2%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
0.3%	0.3%	0.3%	0.3%	0.3%	0.2%	0.2%	0.2%	0.2%	0.2%
99.8%	99.7%	99.7%	99.7%	99.7%	99.8%	99.8%	99.7%	99.7%	99.8%
98.7%	98.1%	98.1%	98.3%	98.6%	99.0%	98.8%	98.7%	98.5%	99.1%
99.8%	99.8%	99.8%	99.9%	99.9%	99.8%	99.9%	99.9%	99.9%	99.9%
99.2%	99.4%	99.6%	99.6%	99.4%	99.6%	99.6%	99.7%	99.6%	99.5%
99.8%	99.8%	99.8%	99.8%	99.8%	99.8%	99.9%	99.8%	99.9%	99.9%
99.6%	99.5%	99.6%	99.6%	99.5%	99.6%	99.6%	99.7%	99.5%	99.7%
99.8%	99.8%	99.8%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%
99.701%	99.691%	99.712%	99.726%	99.730%	99.764%	99.795%	99.766%	99.752%	99.789%

3-Aug-12	10-Aug-12	17-Aug-12	24-Aug-12	31-Aug-12	7-Sep-12	14-Sep-12	21-Sep-12	28-Sep-12
0.3%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
0.7%	0.7%	0.8%	0.5%	0.7%	0.7%	0.8%	0.5%	1.1%
0.1%	0.1%	0.1%	0.1%	0.0%	0.1%	0.0%	0.0%	0.1%
0.2%	0.4%	0.4%	0.3%	0.4%	0.3%	0.3%	0.4%	0.3%
0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%
0.4%	0.3%	0.3%	0.1%	0.0%	0.1%	0.2%	0.1%	0.1%
0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%
0.2%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
99.7%	99.8%	99.8%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%
99.3%	99.3%	99.2%	99.5%	99.3%	99.3%	99.2%	99.5%	98.9%
99.9%	99.9%	99.9%	99.9%	100.0%	99.9%	100.0%	100.0%	99.9%
99.8%	99.6%	99.6%	99.7%	99.6%	99.7%	99.7%	99.6%	99.7%
99.8%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%	100.0%
99.6%	99.7%	99.7%	99.9%	100.0%	99.9%	99.8%	99.9%	99.9%
99.9%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%	99.9%	100.0%
99.785%	99.813%	99.830%	99.897%	99.876%	99.864%	99.876%	99.901%	99.880%

5-Oct-12	12-Oct-12	19-Oct-12	26-Oct-12	2-Nov-12	9-Nov-12	16-Nov-12	23-Nov-12	30-Nov-12
0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	0.1%
0.4%	0.7%	0.5%	0.8%	0.5%	0.4%	0.5%	0.7%	0.3%
0.1%	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%
0.2%	0.4%	0.4%	0.3%	0.2%	0.3%	0.3%	0.3%	0.3%
0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
0.1%	0.2%	0.2%	0.1%	0.1%	0.1%	0.1%	0.0%	0.1%
0.1%	0.1%	0.0%	0.0%	0.0%	0.1%	0.1%	0.0%	0.0%
0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
100.0%	100.0%	100.0%	100.0%	100.0%	99.9%	99.9%	100.0%	99.9%
99.6%	99.3%	99.5%	99.2%	99.5%	99.6%	99.5%	99.3%	99.7%
99.9%	100.0%	100.0%	99.9%	100.0%	100.0%	100.0%	100.0%	100.0%
99.8%	99.6%	99.6%	99.7%	99.8%	99.7%	99.7%	99.7%	99.7%
99.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
99.9%	99.8%	99.8%	99.9%	99.9%	99.9%	99.9%	100.0%	99.9%
99.9%	99.9%	100.0%	100.0%	100.0%	99.9%	99.9%	100.0%	100.0%
99.902%	99.896%	99.907%	99.908%	99.928%	99.905%	99.906%	99.917%	99.930%

7-Dec-12	14-Dec-12	21-Dec-12	28-Dec-12	4-Jan-13	11-Jan-13	18-Jan-13	25-Jan-13	1-Feb-13	8-Feb-13
0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
0.5%	0.5%	0.3%	0.5%	0.4%	0.6%	0.4%	0.5%	0.2%	0.4%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
0.2%	0.2%	0.3%	0.4%	0.4%	0.3%	0.3%	0.3%	0.4%	0.3%
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
0.0%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%
0.1%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%	0.1%	0.0%	0.0%
0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
100.0%	99.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
99.5%	99.5%	99.7%	99.5%	99.6%	99.4%	99.6%	99.5%	99.8%	99.6%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
99.8%	99.8%	99.7%	99.6%	99.6%	99.7%	99.7%	99.7%	99.6%	99.7%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
100.0%	99.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%
99.9%	100.0%	100.0%	100.0%	99.9%	100.0%	100.0%	99.9%	100.0%	100.0%
99.927%	99.919%	99.934%	99.921%	99.900%	99.928%	99.929%	99.921%	99.936%	99.932%

15-Feb-13	22-Feb-13	1-Mar-13	8-Mar-13	15-Mar-13	22-Mar-13	29-Mar-13	5-Apr-13	12-Apr-13
0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
0.3%	0.4%	0.1%	0.2%	0.2%	0.2%	0.3%	0.2%	
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
0.2%	0.3%	0.3%	0.0%	0.1%	0.0%	0.0%	0.0%	
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	
0.1%	0.1%	0.0%	0.1%	0.0%	0.1%	0.0%	0.1%	
0.0%	0.0%	0.1%	0.0%	0.0%	0.0%	0.1%	0.0%	
0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%	
99.9%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	
99.7%	99.6%	99.9%	99.8%	99.8%	99.8%	99.7%	99.8%	
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	
99.8%	99.7%	99.7%	100.0%	99.9%	100.0%	100.0%	100.0%	
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	
99.9%	99.9%	100.0%	99.9%	100.0%	99.9%	100.0%	99.9%	
100.0%	100.0%	99.9%	100.0%	100.0%	100.0%	99.9%	100.0%	
99.941%	99.938%	99.947%	99.970%	99.973%	99.965%	99.965%	99.969%	


Weekly OxyContin Total Prescriptions
Retail Pharmacies, Mail order, and LTC
All Numbers are Absolute
160,000
140,000
120,000
100,000
80,000
60,000
40,000
20,000
-
3-Dec-10
17-Dec-10
31-Dec-10
14-Jan-11
28-Jan-11
11-Feb-11
25-Feb-11
11-Mar-11
25-Mar-11
8-Apr-11
22-Apr-11
6-May-11
20-May-11
3-Jun-11
17-Jun-11
1-Jul-11
15-Jul-11
29-Jul-11
12-Aug-11
26-Aug-11
9-Sep-11
23-Sep-11
7-Oct-11
21-Oct-11
4-Nov-11
18-Nov-11
2-Dec-11
16-Dec-11
30-Dec-11
13-Jan-12
27-Jan-12
10-Feb-12
24-Feb-12
9-Mar-12
23-Mar-12
6-Apr-12
20-Apr-12
4-May-12
18-May-12
1-Jun-12
15-Jun-12
29-Jun-12
13-Jul-12
27-Jul-12
10-Aug-12
24-Aug-12
7-Sep-12
21-Sep-12
5-Oct-12
19-Oct-12
2-Nov-12
16-Nov-12
30-Nov-12
14-Dec-12
28-Dec-12
11-Jan-13
25-Jan-13
8-Feb-13
22-Feb-13
8-Mar-13
22-Mar-13
5-Apr-13
19-Apr-13
3-May-13
17-May-13
OxyContin


OxyContin Total Prescriptions By Strength
Retail Pharmacies, Mail Order, and LTC
All Numbers Absolute
40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000
-
7-Jan-11
21-Jan-11
4-Feb-11
18-Feb-11
4-Mar-11
18-Mar-11
1-Apr-11
15-Apr-11
29-Apr-11
13-May-11
27-May-11
10-Jun-11
24-Jun-11
8-Jul-11
22-Jul-11
5-Aug-11
19-Aug-11
2-Sep-11
16-Sep-11
30-Sep-11
14-Oct-11
28-Oct-11
11-Nov-11
25-Nov-11
9-Dec-11
23-Dec-11
6-Jan-12
20-Jan-12
3-Feb-12
17-Feb-12
2-Mar-12
16-Mar-12
30-Mar-12
13-Apr-12
27-Apr-12
11-May-12
25-May-12
8-Jun-12
22-Jun-12
6-Jul-12
20-Jul-12
3-Aug-12
17-Aug-12
31-Aug-12
14-Sep-12
28-Sep-12
12-Oct-12
26-Oct-12
9-Nov-12
23-Nov-12
7-Dec-12
21-Dec-12
4-Jan-13
18-Jan-13
1-Feb-13
15-Feb-13
1-Mar-13
15-Mar-13
29-Mar-13
12-Apr-13
26-Apr-13
10-May-13
24-May-13
10MG
15MG
20MG
30MG
40MG
60MG
80MG

Embeda Total Prescriptions
IMS NPA
numbers are absolute. Retail pharmacy only.

		20-Jan-12	27-Jan-12	3-Feb-12	10-Feb-12	17-Feb-12	24-Feb-12
Embeda	Total						
	20-0.8mg						
	30-1.8mg						
	60-2.4mg						

2-Mar-12	9-Mar-12	16-Mar-12	23-Mar-12	30-Mar-12	6-Apr-12	13-Apr-12	20-Apr-12	27-Apr-12
1				1				
1								
				1				

4-May-12	11-May-12	18-May-12	25-May-12	1-Jun-12	8-Jun-12	15-Jun-12	22-Jun-12	29-Jun-12
					1			
					1			

6-Jul-12 13-Jul-12 20-Jul-12 27-Jul-12 3-Aug-12 10-Aug-12 17-Aug-12 24-Aug-12 31-Aug-12

7-Sep-12 14-Sep-12 21-Sep-12 28-Sep-12 5-Oct-12 12-Oct-12 19-Oct-12 26-Oct-12 2-Nov-12

9-Nov-12	16-Nov-12	23-Nov-12	30-Nov-12	7-Dec-12	14-Dec-12	21-Dec-12	28-Dec-12	4-Jan-13
1		1						
		1						
1								

11-Jan-13 18-Jan-13 25-Jan-13 1-Feb-13 8-Feb-13 15-Feb-13


Comparison of Weekly OxyContin TRx's
2009-2013
Retail Pharmacies, Mail Order and LTC
160,000
140,000
120,000
100,000
80,000
60,000
40,000
20,000
-
Week 1
Week 3
Week 5
Week 7
Week 9
Week 11
Week 13
Week 15
Week 17
Week 19
Week 21
Week 23
Week 25
Week 27
Week 29
Week 31
Week 33
Week 35
Week 37
Week 39
Week 41
Week 43
Week 45
Week 47
Week 49
Week 51
2009
2010
2011
2012
2013

OxyContin Weekly TRx - Original Formulation and Reformulation							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 1	**Week 2**	**Week 3**	**Week 4**	**Week 5**	**Week 6**
Strength	**Week Ending**	**2-Jan-09**	**9-Jan-09**	**16-Jan-09**	**23-Jan-09**	**30-Jan-09**	**6-Feb-09**
10MG		14,904	18,498	18,242	16,859	16,605	18,379
15MG		1,087	1,490	1,336	1,171	1,128	1,300
20MG		28,407	34,398	32,742	27,630	25,232	28,854
30MG		4,284	5,468	5,380	4,921	4,603	5,327
40MG		25,393	30,567	30,047	27,015	24,862	28,662
60MG		4,336	5,273	5,095	4,783	4,541	5,349
80MG		21,508	26,618	25,483	21,655	20,320	24,194
Total	**2009**	99,919	122,312	118,325	104,034	97,291	112,065
		8-Jan-10	**15-Jan-10**	**22-Jan-10**	**29-Jan-10**	**5-Feb-10**	**12-Feb-10**
10MG		15,812	19,748	18,906	20,664	19,175	20,070
15MG		1,643	2,072	2,007	2,260	2,293	2,542
20MG		26,804	32,159	29,875	30,068	28,571	31,249
30MG		6,994	8,689	8,190	8,997	8,882	9,772
40MG		27,435	33,418	30,776	30,018	28,291	31,702
60MG		7,248	8,574	8,214	8,326	8,203	9,104
80MG		22,376	28,047	26,191	25,286	24,406	27,199
Total	**2010**	108,312	132,707	124,159	125,619	119,821	131,638
		7-Jan-11	**14-Jan-11**	**21-Jan-11**	**28-Jan-11**	**4-Feb-11**	**11-Feb-11**
10MG		27,567	27,181	27,431	26,218	27,359	28,076
15MG		3,125	2,986	2,963	2,913	3,054	3,117
20MG		35,502	34,019	33,496	32,085	33,707	34,570
30MG		11,149	10,736	10,255	9,720	10,743	10,563
40MG		27,583	25,880	24,853	23,601	26,130	26,037
60MG		9,745	9,326	8,988	8,333	9,199	9,239

OxyContin Weekly TRx - Original Formulation and Reformulation							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 1	**Week 2**	**Week 3**	**Week 4**	**Week 5**	**Week 6**
Strength	**Week Ending**	**2-Jan-09**	**9-Jan-09**	**16-Jan-09**	**23-Jan-09**	**30-Jan-09**	**6-Feb-09**
80MG		20,305	20,250	19,480	19,071	21,226	21,141
Total	**2011**	134,976	130,378	127,466	121,941	131,418	132,743
		6-Jan-12	**13-Jan-12**	**20-Jan-12**	**27-Jan-12**	**3-Feb-12**	**10-Feb-12**
10MG		23,413	25,422	24,657	24,317	25,318	25,339
15MG		3,181	3,323	3,275	3,165	3,227	3,349
20MG		30,028	31,200	30,546	29,447	31,100	30,832
30MG		10,274	10,686	10,528	10,002	10,602	10,646
40MG		23,382	24,667	23,720	22,374	24,012	24,017
60MG		8,527	8,821	8,660	8,192	8,907	8,745
80MG		16,876	17,560	16,865	15,856	17,372	17,425
Total	**2012**	115,681	121,679	118,251	113,353	120,538	120,353
		4-Jan-13	**11-Jan-13**	**18-Jan-13**	**25-Jan-13**	**1-Feb-13**	**8-Feb-13**
10MG		23,087	25,231	25,634	23,858	24,986	26,132
15MG		3,595	4,111	3,971	3,681	3,765	4,144
20MG		28,300	30,360	29,828	27,539	28,981	30,406
30MG		11,327	11,931	12,055	10,790	11,542	12,411
40MG		21,885	23,056	22,211	20,069	21,557	22,693
60MG		8,923	9,488	9,336	8,328	9,012	9,660
80MG		15,407	16,099	15,953	13,956	15,229	16,194
Total	**2013**	112,524	120,276	118,988	108,221	115,072	121,640
	1 week % Change						

OxyContin Weekly TRx - Original Formulation and Reformulation							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 1	**Week 2**	**Week 3**	**Week 4**	**Week 5**	**Week 6**
Strength	**Week Ending**	**2-Jan-09**	**9-Jan-09**	**16-Jan-09**	**23-Jan-09**	**30-Jan-09**	**6-Feb-09**
	2009		22.4%	-3.3%	-12.1%	-6.5%	15.2%
	2010		22.5%	-6.4%	1.2%	-4.6%	9.9%
	2011		-3.4%	-2.2%	-4.3%	7.8%	1.0%
	2012		5.2%	-2.8%	-4.1%	6.3%	-0.2%
	2013		6.9%	-1.1%	-9.0%	6.3%	5.7%

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 7	**Week 8**	**Week 9**	**Week 10**	**Week 11**	**Week 12**
Strength	**Week Ending**	**13-Feb-09**	**20-Feb-09**	**27-Feb-09**	**6-Mar-09**	**13-Mar-09**	**20-Mar-09**
10MG		17,330	16,337	16,651	18,382	17,352	16,603
15MG		1,363	1,309	1,274	1,510	1,458	1,345
20MG		28,074	25,718	25,443	29,400	26,232	24,425
30MG		5,470	5,143	5,251	6,063	5,884	5,381
40MG		27,221	24,850	25,527	30,276	27,307	24,659
60MG		5,271	4,996	5,200	6,169	5,591	5,413
80MG		23,351	20,896	21,620	25,823	22,901	20,977
Total	**2009**	108,080	99,249	100,966	117,623	106,725	98,803
		19-Feb-10	**26-Feb-10**	**5-Mar-10**	**12-Mar-10**	**19-Mar-10**	**26-Mar-10**
10MG		18,919	18,743	18,572	20,656	18,741	19,125
15MG		2,422	2,383	2,519	2,658	2,479	2,598
20MG		29,031	28,644	28,009	31,775	28,088	27,174
30MG		9,348	9,392	9,229	10,367	9,849	9,445
40MG		29,560	28,920	28,177	32,938	29,370	28,114
60MG		8,892	8,696	8,694	9,974	9,288	8,899
80MG		25,860	25,378	25,316	29,168	26,063	25,526
Total	**2010**	124,032	122,156	120,516	137,536	123,878	120,881
		18-Feb-11	**25-Feb-11**	**4-Mar-11**	**11-Mar-11**	**18-Mar-11**	**25-Mar-11**
10MG		27,450	25,995	28,804	27,569	26,286	26,368
15MG		3,108	3,010	3,314	3,116	2,844	2,889
20MG		33,726	32,427	37,890	34,704	33,241	32,998
30MG		10,562	9,898	11,629	10,588	10,115	9,991
40MG		25,722	25,009	30,008	26,733	26,005	25,511
60MG		9,083	8,484	10,061	9,130	8,755	8,496

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 7	**Week 8**	**Week 9**	**Week 10**	**Week 11**	**Week 12**
Strength	**Week Ending**	**13-Feb-09**	**20-Feb-09**	**27-Feb-09**	**6-Mar-09**	**13-Mar-09**	**20-Mar-09**
80MG		19,946	19,207	23,133	20,532	19,175	18,743
Total	**2011**	129,597	124,030	144,839	132,372	126,421	124,996
		17-Feb-12	**24-Feb-12**	**2-Mar-12**	**9-Mar-12**	**16-Mar-12**	**23-Mar-12**
10MG		24,539	24,320	26,245	25,819	25,038	24,587
15MG		3,308	3,182	3,453	3,404	3,416	3,222
20MG		30,339	29,474	32,682	31,516	30,350	29,821
30MG		10,254	10,272	11,277	10,982	10,724	10,438
40MG		23,621	22,660	25,519	24,714	23,867	22,869
60MG		8,771	8,308	9,681	9,222	8,802	8,554
80MG		16,881	16,304	18,557	18,062	16,832	16,203
Total	**2012**	117,713	114,520	127,414	123,719	119,029	115,694
		15-Feb-13	**22-Feb-13**	**1-Mar-13**	**8-Mar-13**	**15-Mar-13**	**22-Mar-13**
10MG		25,813	24,646	25,914	26,268	25,511	24,829
15MG		3,910	3,804	4,030	4,198	3,983	3,849
20MG		29,720	27,875	30,374	31,167	29,367	28,215
30MG		11,513	11,117	12,375	12,450	11,612	11,419
40MG		22,037	20,090	22,469	23,244	21,400	20,358
60MG		9,086	8,397	9,655	9,514	9,026	8,713
80MG		15,585	13,943	15,840	16,361	15,207	14,136
Total	**2013**	117,664	109,872	120,657	123,202	116,106	111,519
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 7	**Week 8**	**Week 9**	**Week 10**	**Week 11**	**Week 12**
Strength	**Week Ending**	**13-Feb-09**	**20-Feb-09**	**27-Feb-09**	**6-Mar-09**	**13-Mar-09**	**20-Mar-09**
	2009	-3.6%	-8.2%	1.7%	16.5%	-9.3%	-7.4%
	2010	-5.8%	-1.5%	-1.3%	14.1%	-9.9%	-2.4%
	2011	-2.4%	-4.3%	16.8%	-8.6%	-4.5%	-1.1%
	2012	-2.2%	-2.7%	11.3%	-2.9%	-3.8%	-2.8%
	2013	-3.3%					

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 13	**Week 14**	**Week 15**	**Week 16**	**Week 17**	**Week 18**
Strength	**Week Ending**	**27-Mar-09**	**3-Apr-09**	**10-Apr-09**	**17-Apr-09**	**24-Apr-09**	**1-May-09**
10MG		16,754	17,752	17,975	17,966	18,416	19,519
15MG		1,322	1,411	1,521	1,366	1,358	1,552
20MG		23,351	25,206	24,024	23,246	22,976	24,072
30MG		5,358	5,860	5,860	5,530	5,771	6,125
40MG		24,560	26,463	25,609	24,575	24,212	25,574
60MG		5,401	5,987	5,839	5,641	5,963	6,128
80MG		21,019	22,986	22,665	21,276	21,245	22,540
Total	**2009**	97,765	105,665	103,493	99,600	99,941	105,510
		2-Apr-10	**9-Apr-10**	**16-Apr-10**	**23-Apr-10**	**30-Apr-10**	**7-May-10**
10MG		19,207	19,150	19,508	19,135	18,758	19,222
15MG		2,431	2,580	2,553	2,548	2,525	2,575
20MG		26,432	27,672	27,998	27,269	27,327	27,781
30MG		9,458	9,828	9,880	9,776	9,964	10,001
40MG		27,324	29,084	29,232	28,416	27,871	28,608
60MG		8,918	9,335	9,501	9,191	9,445	9,225
80MG		24,889	26,447	26,590	26,315	26,256	26,575
Total	**2010**	118,659	124,096	125,262	122,650	122,146	123,987
		1-Apr-11	**8-Apr-11**	**15-Apr-11**	**22-Apr-11**	**29-Apr-11**	**6-May-11**
10MG		25,999	26,920	26,486	25,724	26,052	26,976
15MG		2,975	3,076	3,052	2,964	3,042	3,154
20MG		33,707	34,637	33,185	32,785	33,260	35,802
30MG		10,220	10,590	10,316	9,934	10,006	10,915
40MG		26,360	26,853	25,596	25,226	25,665	27,613
60MG		8,772	9,215	8,999	8,445	8,758	9,670

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 13	**Week 14**	**Week 15**	**Week 16**	**Week 17**	**Week 18**
Strength	**Week Ending**	**27-Mar-09**	**3-Apr-09**	**10-Apr-09**	**17-Apr-09**	**24-Apr-09**	**1-May-09**
80MG		19,914	20,125	18,473	18,028	19,072	20,628
Total	**2011**	127,947	131,416	126,107	123,106	125,855	134,758
		30-Mar-12	**6-Apr-12**	**13-Apr-12**	**20-Apr-12**	**27-Apr-12**	**4-May-12**
10MG		24,510	25,298	24,741	24,631	25,096	25,823
15MG		3,293	3,456	3,396	3,479	3,337	3,655
20MG		30,389	31,676	30,161	30,298	30,562	32,072
30MG		10,692	11,134	10,693	10,968	11,218	11,808
40MG		23,292	24,654	23,285	23,106	23,307	25,335
60MG		8,955	9,248	8,737	8,813	9,005	9,673
80MG		16,562	17,712	16,370	16,368	16,598	17,978
Total	**2012**	117,693	123,178	117,383	117,663	119,123	126,344
		29-Mar-13	**5-Apr-13**	**12-Apr-13**	**19-Apr-13**	**26-Apr-13**	**3-May-13**
10MG		24,147	24,786	24,574	24,247	24,428	25,505
15MG		3,806	4,016	4,071	3,886	3,884	4,204
20MG		27,841	29,443	28,561	27,759	28,034	29,677
30MG		11,413	11,917	11,576	11,535	11,556	12,166
40MG		20,331	22,027	20,935	20,003	20,692	22,404
60MG		8,840	9,295	8,954	8,650	8,791	9,372
80MG		14,184	15,501	14,612	13,740	14,138	15,747
Total	**2013**	110,562	116,985	113,283	109,820	111,523	119,075
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 13	**Week 14**	**Week 15**	**Week 16**	**Week 17**	**Week 18**
Strength	**Week Ending**	**27-Mar-09**	**3-Apr-09**	**10-Apr-09**	**17-Apr-09**	**24-Apr-09**	**1-May-09**
	2009	-1.1%	8.1%	-2.1%	-3.8%	0.3%	5.6%
	2010	-1.8%	4.6%	0.9%	-2.1%	-0.4%	1.5%
	2011	2.4%	2.7%	-4.0%	-2.4%	2.2%	7.1%
	2012	1.7%	4.7%	-4.7%	0.2%	1.2%	6.1%
	2013						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 19	**Week 20**	**Week 21**	**Week 22**	**Week 23**	**Week 24**
Strength	**Week Ending**	**8-May-09**	**15-May-09**	**22-May-09**	**29-May-09**	**5-Jun-09**	**12-Jun-09**
10MG		19,962	19,726	20,541	18,667	21,782	20,884
15MG		1,548	1,543	1,540	1,415	1,562	1,569
20MG		24,458	23,655	24,008	22,033	25,528	24,151
30MG		6,267	6,058	6,275	5,740	6,450	6,269
40MG		26,151	24,108	25,010	23,739	27,988	26,033
60MG		6,226	6,030	6,087	5,784	6,626	6,009
80MG		22,607	21,376	21,969	20,676	23,608	21,625
Total	**2009**	107,219	102,496	105,430	98,054	113,544	106,540
		14-May-10	**21-May-10**	**28-May-10**	**4-Jun-10**	**11-Jun-10**	**18-Jun-10**
10MG		20,056	19,914	20,002	20,648	19,283	20,900
15MG		2,607	2,562	2,601	2,775	2,535	2,689
20MG		29,096	27,159	27,586	28,796	27,208	28,398
30MG		10,490	9,983	10,218	10,817	9,730	10,274
40MG		32,256	28,866	28,629	30,133	29,493	29,131
60MG		10,159	9,802	9,480	9,785	9,453	9,650
80MG		29,082	26,528	26,718	27,826	26,558	27,488
Total	**2010**	133,746	124,814	125,234	130,780	124,260	128,530
		13-May-11	**20-May-11**	**27-May-11**	**3-Jun-11**	**10-Jun-11**	**17-Jun-11**
10MG		25,903	25,804	26,764	24,175	26,090	25,752
15MG		3,028	3,006	3,061	2,842	3,074	3,050
20MG		33,201	32,613	33,990	31,701	33,117	32,826
30MG		10,182	10,053	10,407	9,958	10,301	10,233
40MG		25,313	25,048	26,070	24,967	25,279	24,760
60MG		8,642	8,564	9,122	8,602	8,880	8,460

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 19	**Week 20**	**Week 21**	**Week 22**	**Week 23**	**Week 24**
Strength	**Week Ending**	**8-May-09**	**15-May-09**	**22-May-09**	**29-May-09**	**5-Jun-09**	**12-Jun-09**
80MG		18,461	18,078	19,286	18,450	18,580	18,059
Total	**2011**	124,730	123,166	128,700	120,695	125,321	123,140
		11-May-12	**18-May-12**	**25-May-12**	**1-Jun-12**	**8-Jun-12**	**15-Jun-12**
10MG		24,694	24,597	25,260	22,598	25,358	24,612
15MG		3,424	3,510	3,553	3,295	3,662	3,523
20MG		30,482	30,679	31,327	28,725	31,199	30,356
30MG		10,904	11,136	11,668	10,623	11,382	11,231
40MG		23,186	23,106	23,735	22,444	24,047	22,908
60MG		8,827	8,939	9,356	8,707	9,117	8,888
80MG		16,539	16,215	17,171	16,092	16,839	15,903
Total	**2012**	118,056	118,182	122,070	112,484	121,604	117,421
		10-May-13	**17-May-13**	**24-May-13**	**31-May-13**	**7-Jun-13**	**14-Jun-13**
10MG		24,914	24,582				
15MG		4,142	4,010				
20MG		29,288	28,309				
30MG		11,779	11,585				
40MG		20,933	19,867				
60MG		9,166	8,664				
80MG		14,627	13,611				
Total	**2013**	114,849	110,628				
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 19	**Week 20**	**Week 21**	**Week 22**	**Week 23**	**Week 24**
Strength	**Week Ending**	**8-May-09**	**15-May-09**	**22-May-09**	**29-May-09**	**5-Jun-09**	**12-Jun-09**
	2009	1.6%	-4.4%	2.9%	-7.0%	15.8%	-6.2%
	2010	7.9%	-6.7%	0.3%	4.4%	-5.0%	3.4%
	2011	-7.4%	-1.3%	4.5%	-6.2%	3.8%	-1.7%
	2012	-6.6%	0.1%	3.3%	-7.9%	8.1%	-3.4%
	2013						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 25	**Week 26**	**Week 27**	**Week 28**	**Week 29**	**Week 30**
Strength	**Week Ending**	**19-Jun-09**	**26-Jun-09**	**3-Jul-09**	**10-Jul-09**	**17-Jul-09**	**24-Jul-09**
10MG		20,963	20,962	22,353	20,917	21,614	21,439
15MG		1,602	1,514	1,666	1,505	1,590	1,597
20MG		24,357	24,272	26,827	24,524	25,695	25,836
30MG		6,268	6,105	6,919	6,351	6,578	6,392
40MG		27,124	27,548	31,107	27,653	29,049	28,512
60MG		6,364	6,336	6,743	6,290	6,494	6,416
80MG		21,837	21,973	24,120	21,551	22,428	21,947
Total	**2009**	108,515	108,710	119,735	108,791	113,448	112,139
		25-Jun-10	**2-Jul-10**	**9-Jul-10**	**16-Jul-10**	**23-Jul-10**	**30-Jul-10**
10MG		21,669	22,239	23,049	21,109	22,981	22,783
15MG		2,602	2,715	2,874	2,702	2,790	2,724
20MG		28,011	28,836	31,277	27,786	29,917	29,733
30MG		10,551	10,354	11,062	10,063	10,725	10,540
40MG		29,274	30,068	32,789	28,057	29,519	29,807
60MG		9,844	9,622	10,348	9,601	10,050	9,942
80MG		27,328	27,793	29,250	26,144	27,840	28,098
Total	**2010**	129,279	131,627	140,649	125,462	133,822	133,627
		24-Jun-11	**1-Jul-11**	**8-Jul-11**	**15-Jul-11**	**22-Jul-11**	**29-Jul-11**
10MG		25,756	26,776	23,375	25,477	25,092	25,513
15MG		2,991	3,160	2,924	3,089	3,088	2,944
20MG		32,617	35,184	30,589	32,817	32,473	31,894
30MG		10,293	11,014	9,766	10,441	10,091	10,189
40MG		25,288	26,387	23,718	24,752	24,919	25,179
60MG		8,896	9,423	8,281	8,798	8,525	8,755

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 25	**Week 26**	**Week 27**	**Week 28**	**Week 29**	**Week 30**
Strength	**Week Ending**	**19-Jun-09**	**26-Jun-09**	**3-Jul-09**	**10-Jul-09**	**17-Jul-09**	**24-Jul-09**
80MG		18,589	20,021	17,265	18,059	18,218	18,199
Total	**2011**	124,430	131,965	115,918	123,433	122,406	122,673
		22-Jun-12	**29-Jun-12**	**6-Jul-12**	**13-Jul-12**	**20-Jul-12**	**27-Jul-12**
10MG		24,878	24,839	22,927	24,571	24,474	24,189
15MG		3,529	3,479	3,470	3,697	3,597	3,561
20MG		30,061	30,739	29,235	30,567	30,270	29,599
30MG		11,293	11,432	11,211	11,389	11,410	11,245
40MG		23,175	23,246	23,564	23,332	23,257	22,701
60MG		9,219	9,059	9,152	9,112	9,288	9,121
80MG		16,571	16,449	16,595	16,471	16,488	16,151
Total	**2012**	118,726	119,243	116,154	119,139	118,784	116,567
		21-Jun-13	**28-Jun-13**	**5-Jul-13**	**12-Jul-13**	**19-Jul-13**	**26-Jul-13**
10MG							
15MG							
20MG							
30MG							
40MG							
60MG							
80MG							
Total	**2013**						
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 25	**Week 26**	**Week 27**	**Week 28**	**Week 29**	**Week 30**
Strength	**Week Ending**	**19-Jun-09**	**26-Jun-09**	**3-Jul-09**	**10-Jul-09**	**17-Jul-09**	**24-Jul-09**
	2009	1.9%	0.2%	10.1%	-9.1%	4.3%	-1.2%
	2010	0.6%	1.8%	6.9%	-10.8%	6.7%	-0.1%
	2011	1.0%	6.1%	-12.2%	6.5%	-0.8%	0.2%
	2012	1.1%	0.4%	-2.6%	2.6%	-0.3%	-1.9%
	2013						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 31	**Week 32**	**Week 33**	**Week 34**	**Week 35**	**Week 36**
Strength	**Week Ending**	**31-Jul-09**	**7-Aug-09**	**14-Aug-09**	**21-Aug-09**	**28-Aug-09**	**4-Sep-09**
10MG		21,576	21,992	21,636	21,817	22,134	22,820
15MG		1,621	1,700	1,642	1,634	1,650	1,701
20MG		27,017	28,660	28,805	29,855	30,664	33,993
30MG		6,666	6,596	6,828	6,774	6,780	7,302
40MG		29,259	30,165	29,716	29,905	30,487	32,789
60MG		6,558	6,835	6,612	6,708	6,846	7,288
80MG		22,027	22,819	22,374	22,692	22,715	24,140
Total	**2009**	114,724	118,767	117,613	119,385	121,276	130,033
		6-Aug-10	**13-Aug-10**	**20-Aug-10**	**27-Aug-10**	**3-Sep-10**	**10-Sep-10**
10MG		22,890	22,558	22,560	22,605	22,678	23,977
15MG		2,808	2,780	2,753	2,695	2,902	3,121
20MG		29,518	29,945	29,409	30,746	30,977	33,480
30MG		10,523	10,722	10,810	10,896	10,466	11,424
40MG		29,486	29,810	28,567	29,602	29,254	31,078
60MG		9,671	10,114	10,138	10,139	10,045	10,814
80MG		26,984	28,428	28,029	28,195	26,769	27,275
Total	**2010**	131,880	134,357	132,266	134,878	133,091	141,169
		5-Aug-11	**12-Aug-11**	**19-Aug-11**	**26-Aug-11**	**2-Sep-11**	**9-Sep-11**
10MG		24,932	24,760	24,963	25,056	25,649	22,679
15MG		3,073	3,010	3,174	3,144	2,989	2,919
20MG		32,066	31,819	31,968	31,881	32,467	29,616
30MG		10,295	10,140	10,385	10,331	10,239	9,634
40MG		25,196	24,802	25,097	25,350	25,499	23,338
60MG		8,719	8,623	8,641	8,772	8,875	8,099

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 31	**Week 32**	**Week 33**	**Week 34**	**Week 35**	**Week 36**
Strength	**Week Ending**	**31-Jul-09**	**7-Aug-09**	**14-Aug-09**	**21-Aug-09**	**28-Aug-09**	**4-Sep-09**
80MG		17,684	17,567	17,906	17,951	18,126	16,843
Total	**2011**	121,965	120,721	122,134	122,485	123,844	113,128
		3-Aug-12	**10-Aug-12**	**17-Aug-12**	**24-Aug-12**	**31-Aug-12**	**7-Sep-12**
10MG		24,085	23,942	24,305	24,548	24,950	23,222
15MG		3,628	3,559	3,736	3,484	3,695	3,489
20MG		30,017	29,413	30,096	29,863	30,281	28,823
30MG		11,395	11,227	11,692	11,402	11,620	11,057
40MG		23,069	22,792	23,006	22,555	23,184	22,363
60MG		9,116	8,982	9,268	9,253	9,188	8,884
80MG		16,106	16,013	16,373	16,097	16,136	15,987
Total	**2012**	117,416	115,928	118,476	117,202	119,054	113,825
		2-Aug-13	**9-Aug-13**	**16-Aug-13**	**23-Aug-13**	**30-Aug-13**	**6-Sep-13**
10MG							
15MG							
20MG							
30MG							
40MG							
60MG							
80MG							
Total	**2013**						
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 31	**Week 32**	**Week 33**	**Week 34**	**Week 35**	**Week 36**
Strength	**Week Ending**	**31-Jul-09**	**7-Aug-09**	**14-Aug-09**	**21-Aug-09**	**28-Aug-09**	**4-Sep-09**
	2009	2.3%	3.5%	-1.0%	1.5%	1.6%	7.2%
	2010	-1.3%	1.9%	-1.6%	2.0%	-1.3%	6.1%
	2011	-0.6%	-1.0%	1.2%	0.3%	1.1%	-8.7%
	2012	0.7%	-1.3%	2.2%	-1.1%	1.6%	-4.4%
	2013						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 37	**Week 38**	**Week 39**	**Week 40**	**Week 41**	**Week 42**
Strength	**Week Ending**	**11-Sep-09**	**18-Sep-09**	**25-Sep-09**	**2-Oct-09**	**9-Oct-09**	**16-Oct-09**
10MG		20,094	22,738	22,421	22,854	21,841	22,171
15MG		1,587	1,819	1,676	1,809	1,723	1,739
20MG		29,938	33,349	33,400	36,149	33,743	34,078
30MG		6,443	7,158	6,765	7,433	6,870	7,202
40MG		29,230	32,284	32,096	34,177	32,136	32,649
60MG		6,298	7,111	6,808	7,496	6,809	7,144
80MG		21,491	23,682	23,946	25,310	24,334	24,945
Total	**2009**	115,081	128,141	127,112	135,228	127,456	129,928
		17-Sep-10	**24-Sep-10**	**1-Oct-10**	**8-Oct-10**	**15-Oct-10**	**22-Oct-10**
10MG		21,794	23,930	23,708	24,274	23,939	24,310
15MG		2,769	3,020	2,800	3,134	2,988	2,893
20MG		30,411	33,476	32,159	33,860	33,054	33,810
30MG		10,179	11,308	10,774	11,064	10,879	10,990
40MG		26,620	29,020	27,518	28,143	26,424	26,143
60MG		9,828	10,396	9,954	10,447	10,024	9,918
80MG		23,153	24,743	22,512	22,375	20,904	20,552
Total	**2010**	124,754	135,893	129,425	133,297	128,212	128,616
		16-Sep-11	**23-Sep-11**	**30-Sep-11**	**7-Oct-11**	**14-Oct-11**	**21-Oct-11**
10MG		25,600	25,315	25,531	25,173	25,182	25,253
15MG		3,178	3,121	3,173	3,230	3,150	3,163
20MG		32,268	31,633	32,218	32,005	31,677	31,346
30MG		10,415	10,237	10,480	10,386	10,382	10,222
40MG		25,367	24,928	25,082	25,214	24,779	24,444
60MG		8,733	8,654	8,822	8,825	8,634	8,580

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 37	**Week 38**	**Week 39**	**Week 40**	**Week 41**	**Week 42**
Strength	**Week Ending**	**11-Sep-09**	**18-Sep-09**	**25-Sep-09**	**2-Oct-09**	**9-Oct-09**	**16-Oct-09**
80MG		18,183	17,880	17,806	17,842	17,870	17,628
Total	**2011**	123,744	121,768	123,112	122,675	121,674	120,636
		14-Sep-12	**21-Sep-12**	**28-Sep-12**	**5-Oct-12**	**12-Oct-12**	**19-Oct-12**
10MG		24,886	24,754	25,350	25,838	24,616	25,288
15MG		3,852	3,740	3,984	3,855	3,786	3,765
20MG		30,288	30,197	30,675	30,727	29,825	30,326
30MG		11,678	11,500	11,732	11,835	11,606	11,565
40MG		23,113	22,709	23,197	23,543	22,555	22,590
60MG		9,268	9,297	9,042	9,437	9,086	9,190
80MG		16,283	16,064	15,786	16,684	15,758	15,951
Total	**2012**	119,368	118,261	119,766	121,919	117,232	118,675
		13-Sep-13	**20-Sep-13**	**27-Sep-13**	**4-Oct-13**	**11-Oct-13**	**18-Oct-13**
10MG							
15MG							
20MG							
30MG							
40MG							
60MG							
80MG							
Total	**2013**						
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 37	**Week 38**	**Week 39**	**Week 40**	**Week 41**	**Week 42**
Strength	**Week Ending**	**11-Sep-09**	**18-Sep-09**	**25-Sep-09**	**2-Oct-09**	**9-Oct-09**	**16-Oct-09**
	2009	-11.5%	11.3%	-0.8%	6.4%	-5.7%	1.9%
	2010	-11.6%	8.9%	-4.8%	3.0%	-3.8%	0.3%
	2011	9.4%	-1.6%	1.1%	-0.4%	-0.8%	-0.9%
	2012	4.9%	-0.9%	1.3%	1.8%	-3.8%	1.2%
	2013						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							**Weekly Total Presc**
		Week 43	**Week 44**	**Week 45**	**Week 46**	**Week 47**	**Week 48**
Strength	**Week Ending**	**23-Oct-09**	**30-Oct-09**	**6-Nov-09**	**13-Nov-09**	**20-Nov-09**	**27-Nov-09**
10MG		22,567	22,054	21,863	21,463	21,895	18,595
15MG		1,742	1,727	1,885	1,793	1,833	1,706
20MG		34,754	34,649	34,277	32,522	33,862	29,406
30MG		7,103	7,259	7,275	7,391	7,709	6,789
40MG		32,809	32,823	33,577	31,791	32,627	29,053
60MG		6,992	7,228	7,340	7,288	7,468	6,678
80MG		25,436	24,782	25,802	25,325	26,045	23,031
Total	**2009**	131,403	130,522	132,019	127,573	131,439	115,258
		29-Oct-10	**5-Nov-10**	**12-Nov-10**	**19-Nov-10**	**26-Nov-10**	**3-Dec-10**
10MG		24,950	25,222	26,143	26,513	27,687	23,447
15MG		3,042	2,892	3,042	2,983	3,012	2,726
20MG		33,695	34,448	35,145	34,663	35,581	31,196
30MG		10,847	10,495	10,676	10,673	10,876	9,391
40MG		26,126	26,040	27,173	27,400	28,942	25,635
60MG		9,757	9,525	9,716	9,533	9,874	8,537
80MG		19,642	19,000	18,724	18,367	18,836	15,958
Total	**2010**	128,059	127,622	130,619	130,132	134,808	116,890
		28-Oct-11	**4-Nov-11**	**11-Nov-11**	**18-Nov-11**	**25-Nov-11**	**2-Dec-11**
10MG		25,300	25,314	25,302	25,776	22,486	26,481
15MG		3,143	3,109	3,177	3,278	2,899	3,251
20MG		31,483	31,178	31,529	31,779	28,017	33,356
30MG		10,340	10,417	10,255	10,541	9,246	11,315
40MG		24,446	24,252	24,246	24,618	21,864	26,379
60MG		8,761	8,568	8,639	8,952	7,876	9,465

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							**Weekly Total Presc**
		Week 43	**Week 44**	**Week 45**	**Week 46**	**Week 47**	**Week 48**
Strength	**Week Ending**	**23-Oct-09**	**30-Oct-09**	**6-Nov-09**	**13-Nov-09**	**20-Nov-09**	**27-Nov-09**
80MG		17,058	17,364	17,604	17,557	15,654	18,839
Total	**2011**	120,531	120,202	120,752	122,501	108,042	129,086
		26-Oct-12	**2-Nov-12**	**9-Nov-12**	**16-Nov-12**	**23-Nov-12**	**30-Nov-12**
10MG		25,395	24,696	26,154	26,215	23,221	26,489
15MG		3,828	3,765	3,932	3,921	3,491	4,109
20MG		30,000	29,535	30,912	30,176	27,610	31,374
30MG		11,566	11,440	11,920	11,644	10,833	12,244
40MG		22,546	22,344	23,004	22,628	20,580	23,701
60MG		9,068	8,909	9,562	9,410	8,376	9,642
80MG		15,808	15,426	16,294	16,122	14,482	16,100
Total	**2012**	118,211	116,115	121,778	120,116	108,593	123,659
		25-Oct-13	**1-Nov-13**	**8-Nov-13**	**15-Nov-13**	**22-Nov-13**	**29-Nov-13**
10MG							
15MG							
20MG							
30MG							
40MG							
60MG							
80MG							
Total	**2013**						
	1 week % Change						

	OxyContin Weekly TRx - Original Formul						
	Source: IMS Health NPA						
	Retail, LTC, and Mail Order						
	Numbers Are Absolute						**Weekly Total Presc**
		Week 43	**Week 44**	**Week 45**	**Week 46**	**Week 47**	**Week 48**
	Strength	**Week Ending**	**23-Oct-09**	**30-Oct-09**	**6-Nov-09**	**13-Nov-09**	**20-Nov-09**	**27-Nov-09**
		2009	1.1%	-0.7%	1.1%	-3.4%	3.0%	-12.3%
		2010	-0.4%	-0.3%	2.3%	-0.4%	3.6%	-13.3%
		2011	-0.1%	-0.3%	0.5%	1.4%	-11.8%	19.5%
		2012	-0.4%	-1.8%	4.9%	-1.4%	-9.6%	13.9%
		2013						

OxyContin Weekly TRx - Original Formul					
Source: IMS Health NPA					
Retail, LTC, and Mail Order					
Numbers Are Absolute		**riptions**			
		Week 49	**Week 50**	**Week 51**	**Week 52**
Strength	**Week Ending**	**4-Dec-09**	**11-Dec-09**	**18-Dec-09**	**25-Dec-09**
10MG		22,639	20,166	20,630	16,597
15MG		2,035	1,951	2,018	1,640
20MG		36,781	31,249	32,379	26,619
30MG		8,421	7,564	8,002	6,672
40MG		36,299	31,623	32,218	26,653
60MG		8,677	7,583	8,094	6,744
80MG		29,078	25,527	26,567	21,644
Total	**2009**	143,930	125,663	129,908	106,569
		10-Dec-10	**17-Dec-10**	**24-Dec-10**	**31-Dec-10**
10MG		27,965	27,477	28,407	27,439
15MG		3,278	3,051	3,044	2,892
20MG		37,879	35,095	35,533	34,714
30MG		11,649	10,767	10,799	10,408
40MG		31,691	28,560	29,516	27,042
60MG		10,399	9,510	9,414	9,262
80MG		19,510	18,227	19,040	18,086
Total	**2010**	142,371	132,687	135,753	129,843
		9-Dec-11	**16-Dec-11**	**23-Dec-11**	**30-Dec-11**
10MG		25,722	26,431	26,774	21,386
15MG		3,338	3,378	3,332	2,757
20MG		31,760	31,757	32,674	27,251
30MG		10,557	10,790	10,741	9,248
40MG		24,313	24,853	25,292	21,455
60MG		8,662	9,102	9,080	7,741

	OxyContin Weekly TRx - Original Formul					
	Source: IMS Health NPA					
	Retail, LTC, and Mail Order					
	Numbers Are Absolute	**riptions**				
		Week 49	**Week 50**	**Week 51**	**Week 52**	
	Strength	**Week Ending**	**4-Dec-09**	**11-Dec-09**	**18-Dec-09**	**25-Dec-09**
	80MG		17,560	17,690	17,758	15,431
	Total	**2011**	121,912	124,001	125,651	105,269
			7-Dec-12	**14-Dec-12**	**21-Dec-12**	**28-Dec-12**
	10MG		26,517	26,051	27,077	21,021
	15MG		4,032	4,026	4,170	3,207
	20MG		31,846	30,640	31,888	25,515
	30MG		12,447	12,006	12,563	10,004
	40MG		23,716	22,772	23,677	19,428
	60MG		9,734	9,380	9,610	8,046
	80MG		16,967	15,839	16,634	13,946
	Total	**2012**	125,259	120,714	125,619	101,167
			6-Dec-13	**13-Dec-13**	**20-Dec-13**	**27-Dec-13**
	10MG					
	15MG					
	20MG					
	30MG					
	40MG					
	60MG					
	80MG					
	Total	**2013**				
		1 week % Change				

	OxyContin Weekly TRx - Original Formul						
	Source: IMS Health NPA						
	Retail, LTC, and Mail Order						
	Numbers Are Absolute		**riptions**				
			Week 49	**Week 50**	**Week 51**	**Week 52**	
	Strength	**Week Ending**	**4-Dec-09**	**11-Dec-09**	**18-Dec-09**	**25-Dec-09**	
		2009	24.9%	-12.7%	3.4%	-18.0%	
		2010	21.8%	-6.8%	2.3%	-4.4%	
		2011	-5.6%	1.7%	1.3%	-16.2%	
		2012	1.3%	-3.6%	4.1%	-19.5%	
		2013					

Product	2011/04/08 EUTRx	2011/04/15 EUTRx	2011/04/22 EUTRx	2011/04/29 EUTRx
OXYCONTIN 01/1996 PUF	9,245,201	8,798,770	8,573,636	8,811,087
10MG	1,478,660	1,427,631	1,390,912	1,405,432
15MG	183,269	180,224	173,573	179,380
20MG	2,290,945	2,192,332	2,165,596	2,193,475
30MG	692,907	673,958	647,518	666,744
40MG	2,055,364	1,943,620	1,899,504	1,960,507
60MG	671,650	658,988	610,461	638,010
80MG	1,872,406	1,722,017	1,686,072	1,767,539
Grand Total	**9,245,201**	**8,798,770**	**8,573,636**	**8,811,087**

MG Totals

OXYCONTIN 01/1996 PUF				
10MG	14,786,600	14,276,310	13,909,120	14,054,320
15MG	2,749,035	2,703,360	2,603,595	2,690,700
20MG	45,818,900	43,846,640	43,311,920	43,869,500
30MG	20,787,210	20,218,740	19,425,540	20,002,320
40MG	82,214,560	77,744,800	75,980,160	78,420,280
60MG	40,299,000	39,539,280	36,627,660	38,280,600
80MG	149,792,480	137,761,360	134,885,760	141,403,120
Grand Total	**356,447,785**	**336,090,490**	**326,743,755**	**338,720,840**

Millions of MG	4/8/2011	4/15/2011	4/22/2011	4/29/2011
OXYCONTIN 01/1996 PUF				
10MG	15	14	14	14
15MG	3	3	3	3
20MG	46	44	43	44
30MG	21	20	19	20
40MG	82	78	76	78
60MG	40	40	37	38
80MG	150	138	135	141
Grand Total	**356**	**336**	**327**	**339**

2011/05/06 EUTRx	2011/05/13 EUTRx	2011/05/20 EUTRx	2011/05/27 EUTRx	2011/06/03 EUTRx	2011/06/10 EUTRx
9,501,374	8,741,359	8,573,294	9,026,667	8,430,496	8,792,965
1,487,471	1,400,215	1,390,618	1,450,473	1,311,696	1,431,988
185,164	181,782	178,413	184,192	166,081	181,190
2,391,478	2,199,539	2,152,247	2,232,569	2,096,801	2,197,315
717,131	661,119	661,896	689,695	650,666	677,241
2,110,498	1,935,334	1,891,439	2,010,862	1,887,654	1,930,916
700,016	634,357	629,136	664,006	627,137	649,340
1,909,616	1,729,013	1,669,545	1,794,870	1,690,461	1,724,975
9,501,374	**8,741,359**	**8,573,294**	**9,026,667**	**8,430,496**	**8,792,965**

14,874,710	14,002,150	13,906,180	14,504,730	13,116,960	14,319,880
2,777,460	2,726,730	2,676,195	2,762,880	2,491,215	2,717,850
47,829,560	43,990,780	43,044,940	44,651,380	41,936,020	43,946,300
21,513,930	19,833,570	19,856,880	20,690,850	19,519,980	20,317,230
84,419,920	77,413,360	75,657,560	80,434,480	75,506,160	77,236,640
42,000,960	38,061,420	37,748,160	39,840,360	37,628,220	38,960,400
152,769,280	138,321,040	133,563,600	143,589,600	135,236,880	137,998,000
366,185,820	**334,349,050**	**326,453,515**	**346,474,280**	**325,435,435**	**335,496,300**

5/6/2011	5/13/2011	5/20/2011	5/27/2011	6/3/2011	6/10/2011
15	14	14	15	13	14
3	3	3	3	2	3
48	44	43	45	42	44
22	20	20	21	20	20
84	77	76	80	76	77
42	38	38	40	38	39
153	138	134	144	135	138
366	**334**	**326**	**346**	**325**	**335**

2011/06/17 EUTRx	2011/06/24 EUTRx	2011/07/01 EUTRx	2011/07/08 EUTRx	2011/07/15 EUTRx	2011/07/22 EUTRx
8,581,589	8,758,691	9,331,763	8,126,682	8,625,729	8,619,338
1,389,967	1,391,937	1,474,790	1,283,213	1,387,431	1,367,678
177,671	180,557	189,408	170,738	183,608	182,874
2,157,000	2,161,652	2,351,092	2,026,960	2,159,950	2,143,410
673,071	680,089	726,907	641,157	682,731	672,123
1,882,461	1,953,240	2,021,413	1,795,202	1,887,344	1,921,136
618,362	650,976	683,878	604,158	645,302	634,734
1,683,057	1,740,240	1,884,275	1,605,254	1,679,363	1,697,383
8,581,589	**8,758,691**	**9,331,763**	**8,126,682**	**8,625,729**	**8,619,338**

13,899,670	13,919,370	14,747,900	12,832,130	13,874,310	13,676,780
2,665,065	2,708,355	2,841,120	2,561,070	2,754,120	2,743,110
43,140,000	43,233,040	47,021,840	40,539,200	43,199,000	42,868,200
20,192,130	20,402,670	21,807,210	19,234,710	20,481,930	20,163,690
75,298,440	78,129,600	80,856,520	71,808,080	75,493,760	76,845,440
37,101,720	39,058,560	41,032,680	36,249,480	38,718,120	38,084,040
134,644,560	139,219,200	150,742,000	128,420,320	134,349,040	135,790,640
326,941,585	**336,670,795**	**359,049,270**	**311,644,990**	**328,870,280**	**330,171,900**

6/17/2011	6/24/2011	7/1/2011	7/8/2011	7/15/2011	7/22/2011
14	14	15	13	14	14
3	3	3	3	3	3
43	43	47	41	43	43
20	20	22	19	20	20
75	78	81	72	75	77
37	39	41	36	39	38
135	139	151	128	134	136
327	**337**	**359**	**312**	**329**	**330**

2011/07/29 EUTRx	2011/08/05 EUTRx	2011/08/12 EUTRx	2011/08/19 EUTRx	2011/08/26 EUTRx	2011/09/02 EUTRx
8,639,239	8,539,432	8,432,171	8,561,895	8,586,953	8,700,800
1,389,900	1,351,652	1,352,449	1,347,382	1,361,439	1,415,584
176,085	182,481	181,231	186,212	186,411	178,550
2,123,617	2,112,497	2,094,035	2,110,746	2,107,274	2,147,515
667,672	674,468	661,561	678,745	683,683	676,670
1,936,667	1,936,788	1,887,976	1,937,511	1,935,523	1,953,056
645,107	634,667	627,548	634,527	640,278	646,482
1,700,191	1,646,879	1,627,371	1,666,772	1,672,345	1,682,943
8,639,239	**8,539,432**	**8,432,171**	**8,561,895**	**8,586,953**	**8,700,800**

13,899,000	13,516,520	13,524,490	13,473,820	13,614,390	14,155,840
2,641,275	2,737,215	2,718,465	2,793,180	2,796,165	2,678,250
42,472,340	42,249,940	41,880,700	42,214,920	42,145,480	42,950,300
20,030,160	20,234,040	19,846,830	20,362,350	20,510,490	20,300,100
77,466,680	77,471,520	75,519,040	77,500,440	77,420,920	78,122,240
38,706,420	38,080,020	37,652,880	38,071,620	38,416,680	38,788,920
136,015,280	131,750,320	130,189,680	133,341,760	133,787,600	134,635,440
331,231,155	**326,039,575**	**321,332,085**	**327,758,090**	**328,691,725**	**331,631,090**

7/29/2011	8/5/2011	8/12/2011	8/19/2011	8/26/2011	9/2/2011
14	14	14	13	14	14
3	3	3	3	3	3
42	42	42	42	42	43
20	20	20	20	21	20
77	77	76	78	77	78
39	38	38	38	38	39
136	132	130	133	134	135
331	**326**	**321**	**328**	**329**	**332**

2011/09/09 EUTRx	2011/09/16 EUTRx	2011/09/23 EUTRx	2011/09/30 EUTRx	2011/10/07 EUTRx	2011/10/14 EUTRx
7,939,083	8,695,016	8,573,455	8,609,904	8,575,899	8,500,737
1,229,109	1,381,856	1,381,121	1,373,109	1,368,633	1,352,102
175,024	189,614	186,948	190,182	190,450	185,702
1,967,166	2,144,689	2,112,236	2,135,620	2,105,859	2,086,422
636,604	677,628	673,665	691,553	689,623	676,394
1,785,643	1,965,443	1,913,663	1,915,038	1,921,786	1,904,402
590,123	642,338	635,168	644,614	645,360	634,044
1,555,414	1,693,448	1,670,654	1,659,788	1,654,188	1,661,671
7,939,083	**8,695,016**	**8,573,455**	**8,609,904**	**8,575,899**	**8,500,737**

12,291,090	13,818,560	13,811,210	13,731,090	13,686,330	13,521,020
2,625,360	2,844,210	2,804,220	2,852,730	2,856,750	2,785,530
39,343,320	42,893,780	42,244,720	42,712,400	42,117,180	41,728,440
19,098,120	20,328,840	20,209,950	20,746,590	20,688,690	20,291,820
71,425,720	78,617,720	76,546,520	76,601,520	76,871,440	76,176,080
35,407,380	38,540,280	38,110,080	38,676,840	38,721,600	38,042,640
124,433,120	135,475,840	133,652,320	132,783,040	132,335,040	132,933,680
304,624,110	**332,519,230**	**327,379,020**	**328,104,210**	**327,277,030**	**325,479,210**

9/9/2011	9/16/2011	9/23/2011	9/30/2011	10/7/2011	10/14/2011
12	14	14	14	14	14
3	3	3	3	3	3
39	43	42	43	42	42
19	20	20	21	21	20
71	79	77	77	77	76
35	39	38	39	39	38
124	135	134	133	132	133
305	**333**	**327**	**328**	**327**	**325**

2011/10/21 EUTRx	2011/10/28 EUTRx	2011/11/04 EUTRx	2011/11/11 EUTRx	2011/11/18 EUTRx	2011/11/25 EUTRx
8,433,590	8,378,797	8,364,566	8,419,830	8,534,146	7,488,971
1,374,237	1,356,864	1,366,208	1,351,490	1,383,921	1,208,518
188,811	185,808	181,204	187,251	191,323	170,857
2,056,120	2,058,621	2,052,221	2,068,524	2,087,144	1,824,031
676,712	681,559	688,050	676,655	699,901	607,197
1,867,511	1,875,802	1,843,814	1,868,754	1,888,589	1,654,741
638,311	644,857	630,014	630,742	663,539	578,161
1,631,888	1,575,286	1,603,055	1,636,414	1,619,729	1,445,466
8,433,590	**8,378,797**	**8,364,566**	**8,419,830**	**8,534,146**	**7,488,971**

13,742,370	13,568,640	13,662,080	13,514,900	13,839,210	12,085,180
2,832,165	2,787,120	2,718,060	2,808,765	2,869,845	2,562,855
41,122,400	41,172,420	41,044,420	41,370,480	41,742,880	36,480,620
20,301,360	20,446,770	20,641,500	20,299,650	20,997,030	18,215,910
74,700,440	75,032,080	73,752,560	74,750,160	75,543,560	66,189,640
38,298,660	38,691,420	37,800,840	37,844,520	39,812,340	34,689,660
130,551,040	126,022,880	128,244,400	130,913,120	129,578,320	115,637,280
321,548,435	**317,721,330**	**317,863,860**	**321,501,595**	**324,383,185**	**285,861,145**

10/21/2011	10/28/2011	11/4/2011	11/11/2011	11/18/2011	11/25/2011
14	14	14	14	14	12
3	3	3	3	3	3
41	41	41	41	42	36
20	20	21	20	21	18
75	75	74	75	76	66
38	39	38	38	40	35
131	126	128	131	130	116
322	**318**	**318**	**322**	**324**	**286**

2011/12/02 EUTRx	2011/12/09 EUTRx	2011/12/16 EUTRx	2011/12/23 EUTRx	2011/12/30 EUTRx	2012/01/06 EUTRx
9,056,397	8,496,159	8,633,759	8,783,921	7,373,644	8,063,746
1,439,090	1,374,240	1,423,190	1,451,921	1,158,790	1,282,119
193,397	201,119	197,707	198,672	161,569	192,487
2,213,081	2,074,192	2,094,123	2,151,605	1,806,349	1,971,363
756,778	705,047	714,547	714,302	614,514	680,416
2,012,438	1,871,406	1,903,644	1,932,693	1,627,130	1,771,423
699,049	634,440	666,005	672,301	570,244	618,521
1,742,564	1,635,715	1,634,543	1,662,427	1,434,977	1,547,417
9,056,397	**8,496,159**	**8,633,759**	**8,783,921**	**7,373,644**	**8,063,746**

14,390,900	13,742,400	14,231,900	14,519,210	11,587,900	12,821,190
2,900,955	3,016,785	2,965,605	2,980,080	2,423,535	2,887,305
44,261,620	41,483,840	41,882,460	43,032,100	36,126,980	39,427,260
22,703,340	21,151,410	21,436,410	21,429,060	18,435,420	20,412,480
80,497,520	74,856,240	76,145,760	77,307,720	65,085,200	70,856,920
41,942,940	38,066,400	39,960,300	40,338,060	34,214,640	37,111,260
139,405,120	130,857,200	130,763,440	132,994,160	114,798,160	123,793,360
346,102,395	**323,174,275**	**327,385,875**	**332,600,390**	**282,671,835**	**307,309,775**

12/2/2011	12/9/2011	12/16/2011	12/23/2011	12/30/2011	1/6/2012
14	14	14	15	12	13
3	3	3	3	2	3
44	41	42	43	36	39
23	21	21	21	18	20
80	75	76	77	65	71
42	38	40	40	34	37
139	131	131	133	115	124
346	**323**	**327**	**333**	**283**	**307**

2012/01/13 EUTRx	2012/01/20 EUTRx	2012/01/27 EUTRx	2012/02/03 EUTRx	2012/02/10 EUTRx	2012/02/17 EUTRx
8,469,490	8,227,738	7,838,360	8,386,620	8,396,362	8,231,779
1,365,723	1,332,905	1,291,466	1,357,246	1,377,064	1,329,446
198,357	193,226	188,187	194,964	200,601	198,681
2,048,198	2,015,901	1,934,038	2,031,761	2,033,049	2,000,787
708,312	692,645	670,328	712,690	708,927	684,732
1,886,140	1,796,545	1,695,144	1,830,911	1,832,152	1,809,806
650,576	636,444	603,778	654,117	641,919	649,434
1,612,184	1,560,072	1,455,419	1,604,931	1,602,650	1,558,893
8,469,490	**8,227,738**	**7,838,360**	**8,386,620**	**8,396,362**	**8,231,779**

13,657,230	13,329,050	12,914,660	13,572,460	13,770,640	13,294,460
2,975,355	2,898,390	2,822,805	2,924,460	3,009,015	2,980,215
40,963,960	40,318,020	38,680,760	40,635,220	40,660,980	40,015,740
21,249,360	20,779,350	20,109,840	21,380,700	21,267,810	20,541,960
75,445,600	71,861,800	67,805,760	73,236,440	73,286,080	72,392,240
39,034,560	38,186,640	36,226,680	39,247,020	38,515,140	38,966,040
128,974,720	124,805,760	116,433,520	128,394,480	128,212,000	124,711,440
322,300,785	**312,179,010**	**294,994,025**	**319,390,780**	**318,721,665**	**312,902,095**

1/13/2012	1/20/2012	1/27/2012	2/3/2012	2/10/2012	2/17/2012
14	13	13	14	14	13
3	3	3	3	3	3
41	40	39	41	41	40
21	21	20	21	21	21
75	72	68	73	73	72
39	38	36	39	39	39
129	125	116	128	128	125
322	**312**	**295**	**319**	**319**	**313**

2012/02/24 EUTRx	2012/03/02 EUTRx	2012/03/09 EUTRx	2012/03/16 EUTRx	2012/03/23 EUTRx	2012/03/30 EUTRx
7,919,014	8,894,547	8,618,055	8,238,496	7,986,979	8,159,404
1,281,004	1,412,394	1,385,138	1,339,355	1,311,232	1,322,454
189,318	212,086	207,306	205,175	192,796	191,879
1,926,520	2,146,918	2,067,955	1,977,236	1,948,165	1,990,219
683,706	760,671	737,152	714,539	692,787	707,556
1,720,587	1,948,642	1,875,887	1,805,137	1,719,569	1,775,618
614,941	713,838	680,668	645,508	628,753	658,812
1,502,938	1,699,998	1,663,949	1,551,546	1,493,677	1,512,866
7,919,014	**8,894,547**	**8,618,055**	**8,238,496**	**7,986,979**	**8,159,404**

12,810,040	14,123,940	13,851,380	13,393,550	13,112,320	13,224,540
2,839,770	3,181,290	3,109,590	3,077,625	2,891,940	2,878,185
38,530,400	42,938,360	41,359,100	39,544,720	38,963,300	39,804,380
20,511,180	22,820,130	22,114,560	21,436,170	20,783,610	21,226,680
68,823,480	77,945,680	75,035,480	72,205,480	68,782,760	71,024,720
36,896,460	42,830,280	40,840,080	38,730,480	37,725,180	39,528,720
120,235,040	135,999,840	133,115,920	124,123,680	119,494,160	121,029,280
300,646,370	**339,839,520**	**329,426,110**	**312,511,705**	**301,753,270**	**308,716,505**

2/24/2012	3/2/2012	3/9/2012	3/16/2012	3/23/2012	3/30/2012
13	14	14	13	13	13
3	3	3	3	3	3
39	43	41	40	39	40
21	23	22	21	21	21
69	78	75	72	69	71
37	43	41	39	38	40
120	136	133	124	119	121
301	**340**	**329**	**313**	**302**	**309**

2012/04/06 EUTRx	2012/04/13 EUTRx	2012/04/20 EUTRx	2012/04/27 EUTRx	2012/05/04 EUTRx	2012/05/11 EUTRx
8,537,435	8,120,425	8,115,483	8,255,699	8,770,748	8,152,744
1,351,771	1,330,947	1,313,770	1,351,314	1,392,200	1,321,258
205,525	202,082	208,611	198,534	216,422	204,934
2,072,855	1,979,017	1,975,352	1,991,462	2,102,921	1,983,488
741,174	706,575	728,585	741,427	783,483	718,178
1,857,322	1,758,891	1,741,258	1,776,930	1,913,749	1,758,181
685,446	638,319	649,055	657,771	712,984	648,911
1,623,342	1,504,594	1,498,852	1,538,261	1,648,989	1,517,794
8,537,435	**8,120,425**	**8,115,483**	**8,255,699**	**8,770,748**	**8,152,744**

13,517,710	13,309,470	13,137,700	13,513,140	13,922,000	13,212,580
3,082,875	3,031,230	3,129,165	2,978,010	3,246,330	3,074,010
41,457,100	39,580,340	39,507,040	39,829,240	42,058,420	39,669,760
22,235,220	21,197,250	21,857,550	22,242,810	23,504,490	21,545,340
74,292,880	70,355,640	69,650,320	71,077,200	76,549,960	70,327,240
41,126,760	38,299,140	38,943,300	39,466,260	42,779,040	38,934,660
129,867,360	120,367,520	119,908,160	123,060,880	131,919,120	121,423,520
325,579,905	**306,140,590**	**306,133,235**	**312,167,540**	**333,979,360**	**308,187,110**

4/6/2012	4/13/2012	4/20/2012	4/27/2012	5/4/2012	5/11/2012
14	13	13	14	14	13
3	3	3	3	3	3
41	40	40	40	42	40
22	21	22	22	24	22
74	70	70	71	77	70
41	38	39	39	43	39
130	120	120	123	132	121
326	**306**	**306**	**312**	**334**	**308**

2012/05/18 EUTRx	2012/05/25 EUTRx	2012/06/01 EUTRx	2012/06/08 EUTRx	2012/06/15 EUTRx	2012/06/22 EUTRx
8,160,756	8,436,049	7,779,099	8,429,255	8,091,145	8,214,130
1,319,504	1,359,946	1,212,462	1,367,916	1,321,120	1,325,251
210,277	215,693	195,602	216,327	208,959	211,049
1,989,425	2,027,346	1,882,797	2,043,311	1,978,591	1,964,917
738,781	771,686	698,729	751,715	736,161	743,060
1,759,297	1,788,154	1,683,841	1,828,265	1,726,539	1,764,927
657,251	680,108	641,045	664,304	653,013	675,115
1,486,221	1,593,116	1,464,623	1,557,417	1,466,762	1,529,811
8,160,756	**8,436,049**	**7,779,099**	**8,429,255**	**8,091,145**	**8,214,130**

13,195,040	13,599,460	12,124,620	13,679,160	13,211,200	13,252,510
3,154,155	3,235,395	2,934,030	3,244,905	3,134,385	3,165,735
39,788,500	40,546,920	37,655,940	40,866,220	39,571,820	39,298,340
22,163,430	23,150,580	20,961,870	22,551,450	22,084,830	22,291,800
70,371,880	71,526,160	67,353,640	73,130,600	69,061,560	70,597,080
39,435,060	40,806,480	38,462,700	39,858,240	39,180,780	40,506,900
118,897,680	127,449,280	117,169,840	124,593,360	117,340,960	122,384,880
307,005,745	**320,314,275**	**296,662,640**	**317,923,935**	**303,585,535**	**311,497,245**

5/18/2012	5/25/2012	6/1/2012	6/8/2012	6/15/2012	6/22/2012
13	14	12	14	13	13
3	3	3	3	3	3
40	41	38	41	40	39
22	23	21	23	22	22
70	72	67	73	69	71
39	41	38	40	39	41
119	127	117	125	117	122
307	**320**	**297**	**318**	**304**	**311**

2012/06/29 EUTRx	2012/07/06 EUTRx	2012/07/13 EUTRx	2012/07/20 EUTRx	2012/07/27 EUTRx	2012/08/03 EUTRx
8,246,084	8,065,352	8,208,806	8,219,836	8,049,688	8,109,693
1,331,557	1,247,785	1,333,196	1,320,775	1,293,848	1,294,651
207,192	205,022	220,230	213,404	211,946	225,106
2,009,525	1,917,797	1,993,330	1,981,127	1,931,675	1,958,511
754,691	740,361	746,328	753,942	745,686	752,622
1,762,116	1,774,739	1,743,741	1,752,346	1,710,773	1,726,301
669,984	668,827	674,817	680,461	677,459	674,364
1,511,019	1,510,821	1,497,164	1,517,781	1,478,301	1,478,138
8,246,084	**8,065,352**	**8,208,806**	**8,219,836**	**8,049,688**	**8,109,693**

13,315,570	12,477,850	13,331,960	13,207,750	12,938,480	12,946,510
3,107,880	3,075,330	3,303,450	3,201,060	3,179,190	3,376,590
40,190,500	38,355,940	39,866,600	39,622,540	38,633,500	39,170,220
22,640,730	22,210,830	22,389,840	22,618,260	22,370,580	22,578,660
70,484,640	70,989,560	69,749,640	70,093,840	68,430,920	69,052,040
40,199,040	40,129,620	40,489,020	40,827,660	40,647,540	40,461,840
120,881,520	120,865,680	119,773,120	121,422,480	118,264,080	118,251,040
310,819,880	**308,104,810**	**308,903,630**	**310,993,590**	**304,464,290**	**305,836,900**

6/29/2012	7/6/2012	7/13/2012	7/20/2012	7/27/2012	8/3/2012
13	12	13	13	13	13
3	3	3	3	3	3
40	38	40	40	39	39
23	22	22	23	22	23
70	71	70	70	68	69
40	40	40	41	41	40
121	121	120	121	118	118
311	**308**	**309**	**311**	**304**	**306**

2012/08/10 EUTRx	2012/08/17 EUTRx	2012/08/24 EUTRx	2012/08/31 EUTRx	2012/09/07 EUTRx	2012/09/14 EUTRx
7,974,578	8,149,473	8,080,157	8,197,503	7,825,427	8,192,273
1,273,489	1,301,949	1,311,403	1,335,840	1,244,933	1,325,606
213,871	222,794	209,361	223,269	208,040	225,574
1,911,171	1,962,404	1,947,527	1,977,330	1,874,717	1,967,788
734,455	769,565	759,252	761,468	716,018	767,384
1,723,897	1,724,155	1,701,861	1,744,427	1,670,009	1,738,777
657,871	668,116	680,407	674,342	647,370	682,306
1,459,824	1,500,490	1,470,346	1,480,827	1,464,340	1,484,838
7,974,578	**8,149,473**	**8,080,157**	**8,197,503**	**7,825,427**	**8,192,273**

12,734,890	13,019,490	13,114,030	13,358,400	12,449,330	13,256,060
3,208,065	3,341,910	3,140,415	3,349,035	3,120,600	3,383,610
38,223,420	39,248,080	38,950,540	39,546,600	37,494,340	39,355,760
22,033,650	23,086,950	22,777,560	22,844,040	21,480,540	23,021,520
68,955,880	68,966,200	68,074,440	69,777,080	66,800,360	69,551,080
39,472,260	40,086,960	40,824,420	40,460,520	38,842,200	40,938,360
116,785,920	120,039,200	117,627,680	118,466,160	117,147,200	118,787,040
301,414,085	**307,788,790**	**304,509,085**	**307,801,835**	**297,334,570**	**308,293,430**

8/10/2012	8/17/2012	8/24/2012	8/31/2012	9/7/2012	9/14/2012
13	13	13	13	12	13
3	3	3	3	3	3
38	39	39	40	37	39
22	23	23	23	21	23
69	69	68	70	67	70
39	40	41	40	39	41
117	120	118	118	117	119
301	**308**	**305**	**308**	**297**	**308**

2012/09/21 EUTRx	2012/09/28 EUTRx	2012/10/05 EUTRx	2012/10/12 EUTRx	2012/10/19 EUTRx	2012/10/26 EUTRx
8,136,521	8,213,947	8,361,496	7,998,840	8,124,850	8,050,027
1,325,313	1,344,176	1,374,362	1,303,257	1,338,856	1,331,872
225,149	236,966	226,804	220,912	226,671	225,216
1,961,098	1,998,014	1,997,873	1,923,789	1,961,642	1,935,649
755,777	773,138	775,524	760,819	760,116	757,949
1,707,833	1,745,287	1,764,524	1,682,430	1,686,399	1,684,899
680,595	670,088	688,895	666,696	679,457	661,482
1,480,756	1,446,278	1,533,514	1,440,937	1,471,709	1,452,960
8,136,521	**8,213,947**	**8,361,496**	**7,998,840**	**8,124,850**	**8,050,027**

13,253,130	13,441,760	13,743,620	13,032,570	13,388,560	13,318,720
3,377,235	3,554,490	3,402,060	3,313,680	3,400,065	3,378,240
39,221,960	39,960,280	39,957,460	38,475,780	39,232,840	38,712,980
22,673,310	23,194,140	23,265,720	22,824,570	22,803,480	22,738,470
68,313,320	69,811,480	70,580,960	67,297,200	67,455,960	67,395,960
40,835,700	40,205,280	41,333,700	40,001,760	40,767,420	39,688,920
118,460,480	115,702,240	122,681,120	115,274,960	117,736,720	116,236,800
306,135,135	**305,869,670**	**314,964,640**	**300,220,520**	**304,785,045**	**301,470,090**

9/21/2012	9/28/2012	10/5/2012	10/12/2012	10/19/2012	10/26/2012
13	13	14	13	13	13
3	4	3	3	3	3
39	40	40	38	39	39
23	23	23	23	23	23
68	70	71	67	67	67
41	40	41	40	41	40
118	116	123	115	118	116
306	**306**	**315**	**300**	**305**	**301**

2012/11/02 EUTRx	2012/11/09 EUTRx	2012/11/16 EUTRx	2012/11/23 EUTRx	2012/11/30 EUTRx	2012/12/07 EUTRx
7,884,768	8,339,872	8,169,418	7,392,202	8,446,015	8,599,666
1,297,235	1,379,991	1,366,641	1,217,989	1,419,962	1,401,942
222,271	238,223	233,136	208,902	240,382	240,681
1,904,322	2,009,064	1,937,501	1,784,409	2,032,073	2,073,229
750,263	789,110	769,893	707,008	805,363	822,187
1,659,852	1,725,846	1,696,914	1,541,620	1,760,216	1,790,300
645,429	709,182	685,531	606,318	704,753	719,867
1,405,396	1,488,456	1,479,802	1,325,956	1,483,266	1,551,460
7,884,768	**8,339,872**	**8,169,418**	**7,392,202**	**8,446,015**	**8,599,666**

12,972,350	13,799,910	13,666,410	12,179,890	14,199,620	14,019,420
3,334,065	3,573,345	3,497,040	3,133,530	3,605,730	3,610,215
38,086,440	40,181,280	38,750,020	35,688,180	40,641,460	41,464,580
22,507,890	23,673,300	23,096,790	21,210,240	24,160,890	24,665,610
66,394,080	69,033,840	67,876,560	61,664,800	70,408,640	71,612,000
38,725,740	42,550,920	41,131,860	36,379,080	42,285,180	43,192,020
112,431,680	119,076,480	118,384,160	106,076,480	118,661,280	124,116,800
294,452,245	**311,889,075**	**306,402,840**	**276,332,200**	**313,962,800**	**322,680,645**

11/2/2012	11/9/2012	11/16/2012	11/23/2012	11/30/2012	12/7/2012
13	14	14	12	14	14
3	4	3	3	4	4
38	40	39	36	41	41
23	24	23	21	24	25
66	69	68	62	70	72
39	43	41	36	42	43
112	119	118	106	119	124
294	**312**	**306**	**276**	**314**	**323**

2012/12/14 EUTRx	2012/12/21 EUTRx	2012/12/28 EUTRx	2013/01/04 EUTRx	2013/01/11 EUTRx	2013/01/18 EUTRx
8,234,376	8,591,485	6,903,075	7,648,883	8,143,336	8,052,086
1,356,149	1,424,601	1,108,913	1,228,344	1,319,309	1,327,537
243,353	248,169	193,069	210,753	240,570	230,249
1,979,123	2,070,155	1,643,246	1,823,867	1,946,375	1,919,911
792,021	825,149	650,731	743,527	776,260	779,645
1,700,905	1,774,350	1,446,706	1,598,914	1,712,556	1,647,897
692,300	708,922	594,161	657,326	691,962	686,765
1,470,525	1,540,139	1,266,249	1,386,152	1,456,304	1,460,082
8,234,376	**8,591,485**	**6,903,075**	**7,648,883**	**8,143,336**	**8,052,086**

13,561,490	14,246,010	11,089,130	12,283,440	13,193,090	13,275,370
3,650,295	3,722,535	2,896,035	3,161,295	3,608,550	3,453,735
39,582,460	41,403,100	32,864,920	36,477,340	38,927,500	38,398,220
23,760,630	24,754,470	19,521,930	22,305,810	23,287,800	23,389,350
68,036,200	70,974,000	57,868,240	63,956,560	68,502,240	65,915,880
41,538,000	42,535,320	35,649,660	39,439,560	41,517,720	41,205,900
117,642,000	123,211,120	101,299,920	110,892,160	116,504,320	116,806,560
307,771,075	**320,846,555**	**261,189,835**	**288,516,165**	**305,541,220**	**302,445,015**

12/14/2012	12/21/2012	12/28/2012	1/4/2013	1/11/2013	1/18/2013
14	14	11	12	13	13
4	4	3	3	4	3
40	41	33	36	39	38
24	25	20	22	23	23
68	71	58	64	69	66
42	43	36	39	42	41
118	123	101	111	117	117
308	**321**	**261**	**289**	**306**	**302**

2013/01/25 EUTRx	2013/02/01 EUTRx	2013/02/08 EUTRx	2013/02/15 EUTRx	2013/02/22 EUTRx	2013/03/01 EUTRx
7,200,338	7,683,391	8,162,552	7,879,116	7,253,340	8,096,634
1,204,426	1,250,185	1,323,987	1,311,402	1,234,444	1,313,174
218,947	219,310	238,577	226,095	216,995	241,102
1,728,049	1,846,356	1,923,103	1,877,138	1,744,529	1,938,072
690,742	741,895	806,799	748,911	723,181	801,071
1,479,337	1,592,447	1,685,464	1,640,730	1,479,375	1,662,896
610,193	658,830	706,251	655,037	609,224	701,244
1,268,644	1,374,368	1,478,371	1,419,803	1,245,592	1,439,075
7,200,338	**7,683,391**	**8,162,552**	**7,879,116**	**7,253,340**	**8,096,634**

12,044,260	12,501,850	13,239,870	13,114,020	12,344,440	13,131,740
3,284,205	3,289,650	3,578,655	3,391,425	3,254,925	3,616,530
34,560,980	36,927,120	38,462,060	37,542,760	34,890,580	38,761,440
20,722,260	22,256,850	24,203,970	22,467,330	21,695,430	24,032,130
59,173,480	63,697,880	67,418,560	65,629,200	59,175,000	66,515,840
36,611,580	39,529,800	42,375,060	39,302,220	36,553,440	42,074,640
101,491,520	109,949,440	118,269,680	113,584,240	99,647,360	115,126,000
267,888,285	**288,152,590**	**307,547,855**	**295,031,195**	**267,561,175**	**303,258,320**

1/25/2013	2/1/2013	2/8/2013	2/15/2013	2/22/2013	3/1/2013
12	13	13	13	12	13
3	3	4	3	3	4
35	37	38	38	35	39
21	22	24	22	22	24
59	64	67	66	59	67
37	40	42	39	37	42
101	110	118	114	100	115
268	**288**	**308**	**295**	**268**	**303**

2013/03/08 EUTRx	2013/03/15 EUTRx	2013/03/22 EUTRx	2013/03/29 EUTRx	2013/04/05 EUTRx	2013/04/12 EUTRx
8,277,776	7,711,915	7,398,795	7,332,806	7,831,508	7,526,041
1,334,871	1,279,468	1,257,307	1,210,871	1,270,528	1,255,679
242,567	228,095	227,500	216,006	229,814	232,819
1,979,090	1,850,109	1,782,160	1,764,374	1,858,814	1,809,809
802,211	745,368	735,041	734,465	774,321	742,801
1,728,659	1,568,602	1,501,003	1,497,569	1,619,675	1,529,222
694,780	654,045	621,622	636,926	675,819	640,477
1,495,598	1,386,228	1,274,162	1,272,595	1,402,537	1,315,234
8,277,776	**7,711,915**	**7,398,795**	**7,332,806**	**7,831,508**	**7,526,041**

13,348,710	12,794,680	12,573,070	12,108,710	12,705,280	12,556,790
3,638,505	3,421,425	3,412,500	3,240,090	3,447,210	3,492,285
39,581,800	37,002,180	35,643,200	35,287,480	37,176,280	36,196,180
24,066,330	22,361,040	22,051,230	22,033,950	23,229,630	22,284,030
69,146,360	62,744,080	60,040,120	59,902,760	64,787,000	61,168,880
41,686,800	39,242,700	37,297,320	38,215,560	40,549,140	38,428,620
119,647,840	110,898,240	101,932,960	101,807,600	112,202,960	105,218,720
311,116,345	**288,464,345**	**272,950,400**	**272,596,150**	**294,097,500**	**279,345,505**

3/8/2013	3/15/2013	3/22/2013	3/29/2013	4/5/2013	4/12/2013
13	13	13	12	13	13
4	3	3	3	3	3
40	37	36	35	37	36
24	22	22	22	23	22
69	63	60	60	65	61
42	39	37	38	41	38
120	111	102	102	112	105
311	**288**	**273**	**273**	**294**	**279**

2013/04/19 EUTRx	2013/04/26 EUTRx	2013/05/03 EUTRx	2013/05/10 EUTRx	2013/05/17 EUTRx
7,248,633	7,378,376	7,960,202	7,591,448	7,283,133
1,219,931	1,230,749	1,297,032	1,245,752	1,237,341
221,863	221,743	243,182	236,717	228,184
1,751,426	1,759,156	1,877,871	1,838,489	1,783,506
736,584	742,974	790,780	760,706	745,344
1,457,311	1,514,307	1,645,401	1,547,612	1,454,076
622,198	633,976	681,333	661,094	621,112
1,239,320	1,275,471	1,424,066	1,301,078	1,213,570
7,249,798	**7,379,028**	**7,960,361**	**7,591,535**	**7,283,970**

12,199,310	12,307,490	12,970,320	12,457,520	12,373,410
3,327,945	3,326,145	3,647,730	3,550,755	3,422,760
35,028,520	35,183,120	37,557,420	36,769,780	35,670,120
22,097,520	22,289,220	23,723,400	22,821,180	22,360,320
58,292,440	60,572,280	65,816,040	61,904,480	58,163,040
37,331,880	38,038,560	40,879,980	39,665,640	37,266,720
99,145,600	102,037,680	113,925,280	104,086,240	97,085,600
267,423,215	**273,754,495**	**298,520,170**	**281,255,595**	**266,341,970**

4/19/2013	4/26/2013	5/3/2013	5/10/2013	5/17/2013
12	12	13	12	12
3	3	4	4	3
35	35	38	37	36
22	22	24	23	22
58	61	66	62	58
37	38	41	40	37
99	102	114	104	97
267	**274**	**299**	**281**	**266**


Total Weekly OxyContin - M
Millions of MG
400
350
300
250
200
150
100
50
4/8/2011
5/8/2011
6/8/2011
7/8/2011
8/8/2011
9/8/2011
10/8/2011
11/8/2011
12/8/2011
1/8/2012
2/8/2012
3/8/2012
4/8/2012
5/8/2012


Total Weekly OxyContin by Str
Millions of MG
180
160
140
120
100
80
60
40
20
4/8/2011
5/8/2011
6/8/2011
7/8/2011
8/8/2011
9/8/2011
10/8/2011
11/8/2011
12/8/2011
1/8/2012
2/8/2012
3/8/2012
4/8/2012
5/8/2012
6/8/2012


ength - Millions of MG
10MG
15MG
20MG
30MG
40MG
60MG
80MG
8/8/2012
9/8/2012
10/8/2012
11/8/2012
12/8/2012
1/8/2013
2/8/2013
3/8/2013
4/8/2013
5/8/2013
6/8/2013

OxyContin Units and Kg Dispensed
IMS Health NPA
numbers are absolute. Retail pharmacies, mail order and LTC

Product	2011/04/08 EUTRx	2011/04/15 EUTRx	2011/04/22 EUTRx	2011/04/29 EUTRx
OXYCONTIN 01/1996 PUF	9,245,201	8,798,770	8,573,636	8,811,087
10MG	1,478,660	1,427,631	1,390,912	1,405,432
15MG	183,269	180,224	173,573	179,380
20MG	2,290,945	2,192,332	2,165,596	2,193,475
30MG	692,907	673,958	647,518	666,744
40MG	2,055,364	1,943,620	1,899,504	1,960,507
60MG	671,650	658,988	610,461	638,010
80MG	1,872,406	1,722,017	1,686,072	1,767,539
Grand Total	**9,245,201**	**8,798,770**	**8,573,636**	**8,811,087**

Kg Dispensed

OXYCONTIN 01/1996 PUF				
10MG	14.8	14.3	13.9	14.1
15MG	2.7	2.7	2.6	2.7
20MG	45.8	43.8	43.3	43.9
30MG	20.8	20.2	19.4	20.0
40MG	82.2	77.7	76.0	78.4
60MG	40.3	39.5	36.6	38.3
80MG	149.8	137.8	134.9	141.4
Grand Total	**356.4**	**336.1**	**326.7**	**338.7**

Weekly Kg Dispensed Budget	**4-Jan-13**	**11-Jan-13**	**18-Jan-13**	**25-Jan-13**
10mg	12	13	13	13
15mg	3	4	3	3
20mg	38	39	39	37
30mg	24	25	24	23
40mg	65	69	66	62
60mg	43	45	44	41
80mg	119	124	119	111
Total	**306**	**318**	**307**	**291**

2011/05/06 EUTRx	2011/05/13 EUTRx	2011/05/20 EUTRx	2011/05/27 EUTRx	2011/06/03 EUTRx	2011/06/10 EUTRx
9,501,374	8,741,359	8,573,294	9,026,667	8,430,496	8,792,965
1,487,471	1,400,215	1,390,618	1,450,473	1,311,696	1,431,988
185,164	181,782	178,413	184,192	166,081	181,190
2,391,478	2,199,539	2,152,247	2,232,569	2,096,801	2,197,315
717,131	661,119	661,896	689,695	650,666	677,241
2,110,498	1,935,334	1,891,439	2,010,862	1,887,654	1,930,916
700,016	634,357	629,136	664,006	627,137	649,340
1,909,616	1,729,013	1,669,545	1,794,870	1,690,461	1,724,975
9,501,374	**8,741,359**	**8,573,294**	**9,026,667**	**8,430,496**	**8,792,965**

14.9	14.0	13.9	14.5	13.1	14.3
2.8	2.7	2.7	2.8	2.5	2.7
47.8	44.0	43.0	44.7	41.9	43.9
21.5	19.8	19.9	20.7	19.5	20.3
84.4	77.4	75.7	80.4	75.5	77.2
42.0	38.1	37.7	39.8	37.6	39.0
152.8	138.3	133.6	143.6	135.2	138.0
366.2	**334.3**	**326.5**	**346.5**	**325.4**	**335.5**

1-Feb-13	8-Feb-13	15-Feb-13	22-Feb-13	1-Mar-13	8-Mar-13
13	13	12	12	13	13
3	3	3	3	4	3
38	37	37	35	40	39
24	24	23	23	25	24
64	65	63	60	70	67
42	42	42	39	47	44
117	117	113	109	128	124
301	**300**	**293**	**282**	**327**	**316**

2011/06/17 EUTRx	2011/06/24 EUTRx	2011/07/01 EUTRx	2011/07/08 EUTRx	2011/07/15 EUTRx	2011/07/22 EUTRx
8,581,589	8,758,691	9,331,763	8,126,682	8,625,729	8,619,338
1,389,967	1,391,937	1,474,790	1,283,213	1,387,431	1,367,678
177,671	180,557	189,408	170,738	183,608	182,874
2,157,000	2,161,652	2,351,092	2,026,960	2,159,950	2,143,410
673,071	680,089	726,907	641,157	682,731	672,123
1,882,461	1,953,240	2,021,413	1,795,202	1,887,344	1,921,136
618,362	650,976	683,878	604,158	645,302	634,734
1,683,057	1,740,240	1,884,275	1,605,254	1,679,363	1,697,383
8,581,589	**8,758,691**	**9,331,763**	**8,126,682**	**8,625,729**	**8,619,338**

13.9	13.9	14.7	12.8	13.9	13.7
2.7	2.7	2.8	2.6	2.8	2.7
43.1	43.2	47.0	40.5	43.2	42.9
20.2	20.4	21.8	19.2	20.5	20.2
75.3	78.1	80.9	71.8	75.5	76.8
37.1	39.1	41.0	36.2	38.7	38.1
134.6	139.2	150.7	128.4	134.3	135.8
326.9	**336.7**	**359.0**	**311.6**	**328.9**	**330.2**

15-Mar-13	22-Mar-13	29-Mar-13	5-Apr-13	12-Apr-13	19-Apr-13
13	12	12	14	13	13
3	3	3	4	4	4
37	36	37	41	39	39
24	23	24	25	24	25
65	62	63	72	67	67
42	41	43	47	44	44
115	111	114	130	119	120
299	**289**	**297**	**333**	**311**	**311**

2011/07/29 EUTRx	2011/08/05 EUTRx	2011/08/12 EUTRx	2011/08/19 EUTRx	2011/08/26 EUTRx	2011/09/02 EUTRx
8,639,239	8,539,432	8,432,171	8,561,895	8,586,953	8,700,800
1,389,900	1,351,652	1,352,449	1,347,382	1,361,439	1,415,584
176,085	182,481	181,231	186,212	186,411	178,550
2,123,617	2,112,497	2,094,035	2,110,746	2,107,274	2,147,515
667,672	674,468	661,561	678,745	683,683	676,670
1,936,667	1,936,788	1,887,976	1,937,511	1,935,523	1,953,056
645,107	634,667	627,548	634,527	640,278	646,482
1,700,191	1,646,879	1,627,371	1,666,772	1,672,345	1,682,943
8,639,239	**8,539,432**	**8,432,171**	**8,561,895**	**8,586,953**	**8,700,800**

13.9	13.5	13.5	13.5	13.6	14.2
2.6	2.7	2.7	2.8	2.8	2.7
42.5	42.2	41.9	42.2	42.1	43.0
20.0	20.2	19.8	20.4	20.5	20.3
77.5	77.5	75.5	77.5	77.4	78.1
38.7	38.1	37.7	38.1	38.4	38.8
136.0	131.8	130.2	133.3	133.8	134.6
331.2	**326.0**	**321.3**	**327.8**	**328.7**	**331.6**

26-Apr-13	3-May-13	10-May-13	17-May-13	24-May-13	31-May-13
13	14	13	13	13	12
3	4	3	3	3	3
40	40	38	38	39	35
25	25	24	24	25	22
67	72	65	65	67	62
46	46	42	43	45	41
121	129	118	115	122	114
316	**330**	**303**	**301**	**314**	**289**

2011/09/09 EUTRx	2011/09/16 EUTRx	2011/09/23 EUTRx	2011/09/30 EUTRx	2011/10/07 EUTRx	2011/10/14 EUTRx
7,939,083	8,695,016	8,573,455	8,609,904	8,575,899	8,500,737
1,229,109	1,381,856	1,381,121	1,373,109	1,368,633	1,352,102
175,024	189,614	186,948	190,182	190,450	185,702
1,967,166	2,144,689	2,112,236	2,135,620	2,105,859	2,086,422
636,604	677,628	673,665	691,553	689,623	676,394
1,785,643	1,965,443	1,913,663	1,915,038	1,921,786	1,904,402
590,123	642,338	635,168	644,614	645,360	634,044
1,555,414	1,693,448	1,670,654	1,659,788	1,654,188	1,661,671
7,939,083	**8,695,016**	**8,573,455**	**8,609,904**	**8,575,899**	**8,500,737**

12.3	13.8	13.8	13.7	13.7	13.5
2.6	2.8	2.8	2.9	2.9	2.8
39.3	42.9	42.2	42.7	42.1	41.7
19.1	20.3	20.2	20.7	20.7	20.3
71.4	78.6	76.5	76.6	76.9	76.2
35.4	38.5	38.1	38.7	38.7	38.0
124.4	135.5	133.7	132.8	132.3	132.9
304.6	**332.5**	**327.4**	**328.1**	**327.3**	**325.5**

7-Jun-13	14-Jun-13	21-Jun-13	28-Jun-13	5-Jul-13	12-Jul-13
13	13	13	13	13	13
3	3	3	3	3	4
38	37	37	38	38	40
24	23	24	24	24	24
66	63	64	64	68	67
43	42	43	43	44	44
120	113	117	117	122	121
307	**294**	**300**	**301**	**312**	**313**

2011/10/21 EUTRx	2011/10/28 EUTRx	2011/11/04 EUTRx	2011/11/11 EUTRx	2011/11/18 EUTRx	2011/11/25 EUTRx
8,433,590	8,378,797	8,364,566	8,419,830	8,534,146	7,488,971
1,374,237	1,356,864	1,366,208	1,351,490	1,383,921	1,208,518
188,811	185,808	181,204	187,251	191,323	170,857
2,056,120	2,058,621	2,052,221	2,068,524	2,087,144	1,824,031
676,712	681,559	688,050	676,655	699,901	607,197
1,867,511	1,875,802	1,843,814	1,868,754	1,888,589	1,654,741
638,311	644,857	630,014	630,742	663,539	578,161
1,631,888	1,575,286	1,603,055	1,636,414	1,619,729	1,445,466
8,433,590	**8,378,797**	**8,364,566**	**8,419,830**	**8,534,146**	**7,488,971**

13.7	13.6	13.7	13.5	13.8	12.1
2.8	2.8	2.7	2.8	2.9	2.6
41.1	41.2	41.0	41.4	41.7	36.5
20.3	20.4	20.6	20.3	21.0	18.2
74.7	75.0	73.8	74.8	75.5	66.2
38.3	38.7	37.8	37.8	39.8	34.7
130.6	126.0	128.2	130.9	129.6	115.6
321.5	**317.7**	**317.9**	**321.5**	**324.4**	**285.9**

19-Jul-13	26-Jul-13	2-Aug-13	9-Aug-13	16-Aug-13	23-Aug-13
13	13	13	13	14	14
4	3	3	3	3	3
39	38	40	39	40	40
25	24	23	23	24	23
67	65	71	70	70	69
44	44	42	41	42	43
121	118	114	115	117	115
313	**306**	**307**	**305**	**310**	**306**

2011/12/02 EUTRx	2011/12/09 EUTRx	2011/12/16 EUTRx	2011/12/23 EUTRx	2011/12/30 EUTRx	2012/01/06 EUTRx
9,056,397	8,496,159	8,633,759	8,783,921	7,373,644	8,063,746
1,439,090	1,374,240	1,423,190	1,451,921	1,158,790	1,282,119
193,397	201,119	197,707	198,672	161,569	192,487
2,213,081	2,074,192	2,094,123	2,151,605	1,806,349	1,971,363
756,778	705,047	714,547	714,302	614,514	680,416
2,012,438	1,871,406	1,903,644	1,932,693	1,627,130	1,771,423
699,049	634,440	666,005	672,301	570,244	618,521
1,742,564	1,635,715	1,634,543	1,662,427	1,434,977	1,547,417
9,056,397	**8,496,159**	**8,633,759**	**8,783,921**	**7,373,644**	**8,063,746**

14.4	13.7	14.2	14.5	11.6	12.8
2.9	3.0	3.0	3.0	2.4	2.9
44.3	41.5	41.9	43.0	36.1	39.4
22.7	21.2	21.4	21.4	18.4	20.4
80.5	74.9	76.1	77.3	65.1	70.9
41.9	38.1	40.0	40.3	34.2	37.1
139.4	130.9	130.8	133.0	114.8	123.8
346.1	**323.2**	**327.4**	**332.6**	**282.7**	**307.3**

30-Aug-13	6-Sep-13	13-Sep-13	20-Sep-13	27-Sep-13	4-Oct-13
12	11	12	12	13	13
3	3	4	3	4	3
37	36	37	37	37	39
24	24	25	24	25	24
63	61	63	61	63	67
44	43	45	45	44	43
121	121	122	121	119	123
306	**298**	**307**	**303**	**304**	**312**

2012/01/13 EUTRx	2012/01/20 EUTRx	2012/01/27 EUTRx	2012/02/03 EUTRx	2012/02/10 EUTRx	2012/02/17 EUTRx
8,469,490	8,227,738	7,838,360	8,386,620	8,396,362	8,231,779
1,365,723	1,332,905	1,291,466	1,357,246	1,377,064	1,329,446
198,357	193,226	188,187	194,964	200,601	198,681
2,048,198	2,015,901	1,934,038	2,031,761	2,033,049	2,000,787
708,312	692,645	670,328	712,690	708,927	684,732
1,886,140	1,796,545	1,695,144	1,830,911	1,832,152	1,809,806
650,576	636,444	603,778	654,117	641,919	649,434
1,612,184	1,560,072	1,455,419	1,604,931	1,602,650	1,558,893
8,469,490	**8,227,738**	**7,838,360**	**8,386,620**	**8,396,362**	**8,231,779**

13.7	13.3	12.9	13.6	13.8	13.3
3.0	2.9	2.8	2.9	3.0	3.0
41.0	40.3	38.7	40.6	40.7	40.0
21.2	20.8	20.1	21.4	21.3	20.5
75.4	71.9	67.8	73.2	73.3	72.4
39.0	38.2	36.2	39.2	38.5	39.0
129.0	124.8	116.4	128.4	128.2	124.7
322.3	**312.2**	**295.0**	**319.4**	**318.7**	**312.9**

11-Oct-13	18-Oct-13	25-Oct-13	1-Nov-13	8-Nov-13	15-Nov-13
13	13	13	12	13	13
3	3	3	3	3	3
39	39	39	38	38	37
24	23	24	23	24	23
67	67	67	66	65	64
42	43	42	40	43	43
116	117	117	113	119	117
304	**305**	**305**	**295**	**305**	**300**

2012/02/24 EUTRx	2012/03/02 EUTRx	2012/03/09 EUTRx	2012/03/16 EUTRx	2012/03/23 EUTRx	2012/03/30 EUTRx
7,919,014	8,894,547	8,618,055	8,238,496	7,986,979	8,159,404
1,281,004	1,412,394	1,385,138	1,339,355	1,311,232	1,322,454
189,318	212,086	207,306	205,175	192,796	191,879
1,926,520	2,146,918	2,067,955	1,977,236	1,948,165	1,990,219
683,706	760,671	737,152	714,539	692,787	707,556
1,720,587	1,948,642	1,875,887	1,805,137	1,719,569	1,775,618
614,941	713,838	680,668	645,508	628,753	658,812
1,502,938	1,699,998	1,663,949	1,551,546	1,493,677	1,512,866
7,919,014	**8,894,547**	**8,618,055**	**8,238,496**	**7,986,979**	**8,159,404**

12.8	14.1	13.9	13.4	13.1	13.2
2.8	3.2	3.1	3.1	2.9	2.9
38.5	42.9	41.4	39.5	39.0	39.8
20.5	22.8	22.1	21.4	20.8	21.2
68.8	77.9	75.0	72.2	68.8	71.0
36.9	42.8	40.8	38.7	37.7	39.5
120.2	136.0	133.1	124.1	119.5	121.0
300.6	**339.8**	**329.4**	**312.5**	**301.8**	**308.7**

22-Nov-13	29-Nov-13	6-Dec-13	13-Dec-13	20-Dec-13	27-Dec-13
11	13	13	12	13	10
3	3	3	3	4	3
34	38	38	36	38	31
21	24	25	24	25	20
58	65	64	61	64	55
38	44	44	43	44	37
105	119	125	116	122	102
271	**305**	**312**	**296**	**310**	**258**

2012/04/06 EUTRx	2012/04/13 EUTRx	2012/04/20 EUTRx	2012/04/27 EUTRx	2012/05/04 EUTRx	2012/05/11 EUTRx
8,537,435	8,120,425	8,115,483	8,255,699	8,770,748	8,152,744
1,351,771	1,330,947	1,313,770	1,351,314	1,392,200	1,321,258
205,525	202,082	208,611	198,534	216,422	204,934
2,072,855	1,979,017	1,975,352	1,991,462	2,102,921	1,983,488
741,174	706,575	728,585	741,427	783,483	718,178
1,857,322	1,758,891	1,741,258	1,776,930	1,913,749	1,758,181
685,446	638,319	649,055	657,771	712,984	648,911
1,623,342	1,504,594	1,498,852	1,538,261	1,648,989	1,517,794
8,537,435	**8,120,425**	**8,115,483**	**8,255,699**	**8,770,748**	**8,152,744**

13.5	13.3	13.1	13.5	13.9	13.2
3.1	3.0	3.1	3.0	3.2	3.1
41.5	39.6	39.5	39.8	42.1	39.7
22.2	21.2	21.9	22.2	23.5	21.5
74.3	70.4	69.7	71.1	76.5	70.3
41.1	38.3	38.9	39.5	42.8	38.9
129.9	120.4	119.9	123.1	131.9	121.4
325.6	**306.1**	**306.1**	**312.2**	**334.0**	**308.2**

665
176
1,969
1,239
3,389
2,232
6,132
15,801

2012/05/18 EUTRx	2012/05/25 EUTRx	2012/06/01 EUTRx	2012/06/08 EUTRx	2012/06/15 EUTRx	2012/06/22 EUTRx
8,160,756	8,436,049	7,779,099	8,429,255	8,091,145	8,214,130
1,319,504	1,359,946	1,212,462	1,367,916	1,321,120	1,325,251
210,277	215,693	195,602	216,327	208,959	211,049
1,989,425	2,027,346	1,882,797	2,043,311	1,978,591	1,964,917
738,781	771,686	698,729	751,715	736,161	743,060
1,759,297	1,788,154	1,683,841	1,828,265	1,726,539	1,764,927
657,251	680,108	641,045	664,304	653,013	675,115
1,486,221	1,593,116	1,464,623	1,557,417	1,466,762	1,529,811
8,160,756	**8,436,049**	**7,779,099**	**8,429,255**	**8,091,145**	**8,214,130**

13.2	13.6	12.1	13.7	13.2	13.3
3.2	3.2	2.9	3.2	3.1	3.2
39.8	40.5	37.7	40.9	39.6	39.3
22.2	23.2	21.0	22.6	22.1	22.3
70.4	71.5	67.4	73.1	69.1	70.6
39.4	40.8	38.5	39.9	39.2	40.5
118.9	127.4	117.2	124.6	117.3	122.4
307.0	**320.3**	**296.7**	**317.9**	**303.6**	**311.5**

2012/06/29 EUTRx	2012/07/06 EUTRx	2012/07/13 EUTRx	2012/07/20 EUTRx	2012/07/27 EUTRx	2012/08/03 EUTRx
8,246,084	8,065,352	8,208,806	8,219,836	8,049,688	8,109,693
1,331,557	1,247,785	1,333,196	1,320,775	1,293,848	1,294,651
207,192	205,022	220,230	213,404	211,946	225,106
2,009,525	1,917,797	1,993,330	1,981,127	1,931,675	1,958,511
754,691	740,361	746,328	753,942	745,686	752,622
1,762,116	1,774,739	1,743,741	1,752,346	1,710,773	1,726,301
669,984	668,827	674,817	680,461	677,459	674,364
1,511,019	1,510,821	1,497,164	1,517,781	1,478,301	1,478,138
8,246,084	**8,065,352**	**8,208,806**	**8,219,836**	**8,049,688**	**8,109,693**

13.3	12.5	13.3	13.2	12.9	12.9
3.1	3.1	3.3	3.2	3.2	3.4
40.2	38.4	39.9	39.6	38.6	39.2
22.6	22.2	22.4	22.6	22.4	22.6
70.5	71.0	69.7	70.1	68.4	69.1
40.2	40.1	40.5	40.8	40.6	40.5
120.9	120.9	119.8	121.4	118.3	118.3
310.8	**308.1**	**308.9**	**311.0**	**304.5**	**305.8**

2012/08/10 EUTRx	2012/08/17 EUTRx	2012/08/24 EUTRx	2012/08/31 EUTRx	2012/09/07 EUTRx	2012/09/14 EUTRx
7,974,578	8,149,473	8,080,157	8,197,503	7,825,427	8,192,273
1,273,489	1,301,949	1,311,403	1,335,840	1,244,933	1,325,606
213,871	222,794	209,361	223,269	208,040	225,574
1,911,171	1,962,404	1,947,527	1,977,330	1,874,717	1,967,788
734,455	769,565	759,252	761,468	716,018	767,384
1,723,897	1,724,155	1,701,861	1,744,427	1,670,009	1,738,777
657,871	668,116	680,407	674,342	647,370	682,306
1,459,824	1,500,490	1,470,346	1,480,827	1,464,340	1,484,838
7,974,578	**8,149,473**	**8,080,157**	**8,197,503**	**7,825,427**	**8,192,273**

12.7	13.0	13.1	13.4	12.4	13.3
3.2	3.3	3.1	3.3	3.1	3.4
38.2	39.2	39.0	39.5	37.5	39.4
22.0	23.1	22.8	22.8	21.5	23.0
69.0	69.0	68.1	69.8	66.8	69.6
39.5	40.1	40.8	40.5	38.8	40.9
116.8	120.0	117.6	118.5	117.1	118.8
301.4	**307.8**	**304.5**	**307.8**	**297.3**	**308.3**

2012/09/21 EUTRx	2012/09/28 EUTRx	2012/10/05 EUTRx	2012/10/12 EUTRx	2012/10/19 EUTRx	2012/10/26 EUTRx
8,136,521	8,213,947	8,361,496	7,998,840	8,124,850	8,050,027
1,325,313	1,344,176	1,374,362	1,303,257	1,338,856	1,331,872
225,149	236,966	226,804	220,912	226,671	225,216
1,961,098	1,998,014	1,997,873	1,923,789	1,961,642	1,935,649
755,777	773,138	775,524	760,819	760,116	757,949
1,707,833	1,745,287	1,764,524	1,682,430	1,686,399	1,684,899
680,595	670,088	688,895	666,696	679,457	661,482
1,480,756	1,446,278	1,533,514	1,440,937	1,471,709	1,452,960
8,136,521	**8,213,947**	**8,361,496**	**7,998,840**	**8,124,850**	**8,050,027**

13.3	13.4	13.7	13.0	13.4	13.3
3.4	3.6	3.4	3.3	3.4	3.4
39.2	40.0	40.0	38.5	39.2	38.7
22.7	23.2	23.3	22.8	22.8	22.7
68.3	69.8	70.6	67.3	67.5	67.4
40.8	40.2	41.3	40.0	40.8	39.7
118.5	115.7	122.7	115.3	117.7	116.2
306.1	**305.9**	**315.0**	**300.2**	**304.8**	**301.5**

2012/11/02 EUTRx	2012/11/09 EUTRx	2012/11/16 EUTRx	2012/11/23 EUTRx	2012/11/30 EUTRx	2012/12/07 EUTRx
7,884,768	8,339,872	8,169,418	7,392,202	8,446,015	8,599,666
1,297,235	1,379,991	1,366,641	1,217,989	1,419,962	1,401,942
222,271	238,223	233,136	208,902	240,382	240,681
1,904,322	2,009,064	1,937,501	1,784,409	2,032,073	2,073,229
750,263	789,110	769,893	707,008	805,363	822,187
1,659,852	1,725,846	1,696,914	1,541,620	1,760,216	1,790,300
645,429	709,182	685,531	606,318	704,753	719,867
1,405,396	1,488,456	1,479,802	1,325,956	1,483,266	1,551,460
7,884,768	**8,339,872**	**8,169,418**	**7,392,202**	**8,446,015**	**8,599,666**

13.0	13.8	13.7	12.2	14.2	14.0
3.3	3.6	3.5	3.1	3.6	3.6
38.1	40.2	38.8	35.7	40.6	41.5
22.5	23.7	23.1	21.2	24.2	24.7
66.4	69.0	67.9	61.7	70.4	71.6
38.7	42.6	41.1	36.4	42.3	43.2
112.4	119.1	118.4	106.1	118.7	124.1
294.5	**311.9**	**306.4**	**276.3**	**314.0**	**322.7**

2012/12/14 EUTRx	2012/12/21 EUTRx	2012/12/28 EUTRx	2013/01/04 EUTRx	2013/01/11 EUTRx	2013/01/18 EUTRx
8,234,376	8,591,485	6,903,075	7,648,883	8,143,336	8,052,086
1,356,149	1,424,601	1,108,913	1,228,344	1,319,309	1,327,537
243,353	248,169	193,069	210,753	240,570	230,249
1,979,123	2,070,155	1,643,246	1,823,867	1,946,375	1,919,911
792,021	825,149	650,731	743,527	776,260	779,645
1,700,905	1,774,350	1,446,706	1,598,914	1,712,556	1,647,897
692,300	708,922	594,161	657,326	691,962	686,765
1,470,525	1,540,139	1,266,249	1,386,152	1,456,304	1,460,082
8,234,376	**8,591,485**	**6,903,075**	**7,648,883**	**8,143,336**	**8,052,086**

13.6	14.2	11.1	12.3	13.2	13.3
3.7	3.7	2.9	3.2	3.6	3.5
39.6	41.4	32.9	36.5	38.9	38.4
23.8	24.8	19.5	22.3	23.3	23.4
68.0	71.0	57.9	64.0	68.5	65.9
41.5	42.5	35.6	39.4	41.5	41.2
117.6	123.2	101.3	110.9	116.5	116.8
307.8	**320.8**	**261.2**	**288.5**	**305.5**	**302.4**

2013/01/25 EUTRx	2013/02/01 EUTRx	2013/02/08 EUTRx	2013/02/15 EUTRx	2013/02/22 EUTRx	2013/03/01 EUTRx
7,200,338	7,683,391	8,162,552	7,879,116	7,253,340	8,096,634
1,204,426	1,250,185	1,323,987	1,311,402	1,234,444	1,313,174
218,947	219,310	238,577	226,095	216,995	241,102
1,728,049	1,846,356	1,923,103	1,877,138	1,744,529	1,938,072
690,742	741,895	806,799	748,911	723,181	801,071
1,479,337	1,592,447	1,685,464	1,640,730	1,479,375	1,662,896
610,193	658,830	706,251	655,037	609,224	701,244
1,268,644	1,374,368	1,478,371	1,419,803	1,245,592	1,439,075
7,200,338	**7,683,391**	**8,162,552**	**7,879,116**	**7,253,340**	**8,096,634**

12.0	12.5	13.2	13.1	12.3	13.1
3.3	3.3	3.6	3.4	3.3	3.6
34.6	36.9	38.5	37.5	34.9	38.8
20.7	22.3	24.2	22.5	21.7	24.0
59.2	63.7	67.4	65.6	59.2	66.5
36.6	39.5	42.4	39.3	36.6	42.1
101.5	109.9	118.3	113.6	99.6	115.1
267.9	**288.2**	**307.5**	**295.0**	**267.6**	**303.3**

2013/03/08 EUTRx	2013/03/15 EUTRx	2013/03/22 EUTRx	2013/03/29 EUTRx	2013/04/05 EUTRx	2013/04/12 EUTRx
8,277,776	7,711,915	7,398,795	7,332,806	7,831,508	7,526,041
1,334,871	1,279,468	1,257,307	1,210,871	1,270,528	1,255,679
242,567	228,095	227,500	216,006	229,814	232,819
1,979,090	1,850,109	1,782,160	1,764,374	1,858,814	1,809,809
802,211	745,368	735,041	734,465	774,321	742,801
1,728,659	1,568,602	1,501,003	1,497,569	1,619,675	1,529,222
694,780	654,045	621,622	636,926	675,819	640,477
1,495,598	1,386,228	1,274,162	1,272,595	1,402,537	1,315,234
8,277,776	**7,711,915**	**7,398,795**	**7,332,806**	**7,831,508**	**7,526,041**

13.3	12.8	12.6	12.1	12.7	12.6
3.6	3.4	3.4	3.2	3.4	3.5
39.6	37.0	35.6	35.3	37.2	36.2
24.1	22.4	22.1	22.0	23.2	22.3
69.1	62.7	60.0	59.9	64.8	61.2
41.7	39.2	37.3	38.2	40.5	38.4
119.6	110.9	101.9	101.8	112.2	105.2
311.1	**288.5**	**273.0**	**272.6**	**294.1**	**279.3**

2013/04/19 EUTRx	2013/04/26 EUTRx	2013/05/03 EUTRx	2013/05/10 EUTRx	2013/05/17 EUTRx
7,248,633	7,378,376	7,960,202	7,591,448	7,283,133
1,219,931	1,230,749	1,297,032	1,245,752	1,237,341
221,863	221,743	243,182	236,717	228,184
1,751,426	1,759,156	1,877,871	1,838,489	1,783,506
736,584	742,974	790,780	760,706	745,344
1,457,311	1,514,307	1,645,401	1,547,612	1,454,076
622,198	633,976	681,333	661,094	621,112
1,239,320	1,275,471	1,424,066	1,301,078	1,213,570
7,249,798	**7,379,028**	**7,960,361**	**7,591,535**	**7,283,970**

12.2	12.3	13.0	12.5	12.4
3.3	3.3	3.6	3.6	3.4
35.0	35.2	37.6	36.8	35.7
22.1	22.3	23.7	22.8	22.4
58.3	60.6	65.8	61.9	58.2
37.3	38.0	40.9	39.7	37.3
99.1	102.0	113.9	104.1	97.1
267.4	**273.8**	**298.5**	**281.3**	**266.3**

Kg Dispensed Actual V Budget

	4-Jan-13	11-Jan-13	18-Jan-13	25-Jan-13	1-Feb-13	8-Feb-13
Actual Weekly Kg Dispensed	288.5	305.5	302.4	267.9	288.2	307.5
Budget Kg Dispened	305.5	318.2	307.3	290.5	300.9	300.1
Weekly Difference	(17.02)	(12.69)	(4.87)	(22.62)	(12.77)	7.46
Weekly % variance	-5.6%	-4.0%	-1.6%	-7.8%	-4.2%	2.5%
YTD Actual Total	288.5	594.06	896.50	1,164.39	1,452.54	1,760.09
YTD Budget Total	305.5	623.76	931.08	1,221.59	1,522.51	1,822.60
YTD Total Difference	(17.02)	(29.71)	(34.58)	(57.20)	(69.97)	(62.51)
YTD % Variance	-5.6%	-4.8%	-3.7%	-4.7%	-4.6%	-3.4%
2013 Kg Disp Goal	15,801.3					
YTD Actual	5,731.8	<- change each week				
YTD Budget	6,129.4	<- change each week				
Actual YTD % of 2013 Goal	36.3%					
Budget YTD % of 2013 Goal	38.8%					



15-Feb-13	22-Feb-13	1-Mar-13	8-Mar-13	15-Mar-13	22-Mar-13	29-Mar-13	5-Apr-13	12-Apr-13
295.0	267.6	303.3	311.1	288.5	273.0	272.6	294.1	279.3
293.3	281.8	326.8	315.6	299.0	289.0	297.0	332.5	310.8
1.72	(14.21)	(23.50)	(4.48)	(10.54)	(16.04)	(24.43)	(38.44)	(31.45)
0.6%	-5.0%	-7.2%	-1.4%	-3.5%	-5.6%	-8.2%	-11.6%	-10.1%
2,055.12	2,322.68	2,625.94	2,937.06	3,225.52	3,498.47	3,771.07	4,065.17	4,344.51
2,115.91	2,397.68	2,724.44	3,040.03	3,339.04	3,628.02	3,925.05	4,257.58	4,568.38
(60.78)	(75.00)	(98.50)	(102.97)	(113.51)	(129.55)	(153.98)	(192.42)	(223.87)
-2.9%	-3.1%	-3.6%	-3.4%	-3.4%	-3.6%	-3.9%	-4.5%	-4.9%



19-Apr-13	26-Apr-13	3-May-13	10-May-13	17-May-13	24-May-13	31-May-13	7-Jun-13	14-Jun-13
267.4	273.8	298.5	281.3	266.3				
311.3	315.9	329.9	302.9	301.0				
(43.90)	(42.17)	(31.37)	(21.65)	(34.64)				
-14.1%	-13.3%	-9.5%	-7.1%	-11.5%				
4,611.94	4,885.69	5,184.21	5,465.47	5,731.81				
4,879.70	5,195.63	5,525.52	5,828.43	6,129.41				
(267.77)	(309.94)	(341.31)	(362.96)	(397.60)				
-5.5%	-6.0%	-6.2%	-6.2%	-6.5%				

Copy formulae above each week. Actual Data entered in the 'Kg Weekly OxyContin'

21-Jun-13	28-Jun-13	5-Jul-13	12-Jul-13	19-Jul-13	26-Jul-13	2-Aug-13	9-Aug-13	16-Aug-13

worksheet

23-Aug-13	30-Aug-13	6-Sep-13	13-Sep-13	20-Sep-13	27-Sep-13	4-Oct-13	11-Oct-13	18-Oct-13

25-Oct-13	1-Nov-13	8-Nov-13	15-Nov-13	22-Nov-13	29-Nov-13	6-Dec-13	13-Dec-13	20-Dec-13

27-Dec-13

Message

From: [redacted]

Sent: 5/30/2013 10:48:07 AM

To: Sackler, Dr Raymond R [redacted] Sackler, Beverly [redacted] Sackler, Dame Theresa [redacted] Sackler, Dr Richard [redacted] Sackler Lefcourt, Ilene [redacted] Sackler, Dr Kathe [redacted] Sackler, Jonathan [redacted] Sackler Hunt, Samantha [redacted] Sackler, Mortimer D.A. [redacted] Sackler, David [redacted] Boer, Peter [redacted] Boer, Peter [redacted] Lewent, Judy [redacted] Pickett, Cecil [redacted] Costa, Paulo [redacted] Snyderman, Ralph [redacted]

CC: Roncalli, Anthony [redacted] Baker, Stuart D. [redacted] Mahony, Edward [redacted] Gasdia, Russell [redacted] Stewart, John H. (US) [redacted] Landau, Dr. Craig [redacted] Rosen, David (Sales and Marketing [redacted]

BCC: Stewart, John H. (US) [redacted]

Subject: FW: Board Presentation Materials for Budget Meeting June 6th

Attachments: RHYTHM BOARD JUNE 7 2013.pptx; 5-29-13 FDA Opana ER Decision (FINAL).pptx; 2013 10-Year Plan Presentation at MidYear 201300529 FINAL.PPTX; June 2013 Mid-Yr Presentation 5.25.pptx; Sales and Budget Update June 2013.pptx

Colleagues:

On behalf of John Stewart, attached please find the presentations for the US Agenda scheduled for Thursday June 6, 2013. Hard copies of all presentations will be handed out at the Board Meeting as well.

Any questions please feel free to contact John, Ed or myself.

Regards,

[redacted]

From: [redacted]
Sent: Thursday, May 30, 2013 7:24 AM
To: [redacted]
Cc: Stewart, John H. (US); Strassburger, Philip; Gasdia, Russell; [redacted]; Mahony, Edward; [redacted] Rosen, David (Sales and Marketing); [redacted]
Subject: Board Presentation Materials for Budget Meeting June 6th

Tony:

Attached please find the following presentations (and presenters) for the US agenda items at the Budget Meeting next week:

1. **Managed Care** – [redacted]
2. **Sales & Budget Update** – Russ Gasdia/Ed Mahony/David Rosen
3. **US Business Development- Rhythm Pharmaceuticals – Ghrelin Agonist** – [redacted]
4. **10 Year Plan Presentation** – John Stewart/Ed Mahony/David Rosen/Russ Gasdia
5. **FDA Opana ER Decision** – [redacted]

Redacted

Regards,

[redacted]

Rhythm Pharmaceuticals
Boston, MA

RM-131 Ghrelin Agonist in Ph2
for Diabetic Gastroparesis

Mid-year Meeting
Greenwich, June 6, 2013

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Rhythm RM-131 ghrelin agonist for diabetic gastroparesis

- RM-131 s.c. injectable (5 amino acid peptide) ghrelin agonist
- Agonist of Growth Hormone Secretagogue Receptor; gastric motility and stomach emptying
- In a Phase 1B study (N=20), RM-131 demonstrated increased gut motility and improved symptoms in diabetic patients with gastroparesis
- Ph2 study Proof-of-Concept results due in September: (4 week, double-blind, placebo-controlled, parallel groups, N=200)
- Preliminary sales estimate: $500 MM peak sales in U.S.
- Quantitative market research / forecast due June 14, 2013
- NCE patent life through 2024 with possible extensions
- Lifecycle development opportunities: multi-dose injector pen, microneedle patch, refractory GI motility disorders (Parkinson's gastroparesis), etc.

2

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014815

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Approximately 40% or 1.3 MM of Diabetic Gastroparesis Patients Are Treated Annually

Patients suffering from diabetic gastroparesis in the U.S. (2016F)
Percent



- ~10% of the U.S. population is expected to have diabetes in 2016 (30M), of which ~70% are expected to be diagnosed (22M)
- Of the 22M diagnosed diabetics, ~15% are expected to suffer from symptoms of gastroparesis*
- An estimated ~40% of diabetic gastroparesis patients, or 1.3M, are expected to be treated for gastroparesis
- Analysts project the number of treated gastoparesis patients to grow at least 2% to 3% due to the increasing prevalence of diabetes and an increased awareness of gastroparesis

Our high-level estimate of treated patients is on par with Rhythm's estimate of ~1.4M

*Note: * Estimates of the percent of diabetics with gastroparesis range from 11% (Cowen) to 22% (Purdue physician survey)*

Source: American Diabetes Association; Canaccord; CDC; Cowen; Purdue; Temple Digestive Diseases Center; U.S. Census; L.E.K. analysis

4

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014817

Evidence of Unmet Need: Propulsid Case Study

Propulsid's rapid uptake is indicative of the high level of unmet need in refractory GI motility disorders

- Propulsid (cisapride) was approved in 1993 to treat **nocturnal heartburn associated with GERD**
- Within 4 years of launch, Propulsid was a **billion dollar drug** and was growing 3-6% quarter over quarter, selling approximately **7.2 MM TRxs in 1997 in the US**
- In the market research conducted, some physicians indicated that their severe gastroparesis patients were purchasing Propulsid from abroad to treat gastroparesis, indicating the high unmet need in this indication specifically
- Concerns about QT prolongation, especially in children, prompted label changes and the eventual voluntary removal of the drug from the market in 1999

Propulsid Sales (1993-1999)



Propulsid's fast uptake and peak revenue indicate that there is high unmet need in GI disorders

Sources: Company analyst reports/annual reports 1996-2001
Pharmaceuticals: Prescription Update – Industry Report (Dec 29th, 1997), Painewebber, Inc.

5

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014818

Rhythm Clinical Development Timeline with Phase 2b



6

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

U.S. gastroparesis pipeline products May 2013

Compound	Phase	Company	Description	Timing
RM-131	Phase II	Rhythm	● Injectable ghrelin agonist peptide	● Ph2 data Sep 2013
EVK-001	Phase II	Evoke Pharma	● Intranasal metoclopramide spray	● Phase 2 completed in 2011
TZP-102	Phase IIb	Tranzyme	● Oral small molecule ghrelin receptor agonist	● Development discontinued late 2012
GSK 962040	Phase II	GSK	● Oral small molecule, non-peptide motilin receptor agonist	● Phase 2 trial titled "Dose Response of 28 days of dosing of GSK-962040 in Diabetic subjects with Gastroparesis" – Read out 2Q2013
TD-5108	Phase II	Theravance / Alfa Wasserman	● Velusetrag 5-HT4 agonist; Oral	● 32 patient study; primary endpoint: GE time; 12/14 end
IW-9179	Phase I	Ironwood	● Oral guanylate cyclase agonist	● Next-gen after linaclotide ● Ph2 for dyspepsia
Other Drugs in Development				
Anamorelin	Phase III	Helsinn	● Ghrelin agonist	● Anorexia/cachexia in NSCLC
Capromorelin	Phase II	RaQualia/Shire	● Ghrelin agonist ● GH secretagogue	● In development for "GI disorders"
ST-1141	Phase I	Helsinn	● Ghrelin Agonist	● In development for OBD

Sources: Pipeline; Cowen; Company websites; L.E.K. interviews (5 conducted) and analysis; Trinity Partners; Thomson-Pharma

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014820

Rhythm Pharmaceuticals & RM-131

rhythm

- RM-131 licensed from Ipsen in March 2010 for milestones and royalties
- Ipsen holds 17% equity for RM-131 & RM-493*

*RM-493: MC4 receptor agonist for obesity, diabetes, other metabolic disorders

Venture Capital Syndicate

Series A (9/2010)
Total - **$40M**
- Third Rock
- NEA
- MPM Capital

Series B (11/2012)
Total - **$33M**
- Third Rock
- NEA
- MPM Capital
- Pfizer Ventures

- Rhythm plans on splitting into 2 companies for divestiture
  - 1 company holding RM-493
  - 1 company holding RM-131

Deal Target

8

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Redacted

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Redacted

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Redacted

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Redacted

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Redacted

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Redacted

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Redacted

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2013

10-Year Plan

CONFIDENTIAL
June 2013

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Table of Contents

1. Introduction — P. 3
   John H. Stewart
2. Sales — P. 8
   Russ Gasdia
3. Financial Summary — P. 20
   Ed Mahony

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

John H. Stewart

INTRODUCTION

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Introduction

- Objective continues to be to grow and diversify the business, while delivering industry leading profitability
- Continue OxyContin "exclusivity" beyond 2013

  FDA decision of April 16

  - Recognizes that the new formulation is "safer"
  - Strong confirmation of the comprehensive nature of the company's abuse-deterrence testing
  - Further strengthens the company's recognition/reputation as leaders in AD product development
  - Creates significant obstacles for generic AD competitors
  - Projected to add an additional 3 years of exclusivity

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Introduction (cont.)

- Advances the Abuse-Deterrent Strategy
  - FDA now considers AD properties as part of the benefit/risk analysis for opioid products
  - All opioids in development at Purdue have substantial AD properties
  - Political support for AD formulations continues to be strong
  - Working on development of pharmacoeconomic evidence in support of AD formulations

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Introduction (cont.)

- Moving beyond opioid analgesics
  - NCE program with TRPV1 in Phase 2 for OA and PHN
  - NCE program with ORL1 to proceed to dental pain trial
  - LBD pursuing complimentary product opportunities
- Move opportunistically into new therapeutic areas
  - Sleep disorders via Intermezzo has been a major disappointment
  - For treatment of opioid bowel dysfunction via Targiniq
  - Pursuing opportunities in the area of GI motility disorders

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Introduction (cont.)

- Responding to changes in the marketplace
  - Significant anti-opioid activities
  - Pricing pressure from Managed Care Organizations
  - Demand for products with distinct clinical differentiation and demonstrable treatment benefits
  - Difficult to increase size of branded opioid analgesic market
- Focus resources to provide the evidence, outcomes and rational for use of the company's products and services.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Russ Gasdia

SALES

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

10-Year Plan: Gross Sales

Non-Risk Adjusted



	2012 A	2013F	2014	2015	2016	2017	2018	2019	2020	2021	2022
2012's 10-Year Plan	3,168	3,087	3,242	3,738	4,295	4,540	2,805	3,270	2,337		
2013's 10-Year Plan	3,005	2,821	3,044	3,034	3,288	3,347	3,441	3,622	3,621	1,529	1,638

NON-RISK ADJUSTED	$000s
Marketed Products - Gross Sales	**2012-2020**
10-Year Plan, presented in 2012	21,512,820
10-Year Plan, presented in 2013	24,547,780
Variance - Higher/(Lower)	3,034,960
Components of Variance	
OxyContin	6,738,130
Butrans [1st Gen: 3-2014]	(520,304)
Intermezzo	(3,109,249)
Others	(73,917)
Total Variance	3,034,960
Pipeline Products - Gross Sales	**2012-2020**
10-Year Plan, presented in 2012	8,969,057
10-Year Plan, presented in 2013	4,675,193
Variance - Higher/(Lower)	(4,293,865)
Components of Variance	
Butrans (2nd Gen)	(1,999,456)
Targiniq (ONU)	(1,496,798)
Hydrocodone CD (HYD)	329,048
Oxycodone AD IR (OCD)	240,000
PAAH	(432,539)
TRPV1 (VND)	(840,305)
ORL-1	(193,814)
Total Variance	(4,293,865)
Total Products - Gross Sales	**2012-2020**
10-Year Plan, presented in 2012	30,481,877
10-Year Plan, presented in 2013	29,222,972
Variance - Higher/(Lower)	(1,258,905)

Confidential 9

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Gross Sales Review: OxyContin Reformulated



	2013F	2014	2015	2016	2017	2018	2019	2020
2012's 10-Year Plan	2,595	2,477	2,424	2,393	2,380	228	145	100
2013's 10-Year Plan	2,553	2,748	2,558	2,445	2,299	2,305	2,340	2,333

Positive Impacts

- Brand exclusivity assumption is extended by 3 years to 2020-Q3
- Remoxy is not likely to file until 2015 at the earliest
- Reduced Nucynta ER promotion

Negative Impacts

- Increasing pricing and reimbursement pressure
- Anti-opioid environment leads to decreased OxyContin and ERO prescribing.

Product	2012's Plan Assumptions	2013's Plan Assumptions
OxyContin Reformulated	• End of exclusivity in 2017-Q4 • Generic settlements totaled $1.1B • Extended-release opioid market growth at ≈2% p.a.	• End of exclusivity in 2020-Q4 (3 additional years) • Generic settlements from 2014 to 2017 (2014-2017 total $1.3 billion) increased by $212 million while generic settlements are added in 2018 and 2020 of $841 million (2014-2020 total $2.2 billion) • Extended-release opioid market growth at ≈1% p.a.

Confidential 10

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Gross Sales Review: Butrans, 1st and 2nd Generation (5-20μg)



	2013F	2014	2015	2016	2017	2018	2019	2020
2012's 10-Year Plan	231	308	475	531	622	656	692	70
2013's 10-Year Plan	160	199	240	283	235	31	24	16

Positive Impacts

- BEMA, a potential competitor with twice-a-day thin-film buprenorphine, is not likely to file >2015
- Paper-filing strategy for higher doses has upside potential

Negative Impacts

- Brand exclusivity is assumed to end in 2017-Q3
- 2nd Gen patch formulation is unlikely to provide exclusivity

Product	2012's Plan Assumptions	2013's Plan Assumptions
Butrans	• 1st Gen peak net sales at $394 million • 2nd Gen launch in 2015-Q2 • 2nd Gen IP expiry in 2019-Q4 • Higher strengths with efficacy clinical trials	• 1st Gen peak net sales at $179 million • 2nd Gen launch in 2017-Q1 • 2nd Gen IP expiry in 2017-Q3 (same as 1st Gen) • Doses higher than 20μg/day provided in labeling –with paper filing strategy

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014839

Gross Sales Review: Targiniq (ONU), Pain+OIC



	2013F	2014	2015	2016	2017	2018	2019	2020
2012's 10-Year Plan	-	46	230	454	604	692	791	79
2013's 10-Year Plan	-	-	41	164	266	431	452	45

Positive Impacts

- Number of potential competitors has been reduced significantly and the launch dates for remaining competition have been delayed

Negative Impacts

- Payor resistance
- OIC's launch in 2016-Q3 only has 3.2 years of brand exclusivity
- ERO category growth slower than previously expected

Product	2012's Plan Assumptions	2013's Plan Assumptions
Targiniq (ONU)	• Pain-only NDA launch in 2014-Q3 • OIC sNDA launch in 2015-Q2 • Peak net sales at $599 million	• Pain-only NDA launch in 2015-Q1 • OIC sNDA launch in 2016-Q3 • Peak net sales at $315 million (driven mainly by a reduction in prescriptions captured from Vicodin and lower average prescription value)

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014840

Targiniq Forecast Model



CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014841

Targiniq Forecast Model

Final factored Rx's

×

WAC price

=

Peak sales

↓

Apply launch curve to determine sales trajectory

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Targiniq Forecasting Studies: Methodology and Sample

- **2012 10-Year Plan**
  - Synovate
  - Date: April, 2011
  - 150 physicians; 75 PCP's, 75 specialists (pain spec, anesthesiology, phys med & rehab, neurologists, rheumatologists).
- **2013 10-Year Plan**
  - Burke
  - March, 2013
  - 202 physicians; 101 PCP's, 101 specialists (pain spec, anesthesiology, phys med & rehab, neurology)

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014843

Targiniq Forecasting Research Profile Key Differences

	2012 10-Yr Plan (Synovate)			2013 10-Yr Plan (Burke)	
Indication and dose ceiling	Management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time in patients requiring management of opioid-induced constipation(160 mg/day)			Management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time in patients requiring management of opioid-induced constipation(80 mg/day)	
GI Adverse Events		ONU	Placebo	ONU	Placebo
	Nausea	15%	11%	12.2%	3.7%
	Vomiting	9%	7%	6.4%	1.9%
	Constipation	12%	7%	3.8%	1.1%
	Diarrhea	5%	4%	6.4%	1.9%
	Source: Targin EU publications			Source: ONU 3701	
Abuse Deterrence Language	- 87.5% of patients had some degree of reduction in liking and 69% had reduction in euphoria (oral and intranasal with crushed ONU) compared to oxycodone alone - 71% had reduction in euphoria (IV with crushed ONU) compared to oxycodone alone			- In opioid-dependent subjects, (ONU) effectively reduced the potential for misuse and abuse when chewed; in some cases at doses ≥ 60/30 mg, there was mild subjective withdrawal. In non-opioid-dependent subjects, (ONU) effectively reduced the potential for misuse and abuse when snorted or intravenously administered.	

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2019 Peak Sales Version Comparison

	2012 160mg w/OIC	2013 80mg w/OIC
Market Basket	329MM Rx's -- All IR & ER Opioids, incl. tramadol CAGR 2011-2019 2.1%	27MM ERO Rx's CAGR 2012-2019 0.5%
Peak Share	12.8% of ERO's (1.2% of total market) from 2011 mkt. research assuming 160mg/day maximum dose (3.9MM Rx's)	8.1% from 2013 mkt. research assuming 80mg/day maximum dose (2.2MM Rx's)
Managed Care Adjustment based on research with payers, physicians and patients	-35% based on mkt. research (2.5MM Rx's) Assumes peak commercial tier 2 coverage at 22% of lives	-35% based on mkt. research (1.4MM Rx's) Assumes peak commercial tier 2 coverage at 22% of lives
Reduction for Sales Force Reach	-25%: Attain peak share in top 5 deciles reached. Share in bottom 5 deciles not called on 50% of peak based on consultant advice (2.1MM Rx's)	-33.5%: Attain peak share in top 5 deciles reached. Share in bottom 5 deciles not called on 25% of peak based on Butrans actuals (1.0MM Rx's)
Competition	-30% for Remoxy, generic OxyContin and Nektar 118 (1.5MM Rx's)	-0.8% Remoxy (0.95 MM Rx's)
Growth in ERO switches for Prophylactic treatment of OIC	N/A (Final factored Rx's = 1.5MM Rx's)	Additional usage from IRO's (Final factored Rx's = 1.1MM Rx's)
Multiply by Average WAC Rx price to obtain peak sales	$526 based on 10% premium over Oxy avg. Rx price. 3% annually price increase.	$395 based on 5% premium over Oxy avg. Rx price adj. for 80mg ceiling. 3% annual price increase.
Peak Sales	$791MM	$452MM
Launch Curve	Based on McKinsey research. OIC indication assumed to launch 2Q15, 9 months after pain indication.	Based on blend of Opana ER and Nucynta ER. OIC indication assumed to launch 3Q16, 18 months after pain indication.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Gross Sales Review: Hydrocodone Once-a-Day (HYD)

	2013F	2014	2015	2016	2017	2018	2019	2020
2012's 10-Year Plan			68	275	300	412	495	520
2013's 10-Year Plan			89	271	401	531	548	558

Positive Impacts

- Assume 1st hydrocodone ER to market with 3 years data exclusivity
- Number of potential competitors has been reduced significantly and the launch dates have been delayed for remaining competition
- HYD/APAP switch to schedule II creates opportunity for HYD

Negative Impacts

- Payors resistance in switching from low-cost immediate-release hydrocodone combos
- Latest market research suggests less capture of IR HYD/APAP

Product	2012's Plan Assumptions	2013's Plan Assumptions
Hydrocodone QD (HYD)	• Second ER hydrocodone to market • Launch in 2015-Q3 (standard review) • Peak net sales at $410 million	• First ER hydrocodone to market • Launch in 2015-Q1 (priority review) • Peak net sales at $403 million (favorable 1st entry offset by lower share assumption from updated market research)

Confidential 18

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014846

2013 10-Year Plan: Gross-to-Net Sales Summary

Summary of Product Sales (Non-Risk Adjusted) — Note: These sales do not account for CIRP settlements with generic manufacturers — $000s

Products (Gross Sales)	2011A	2012A	2013F	2014	2015	2016	2017	2018	2019	2020	2021	2022
OxyContin/ORF/OIR	2,781,018	2,777,064	2,553,108	2,748,054	2,557,559	2,444,874	2,299,352	2,304,613	2,340,154	2,332,720	169,009	64,338
Butrans [1st→2nd Gen. (5-20µg)]	73,531	112,887	160,025	199,441	240,445	283,444	235,032	30,613	23,529	16,172	13,069	8,893
Intermezzo		16,556	13,860									
Dilaudid	24,842	23,769	16,981	16,875	16,600	16,118	15,787	15,736	15,427	15,122	14,855	14,692
MS Contin	13,339	12,974	11,642	11,469	11,435	11,078	10,849	10,670	10,456	10,247	10,042	9,841
Laxatives	51,134	51,514	49,287	51,503	51,603	51,709	51,812	51,915	52,018	52,116	52,228	52,323
Slow-Mag	5,352	5,554	5,316	5,333	5,334	5,344	5,343	5,323	5,328	5,326	5,336	5,316
Betadine/Betasept	11,121	11,592	11,136	11,109	11,108	11,107	11,101	11,082	11,066	11,072	11,067	10,977
Subtotal - Marketed Products	**2,971,161**	**3,004,905**	**2,821,354**	**3,043,783**	**2,894,083**	**2,823,675**	**2,629,276**	**2,429,951**	**2,457,978**	**2,442,775**	**275,606**	**166,381**
Targiniq (ONU) - Pain→OIC					41,255	163,512	286,135	430,651	452,302	45,150	29,536	21,185
Hydrocodone QD (HYD)					88,911	271,101	401,296	530,777	548,292	557,856	465,740	44,128
Oxycodone ADIR (OCI)					10,000	30,000	50,000	50,000	50,000	50,000	50,000	50,000
TRPV1 (VND)									113,097	524,859	707,587	1,356,087
Subtotal - Pipeline					**140,166**	**464,612**	**717,431**	**1,011,428**	**1,163,690**	**1,177,865**	**1,252,963**	**1,471,400**
TOTAL GROSS SALES - MARKETED & PIPELINE	**2,971,161**	**3,004,905**	**2,821,354**	**3,043,783**	**3,034,249**	**3,288,287**	**3,346,707**	**3,441,379**	**3,621,668**	**3,620,640**	**1,528,569**	**1,637,782**
Gross to Net Sales Deduction	(748,666)	(806,438)	(714,147)	(1,157,226)	(1,181,440)	(1,277,712)	(1,436,887)	(1,403,379)	(1,380,316)	(1,318,384)	(426,522)	(568,640)
TOTAL NET SALES - MARKETED & PIPELINE	**2,222,495**	**2,198,467**	**2,107,207**	**1,886,557**	**1,852,809**	**2,010,575**	**1,909,820**	**2,038,000**	**2,241,352**	**2,302,256**	**1,102,047**	**1,069,142**

Summary of Product Gross Sales (Risk-Adjusted)

Products (Gross Sales)	Probability	2011A	2012A	2013F	2014	2015	2016	2017	2018	2019	2020	2021	2022
Marketed Products	100%	2,971,161	3,004,905	2,821,354	3,043,783	2,894,083	2,823,675	2,629,276	2,429,951	2,457,978	2,442,775	275,606	166,381
Targiniq (ONU) - Pain→OIC	80%	-	-	-	-	33,004	130,809	212,908	344,521	361,841	36,120	23,709	16,948
Hydrocodone QD (HYD)	80%	-	-	-	-	71,129	216,880	321,037	424,622	438,633	446,285	372,592	35,302
Oxycodone ADIR (OCI)	90%	-	-	-	-	9,000	27,000	45,000	45,000	45,000	45,000	45,000	45,000
TRPV1 (VND)	15%	-	-	-	-	-	-	-	-	16,965	78,729	106,138	203,413
Subtotal - Pipeline		-	-	-	-	113,133	374,690	578,944	814,143	862,439	606,134	547,439	300,664
TOTAL GROSS SALES - MARKETED & PIPELINE (RA)		**2,971,161**	**3,004,905**	**2,821,354**	**3,043,783**	**3,007,216**	**3,198,365**	**3,208,221**	**3,244,093**	**3,320,417**	**3,048,909**	**823,045**	**467,045**
Gross to Net Sales Deduction		(748,666)	(806,438)	(714,147)	(1,157,226)	(1,172,900)	(1,252,132)	(1,397,671)	(1,342,429)	(1,288,489)	(1,152,308)	(190,504)	(106,118)
TOTAL NET SALES - MARKETED & PIPELINE (RA)		**2,222,495**	**2,198,467**	**2,107,207**	**1,886,557**	**1,834,316**	**1,946,233**	**1,810,549**	**1,901,664**	**2,031,928**	**1,896,600**	**632,541**	**360,927**

Confidential 19

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Ed Mahony

FINANCIAL SUMMARY

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

10-Year Plan: Financial Highlights

Non-Risk Adjusted

($ millions)	2012 Actual	2013 Forecast	2014 Plan	2015 Plan	2016 Plan	2017 Plan	2018 Plan	2019 Plan	2020 Plan	2021 Plan	2022 Plan
Gross Branded Product Sales	3,004.9	2,821.4	3,043.8	3,034.2	3,288.3	3,346.7	3,441.4	3,621.7	3,620.6	1,528.6	1,637.8
OxyContin Settlements	-	-	(313.6)	(302.9)	(291.6)	(403.4)	(342.3)	(266.1)	(232.7)	-	-
Net Branded Sales	2,200.9	2,107.2	1,891.3	1,858.5	2,017.6	1,917.1	2,045.3	2,248.7	2,309.6	1,319.7	1,111.9
Operating Margin (before Incentive, Settlements & Other Items)	**1,037.8**	**952.6**	**748.5**	**667.4**	**835.4**	**713.9**	**824.6**	**947.2**	**970.4**	**539.4**	**308.9**
Operating Margin % Net Branded Sales	*47.2%*	*45.2%*	*39.6%*	*35.9%*	*41.4%*	*37.2%*	*40.3%*	*42.1%*	*42.0%*	*40.9%*	*27.8%*
Pre-Tax Profit / (Loss)	1,010.9	916.3	604.2	557.8	769.7	681.5	780.2	898.6	917.8	444.6	271.1
EBITDA	1,038.6	944.0	631.9	585.6	797.5	709.2	807.9	926.3	945.5	472.3	298.8
Tax Distributions	459.2	331.8	298.5	275.3	381.2	337.0	386.3	445.4	454.9	220.3	133.5
Total Equity (all Companies in Pharmaceutical Group reported to Management Revisions)	671.7	590.0	590.0	590.0	590.0	590.0	590.0	590.0	590.0	450.4	400.0
Unrestricted Cash	755.6	576.0	598.9	603.8	618.8	637.5	644.3	661.8	659.2	300.0	300.0

Product	Launch	Exclusivity Expiry
OxyContin	2010-Q3	2020-Q4
Butrans	2011-Q1	2017-Q3
Targiniq (ONU)	2015-Q1	2019-Q4
Hydrocodone QD (HYD)	2015-Q1	2021-Q4
TRPV1 (VND)	2019-Q1	2032-Q4

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014849

10-Year Plan: Net Sales Reconciliation (2015-2018 Cumulative)

Non-Risk Adjusted



Net Sales - Reconciliation (2015-2018)	$ millions	
OxyContin:		
OxyContin remains exclusive in 2018 (1 addl year)	1,014	
OxyContin settlements higher than 2012's Plan	(173)	
Higher rebates due to reimbursement environment	(478)	
		363
Intermezzo and Pipeline:		
Intermezzo sales end EOY 2013	(1,743)	
Butrans - exclusivity ends in 2017-Q3 vs 2019-Q4	(544)	
Butrans - lower sales projection	(650)	
Targiniq - lower sales projection	(884)	
HYD - higher sales projection assuming 1st to launch	117	
Oxycodone AD IR (new in 2013 Plan)	140	
TRPV1, FAAH, and Others	(25)	
		(3,590)
Net Sales - Reduction (2015-2018)		**(3,227)**

	2013F	2014	2015	2016	2017	2018	2019	2020	2021	2022
2012's 10-Year Plan	2,278	2,179	2,576	3,014	3,125	2,324	2,576	1,861		
2013's 10-Year Plan	2,107	1,887	1,853	2,011	1,910	2,038	2,241	2,302	1,102	1,069

Confidential 22

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

10-Year Plan: Operating Expenses

Non-Risk Adjusted



	2012 A	2013F	2014	2015	2016	2017	2018	2019	2020	2021	2022
2012's 10-Year Plan	967	985	1,008	1,094	1,133	1,128	1,090	1,062	793		
2013's 10-Year Plan	883	872	863	890	840	843	853	907	888	445	418

2012's 10-Year Plan Operating Expenses	$ millions	2012-2020
R&D		2,863
S&P		4,369
Redacted		
Others		344
Total, Presented in 2012's 10-Year Plan		Redacted

2013's 10-Year Plan Operating Expenses	2012-2020
R&D	2,440
S&P	3,001
Redacted	
Others	321
Total, Presented in 2013's 10-Year Plan	Redacted

Change (2012 vs 2013's 10-Year Plan) 2013 Increase / (Decrease) from 2012	2012-2020
R&D	(423)
S&P	(1,368)
Redacted	
Others	30
Total, 2013 vs 2012 Plan	Redacted

Variance Discussion

R&D - 2013 Plan does not have FAAH and Butrans Higher Doses development expenses.

S&P - 2013 Plan assumes field sales force headcount cap at 518 people versus 2012 Plan increasing to 900+. 2013 Plan does not include promotion budget for Intermezzo, Butrans Higher Doses, 3 years of Butrans 2nd Gen exclusivity, FAAH, and a 1-year delay of TRPVT.

Confidential 23

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014851

10-Year Plan: Operating Profits

Non-Risk Adjusted



	2012 A	2013F	2014	2015	2016	2017	2018	2019	2020	2021	2022
2012's 10-Year Plan	1,044	944	794	1,035	1,308	1,357	883	968	623		
2013's 10-Year Plan	993	919	705	623	790	668	778	899	921	515	284

$ millions Operating Profits (after inc/sett)	2012-2020
Presented in 2012 Plan	8,957
Presented in 2013 Plan	7,349
Change, 2013 vs 2012 Plan	**(1,608)**
Variance Analysis (approx.)	
Intermezzo, not in 2013 Plan	(970)
Butrans 2nd Gen, exclusivity ends 2017-Q3	(890)
Butrans, lower sales expectation	(218)
OxyContin, 3 additional exclusivity years	2,533
offset by higher rebates and settlements	(891)
Targiniq, lower sales expectation	(750)
TRPV1/ORL-1/FAAH	(422)
Total Change	**(1,608)**

Confidential 24

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2013 10-Year Plan: P&L

Non-Risk Adjusted

($000's)	2012 Actual	2013 Forecast	2014	2015	2016	2017	2018	2019	2020	2021	2022
Gross Branded Product Sales	$3,664,906	$2,821,387	$2,045,783	$3,024,249	$3,288,257	$3,346,797	$3,441,378	$3,621,665	$3,620,640	$1,626,669	$1,657,782
OxyContin Settlements	0	0	(310,648)	(302,939)	(291,578)	(403,400)	(342,293)	(266,121)	(232,960)	0	0
Fee for Service	(69,312)	(57,987)	(61,908)	(61,542)	(66,809)	(67,641)	(69,333)	(72,963)	(72,900)	(29,681)	(31,723)
Discounts and Allowances	(134,032)	(54,066)	(67,031)	(31,667)	(32,984)	(31,689)	(35,879)	(91,837)	(91,931)	(45,925)	(54,939)
Patient Savings Card Discounts	(26,104)	(41,334)	(31,499)	(37,441)	(55,239)	(66,533)	(74,793)	(80,292)	(71,194)	(54,919)	(55,233)
Additional Oxy Rebates on Final Proposed Rule	(60,383)	(73,892)	(44,238)	(43,897)	(41,977)	(39,480)	(39,609)	(40,240)	(33,837)	0	0
Rebates on Branded Sales	(517,606)	(488,582)	(639,001)	(663,963)	(733,357)	(779,144)	(791,472)	(823,513)	(816,832)	(286,997)	(428,746)
Rebates as % of Gross Branded Sales	19.2%	19.9%	26.0%	26.5%	26.8%	27.5%	25.5%	26.9%	26.1%	12.4%	25.1%
NET BRANDED REVENUES	**2,158,467**	**2,195,556**	**1,036,557**	**1,852,599**	**2,010,575**	**1,909,829**	**2,033,000**	**2,241,252**	**2,392,256**	**1,182,647**	**1,069,142**
AG Income	-	-	-	-	-	-	-	-	-	210,293	39,369
3rd Party Royalty Income	2,455	1,651	4,712	5,725	6,993	7,290	7,320	7,320	7,360	7,360	7,360
NET BRANDED REVENUES + AG & PROFIT SHARE INCOME	**2,200,922**	**2,197,207**	**1,891,269**	**1,858,534**	**2,017,568**	**1,917,169**	**2,045,319**	**2,248,571**	**2,399,616**	**1,319,700**	**1,111,867**
Cost of Goods Sold	(146,479)	(149,240)	(147,128)	(165,670)	(190,533)	(218,052)	(224,943)	(243,399)	(274,948)	(256,124)	(297,535)
COGS as % of Gross Branded Product Sales	4.0%	5.3%	5.4%	5.1%	5.8%	7.4%	7.2%	7.3%	5.1%	15.5%	15.2%
Royalty Expense	(120,268)	(122,339)	(122,278)	(125,841)	(133,278)	(131,577)	(131,940)	(140,399)	(166,283)	(71,364)	(79,661)
Shipping and Warehousing	(11,314)	(11,356)	(10,159)	(9,810)	(10,272)	(10,740)	(10,794)	(10,989)	(10,849)	(7,675)	(7,778)
GROSS PROFIT	**1,920,866**	**1,924,272**	**1,611,711**	**1,557,213**	**1,676,454**	**1,556,731**	**1,677,742**	**1,853,524**	**1,948,536**	**954,554**	**726,906**
G&A	(154,289)	(158,426)	(196,044)	(171,252)	(177,667)	(184,093)	(190,536)	(197,209)	(204,107)	(90,000)	(90,000)
G&A as % of Net Sales	7%	7%	10%	9%	9%	10%	9%	9%	9%	7%	7%
R&D / Medical Affairs	**(212,139)**	**(221,524)**	**(150,304)**	**(128,251)**	**(122,041)**	**(115,387)**	**(120,386)**	**(127,131)**	**(134,248)**	**(141,186)**	**(30,048)**
R&D - unallocated	-	-	-	-	(15,041)	(47,647)	(120,136)	(152,564)	(124,061)	(31,924)	(26,094)
R&D Other - Milestone and Alliances	(2,284)	(10,952)	(4,181)	(4,181)	(4,181)	(3,791)	171	171	171	56	56
R&D as % of Net Sales	14%	15%	15%	15%	12%	12%	11%	11%	10%	10%	10%
Sales and Promotion	(303,110)	(288,313)	(289,765)	(334,969)	(340,946)	(342,045)	(337,304)	(379,426)	(380,915)	(195,559)	(150,474)
SGP as % of Net Sales	14%	14%	15%	15%	17%	15%	17%	17%	17%	17%	17%
Health Care Reform Fee	(31,291)	(31,800)	(32,529)	(31,326)	(31,228)	(45,123)	(47,072)	(33,056)	(34,788)	(34,778)	(14,583)
Other - US	(17,933)	(439)	(12,123)	(4,121)	(4,107)	(4,036)	(4,031)	(4,026)	(4,026)	(4,020)	(4,014)
OPERATING EXPENSES	**(832,803)**	**(871,662)**	**(686,169)**	**(689,662)**	**(540,556)**	**(642,969)**	**(653,120)**	**(906,880)**	**(888,152)**	**(446,163)**	**(410,040)**
Operating Expenses as % of Net Sales	45.1%	47.4%	48.5%	45.0%	41.3%	44.1%	41.0%	40.5%	35.5%	42.4%	39.1%
OPERATING MARGIN BEFORE INCENTIVE & SETTLEMENTS	**$1,037,792**	**$952,930**	**$746,612**	**$667,551**	**$836,399**	**$710,880**	**$824,623**	**$847,364**	**$970,384**	**$539,331**	**$302,866**
Operating Margin as % of Net Sales	47.2%	43.2%	39.7%	35.9%	41.5%	37.4%	40.5%	42.3%	40.1%	45.0%	25.2%
Incentive Bonus	(34,285)	(35,618)	(36,330)	(37,057)	(37,798)	(38,554)	(39,325)	(40,112)	(40,914)	(20,457)	(20,868)
Insurance Income	3,520	3,558	340	-	-	-	-	-	-	-	-
Settlement Expense	(14,247)	(1,900)	-	-	-	-	-	-	-	-	-
TOTAL INCENTIVES AND SETTLEMENTS	**(45,012)**	**(33,960)**	**(35,990)**	**(37,057)**	**(37,798)**	**(38,554)**	**(39,325)**	**(40,112)**	**(40,914)**	**(20,457)**	**(20,868)**
OPERATING MARGIN AFTER INCENTIVES AND SETTLEMENTS	**992,780**	**918,880**	**712,622**	**630,294**	**797,601**	**672,309**	**785,297**	**807,252**	**929,440**	**518,874**	**282,998**
Other Items											
Royalty Income - ex US	33,961	40,692	39,031	37,664	37,777	37,855	34,721	31,429	28,387	25,662	23,214
Ex US Expenses	(65,083)	(164,309)	(144,477)	(107,075)	(62,489)	(23,398)	(36,385)	(36,385)	(36,385)	(36,385)	(36,385)
One Time Charges/Other Items	(2,148)	(2,966)	(3,021)	(3,196)	(3,314)	(3,437)	(3,565)	(3,698)	(3,836)	(63,744)	(3,894)
Gain on sale of infinity stock		124,591									
Interest (Expense) / Income	1,364	172	172	172	172	172	172	172	172	172	172
TOTAL OTHER ITEMS	**13,106**	**(2,400)**	**(108,369)**	**(72,444)**	**(27,854)**	**8,192**	**(6,058)**	**(8,483)**	**(11,963)**	**(74,295)**	**(19,893)**
PROFIT/LOSS BEFORE TAX	**$1,010,866**	**$916,280**	**$604,207**	**$557,850**	**$769,747**	**$681,601**	**$793,241**	**$809,806**	**$917,777**	**$444,828**	**$271,108**
Pre Tax Profit as % of Net Sales	46.0%	43.5%	32.0%	30.1%	38.2%	35.7%	38.8%	40.1%	38.2%	42.3%	24.4%

Redacted

Confidential 25

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2013 10-Year Plan: Balance Sheet

Non-Risk Adjusted

Balance Sheet *Non-Risk Adjusted* ($000)	**2011** Actual	**2012** Actual	**2013** Forecast	**2014** Plan	**2015** Plan	**2016** Plan	**2017** Plan	**2018** Plan	**2019** Plan	**2020** Plan	**2021** Plan	**2022** Plan
Assets												
Current Assets:												
Cash and cash equivalents	$ 606,494	$ 755,593	$ 576,026	$ 598,892	$ 603,842	$ 618,794	$ 637,519	$ 644,257	$ 661,805	$ 659,193	$ 300,004	$ 300,004
Restricted Cash	16,000	23,927	4,800	-	-	-	-	-	-	-	-	-
Accounts and other receivable:												
Trade (net)	218,801	187,137	136,623	192,773	192,169	208,258	211,958	217,954	229,372	229,307	96,809	103,726
Associated companies	27,820	31,819	13,673	9,758	9,414	9,444	9,464	8,680	7,856	7,097	6,415	5,803
Other receivables	10,075	2,957	7,250	6,178	6,431	6,748	6,820	6,830	6,830	6,840	6,840	6,840
Total accounts and other receivable	256,696	221,913	157,545	208,709	208,014	224,451	228,242	233,464	244,059	243,244	110,065	116,370
Inventories	44,207	50,531	42,881	36,782	41,417	49,633	54,513	56,211	60,850	68,737	64,031	74,384
Prepaid expenses and other assets	32,658	22,144	23,670	23,670	23,670	23,670	23,670	23,670	23,670	23,670	23,670	23,670
Total current assets	956,055	1,074,208	804,923	868,052	876,943	916,547	943,944	957,602	990,383	994,844	497,770	514,427
Property, plant and equipment - net	143,163	149,483	159,119	210,619	220,028	222,958	221,428	221,143	221,938	223,675	226,237	229,527
Investments	19,787	7,871	69,111	69,111	69,111	69,111	69,111	69,111	69,111	69,111	69,111	69,111
Due from associated companies	3,250	3,000	3,250	3,250	3,250	3,250	3,250	3,250	3,250	3,250	3,250	3,250
Intangible assets, net	191,602	196,545	189,805	181,605	173,405	166,394	159,383	152,372	145,612	140,594	137,402	134,916
Other assets	90,454	231,856	38,672	38,672	38,672	38,672	38,672	38,672	38,672	38,672	38,672	38,672
Restricted cash	42,469	17,205	21,700	31,700	31,700	31,700	31,700	31,700	31,700	31,700	31,700	31,700
Total assets	$1,445,780	$1,680,268	$1,286,580	$1,403,009	$1,413,109	$1,448,632	$1,467,488	$1,473,851	$1,500,667	$1,501,846	$1,004,142	$1,021,603
Liabilities												
Current liabilities:												
Accounts payable	$ 87,361	$ 71,181	$ 81,600	$ 78,050	$ 81,038	$ 76,476	$ 75,559	$ 76,268	$ 83,412	$ 81,752	$ 38,867	$ 38,059
Accrued expenses and taxes	632,809	694,721	360,628	480,572	488,983	530,366	551,437	558,388	579,359	583,497	269,531	339,580
Due to associated companies	11,346	12,392	13,000	13,000	13,000	13,000	13,000	13,000	13,000	13,000	13,000	13,000
Total current liabilities	731,516	778,294	455,228	571,623	583,020	619,842	639,996	647,656	675,771	678,248	321,399	390,640
Other long-term obligations	223,628	230,249	241,382	241,382	240,084	238,786	237,488	236,190	234,892	233,594	232,296	230,998
Total liabilities	955,144	1,008,543	696,610	813,005	823,104	858,628	877,484	883,846	910,663	911,842	553,695	621,638
Equity:												
Capital stock-Common	9	9	9	9	9	9	9	9	9	9	9	9
Additional paid in capital	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982
Retained earnings and partners' capital	635,780	713,199	717,414	717,449	717,449	717,448	717,448	717,449	717,448	717,448	577,892	527,410
Minimum pension liability adjustment	(145,136)	(139,935)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)
Unrealized gain on Infinity Stock /FX Translation	-	97,469	-	-	-	-	-	-	-	-	-	-
Subscription Receivable	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)
Total stockholder's equity	491,636	671,725	589,970	590,005	590,005	590,004	590,004	590,005	590,004	590,004	450,448	399,966
Total liabilities and stockholder's equity	$1,445,780	$1,680,268	$1,286,580	$1,403,010	$1,413,109	$1,448,633	$1,467,489	$1,473,851	$1,500,667	$1,501,846	$1,004,142	$1,021,603

Confidential 26

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2013 10-Year Plan: Statement of Cash Flows

Non-Risk Adjusted

Statement of Cash Flows *Non-Risk Adjusted* ($000)	2011 Actual	2012 Actual	2013 Forecast	2014 Plan	2015 Plan	2016 Plan	2017 Plan	2018 Plan	2019 Plan	2020 Plan	2021 Plan	2022 Plan
Operating activities												
Net income (loss) after tax before extraordinary item	$1,144,453	$1,008,308	$ 911,586	$ 597,067	$ 550,567	$ 762,319	$ 673,924	$ 772,512	$ 890,723	$ 909,736	$ 440,608	$ 267,005
Non-cash charges (credits) to net income:												
Depreciation	25,564	24,120	25,364	25,000	33,091	34,570	35,030	34,790	34,745	34,870	35,143	35,545
Amortization	2,740	4,939	6,840	8,200	8,200	7,011	7,011	7,011	6,760	5,018	3,192	2,486
Loss on equity investment companies	112,368	101,005	163,066	144,477	107,075	62,489	28,398	36,385	36,385	36,385	36,385	36,385
Working capital changes	162,044	88,604	(271,229)	67,416	7,113	12,200	11,502	(44)	12,057	(5,355)	(219,646)	51,972
Extraordinary Item Payout / Reduction in Infinity	(988)		189,500	-	-	-	-	-	-	-	-	-
Long-term assets and liabilities	29,846	(2,012)	(71,153)	-	(1,298)	(1,298)	(1,298)	(1,298)	(1,298)	(1,298)	(1,298)	(1,298)
Cash flow from operations	1,475,761	1,242,391	953,974	842,160	704,748	877,290	754,567	849,356	979,373	979,356	294,384	392,095
Investing activities												
Capital expenditure	(26,823)	(30,487)	(35,000)	(76,500)	(42,500)	(37,500)	(33,500)	(34,505)	(35,540)	(36,606)	(37,705)	(38,836)
Restricted Cash, net	12,944	17,337	14,632	(5,200)	-	-	-	-	-	-	-	-
Investments in JV and associates	(100,323)	(89,089)	(224,306)	(144,477)	(107,075)	(62,489)	(28,398)	(36,385)	(36,385)	(36,385)	(36,385)	(36,385)
Cash flow used by investing	(174,202)	(159,701)	(244,674)	(226,177)	(149,575)	(99,989)	(61,898)	(70,890)	(71,925)	(72,991)	(74,090)	(75,221)
Financing activities												
Proceeds from (to) associated companies, net	(3,823)	(2,703)	18,504	3,915	344	(31)	(20)	783	824	760	681	612
Distributions for Required Tax Payments	(553,393)	(459,245)	(331,772)	(298,534)	(275,283)	(381,159)	(336,962)	(386,256)	(445,362)	(454,868)	(220,304)	(133,502)
Distributions Non Tax	(575,246)	(471,643)	(575,600)	(298,498)	(275,284)	(381,160)	(336,962)	(386,256)	(445,362)	(454,868)	(359,860)	(183,985)
Cash flow provided by financing	(1,132,159)	(933,591)	(888,868)	(593,117)	(550,223)	(762,350)	(673,944)	(771,729)	(889,900)	(908,976)	(579,483)	(316,875)
Increase in cash and cash equivalents	169,400	149,099	(179,568)	22,867	4,950	14,952	18,726	6,738	17,548	(2,612)	(359,188)	(1)
Unrestricted Cash at beginning of period	437,094	606,494	755,593	576,025	598,892	603,842	618,794	637,519	644,257	661,805	659,193	300,004
Unrestricted Cash at end of period	**$ 606,494**	**$ 755,593**	**$ 576,025**	**$ 598,892**	**$ 603,842**	**$ 618,794**	**$ 637,519**	**$ 644,257**	**$ 661,805**	**$ 659,193**	**$ 300,004**	**$ 300,004**

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014855

BACK UP

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Table of Contents

1. Updates of Key Assumptions P. 30
2. Pipeline Recertification P. 32
3. IP Update P. 36
   ORF, Butrans, ONU, HYD
4. Financial Backup Schedules P. 41
   (non-risk adjusted / risk-adjusted)

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

10-Year Plan Key Changes of Assumptions: 2012 vs 2013

Product	2012's Plan Assumptions	2013's Plan Assumptions
OxyContin Reformulated	• End of exclusivity in 2017-Q4 • Generic settlements totaled $1.1B • Extended-release opioid market growth at ≈2% p.a.	• End of exclusivity in 2020-Q4 (3 additional years) • Generic settlements from 2014 to 2017 (2014-2017 total $1.3 billion) increased by $212 million while generic settlements are added in 2018 and 2020 of $841 million (2014-2020 total $2.2 billion) • Extended-release opioid market growth at ≈1% p.a.
Butrans	• 1st Gen peak net sales at $394 million • 2nd Gen launch in 2015-Q2 • 2nd Gen IP expiry in 2019-Q4 • Higher strengths with efficacy clinical trials	• 1st Gen peak net sales at $179 million • 2nd Gen launch in 2017-Q1 • 2nd Gen IP expiry in 2017-Q3 (same as 1st Gen) • Doses higher than 20µg/day provided in labeling –with paper filing strategy
Targiniq (ONU)	• Pain-only NDA launch in 2014-Q3 • OIC sNDA launch in 2015-Q2 • Peak net sales at $599 million	• Pain-only NDA launch in 2015-Q1 • OIC sNDA launch in 2016-Q3 • Peak net sales at $315 million (driven mainly by a reduction in prescriptions captured from Vicodin and lower average prescription value)
Hydrocodone QD (HYD)	• Second ER hydrocodone to market • Launch in 2015-Q3 (standard review) • Peak net sales at $410 million	• First ER hydrocodone to market • Launch in 2015-Q1 (priority review) • Peak net sales at $403 million (favorable 1st entry offset by lower share assumption from updated market research)
Rebates	• Overall rebate as % of sales at ≈19% (2012-2020)	• Overall rebate as % of sales at ≈24% (2013-2022)

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Pipeline Recertification Comparison: 2012 vs 2013

Non-Risk Adjusted

Portfolio		Launch Date		Additional Net Sales (AUC)[1] till Generic Competition ($mms)		Net Present Value, After-Tax ($mms, start in 2013)	
		2012 Plan	**2013 Plan**	2012 Plan	**2013 Plan**	2012 Plan	**2013 Plan**
OxyContin Reformulated	2012-2017:	2010-Q3	2010-Q3	$10,119	$9,553	n/a	n/a
	2018-2020:			$402	$3,907		
	2012-2020:			**$10,521**	**$13,460**		
Butrans [1st Gen: (5-20µg)]		2011-Q1	2011-Q1	$1,307	$752	$198	$100
Butrans [2nd Gen: (5-20µg)]		2015-Q2	2017-Q1	$1,474	none	$257	none
Butrans [1st→2nd Gen: (25-40µg)]		2017-Q1	none	$1,237	none	$220	none
Intermezzo (2012-2019/2013)		2012-Q2	2012-Q2	$2,633	$17 [2]	$264	($61) [2]
Targiniq (ONU) - Pain only		2014-Q3	2015-Q1	$1,082	$691	$81	$23
Targiniq (ONU) - Pain + OIC sNDA		2015-Q2	2016-Q3	$1,079	$265	$70	$9
Hydrocodone QD (HYD) [1st to Launch]		2015-Q3	2015-Q1	$2,756	$2,081	$240	$185
Oxycodone ADIR (OCI) [new in 2013]		none	2015-Q2	n/a	n/a	~	$100
TRPV1 (VND)		2018-Q3	2019-Q1	$24,454	$18,402	$1,213	$817

(1) AUC = Area Under Curve from 2013 (or 2012 for OxyContin) and on.

(2) Since inception

Confidential 31

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

10-Year Plan: Pipeline Launches and Exclusivity

Product	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
OxyContin Reformulated													
Butrans (1st Gen: 5-20μg)													
Intermezzo													
Targiniq (ONU) Pain													
Hydrocodone QD (HYD)													
Oxycodone ADIR (OCI)													
Targiniq (ONU) Pain+OIC													
Butrans (2nd Gen: 5-20μg)													
TRPV1 (VND)													
ORL-1 (OAG)											≥2020		

Launched and IP Exclusive
IP Expired and Generic Competition

Confidential 32

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014860

Pipeline Recertification

Line	Fundamental	Timing	Prelaunch R&D					Financial Metrics (1)								IP
	Project Name	Projected Year of Approval / Launch	2013 to Approval	2013	2014	2015	> 2015	Peak Gross Sales	# Year from Launch Till First P&L Positive	Net Present Value (NPV)	Internal Rate of Return (IRR)	Additional Net Sales (AUC)[2] till Generic Competition	Free Cash Flows (AUC) till Generic Competition[4]	Free Cash Flows (AUC) / Prelaunch R&D-to-Go	Number of Years from Launch till Generic Competition	Assumed IP Exclusivity (till end of)
			$ millions					$MMs	Yrs	$MMs	%	$MMs	$MMs		Yrs	
1	Targiin (ONU) - Pain Only (15)	2015	69.4	56.5	5.3	7.7		310.0	2.2	22.8	18.6%	691.0	80.9	1.2	5.0	2019-Q4
2	HYD (Hydrocodone QD)	2015	186.4	78.0	57.9	33.0	17.4	557.9	1.0	184.9	40.0%	2,080.8	442.5	2.4	7.0	2021-Q4
3	OxyADIR (OCI) (4)	2015	23.3	14.7	8.1	0.6	-	50.0	2.0	100.0	~	~	~	~	-	~
4	Targiin (ONU) - OIC (16 sNDA)	2016	113.1	28.5	53.9	25.0	5.8	142.3	2.1	8.7	17.6%	264.6	47.3	0.4	3.5	2019-Q4
5	Butrans (2nd Gen; 5-20 µg)	2017	25.8	2.9	9.9	8.7	4.3	~	~	~	~	~	~	~	0.8	2017-Q3
6	TRPV1 (Purdue)	2019	385.7	27.0	55.9	118.5	184.4	3,253.1	2.0	816.9	30.7%	16,401.9	5,055.0	13.1	14.0	2032-Q4
A	OxyContin Reformulated (ORF) (3)	2010						2,332.7	~	~	~	11,712.6	5,092.2	~	10.5	2020-Q4
B	Butrans (1st Gen; 5-20 µg)	2011						283.4	3.5	100.5	74.3%	752.6	123.2	n/a	6.8	2017-Q3
								TOTAL:		1,233.8						

Note:
1. Financials from 10-Year Plan case are provided above
2. AUC - Area under the curve from 2013 and on
3. ORF peak gross sales are from 2009, the last year of Peak activity
4. OCI's NPV is approximated by 2x sales
5. Include the additional year post generics entry to account for release of working capital
Italics numbers are incremental value

Confidential 33

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014861

Pipeline Recertification – NPV Ranking

The Higher The Better



Confidential 34

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Pipeline Recertification – r-NPV Ranking

The Higher The Better



Confidential 35

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Phil Strassburger

IP UPDATE

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Redacted

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Redacted

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Redacted

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Redacted

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

FINANCIAL BACKUP SCHEDULES

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Comparison with Public Pharma and Biotech Companies (1)

Gross Margin and Earnings from Continuing Operations

Non-Risk Adjusted



Note: Data from public companies within the S&P and Russell indexes are based on last twelve months performance with sales > $300 million. Purdue's data are based on average of 2013-2022.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Comparison with Public Pharma and Biotech Companies (2)

R&D and SG&A as % of Net Revenues

Non-Risk Adjusted



Note: Data from public companies within the S&P and NASDAQ indexes are based on last twelve months performance. Purdue's data are based on average of 2011-2020.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014871

2013 10-Year Plan: Gross-to-Net Sales Summary

Summary of Product Sales (Non-Risk Adjusted) — *Note: These sales do not account for DEA settlements with generic entry/launches* — $000s

Products (Gross Sales)	2011A	2012A	2013F	2014	2015	2016	2017	2018	2019	2020	2021	2022
OxyContin/ORF/OIR	2,781,018	2,777,064	2,553,108	2,748,054	2,557,559	2,444,874	2,299,352	2,304,613	2,340,154	2,332,720	169,009	64,338
Butrans [1st→2nd Gen: (5-20µg)]	73,531	112,887	160,025	199,441	240,445	283,444	235,032	30,613	23,529	16,172	13,069	8,893
Intermezzo		16,556	13,860									
Dilaudid	24,842	23,769	16,981	16,875	16,600	16,118	15,787	15,736	15,427	15,122	14,855	14,592
MS Contin	13,339	12,974	11,642	11,469	11,435	11,078	10,849	10,670	10,456	10,247	10,042	9,841
Laxatives	51,134	51,514	49,287	51,503	51,603	51,709	51,812	51,915	52,018	52,116	52,228	52,323
Slow-Mag	5,352	5,554	5,316	5,333	5,334	5,344	5,343	5,323	5,328	5,326	5,336	5,316
Betadine/Betasept	11,121	11,592	11,136	11,109	11,108	11,107	11,101	11,082	11,066	11,072	11,067	10,977
Subtotal - Marketed Products	**2,971,161**	**3,004,905**	**2,821,354**	**3,043,783**	**2,894,083**	**2,823,675**	**2,629,276**	**2,429,951**	**2,457,978**	**2,442,775**	**275,606**	**166,381**
Tanganiq (ONU) - Pain→OIC					41,255	163,512	266,135	430,651	452,302	45,150	29,636	21,185
Hydrocodone QD (HYD)					88,911	271,101	401,296	530,777	548,292	557,856	465,740	44,128
Oxycodone ADIR (OCI)					10,000	30,000	50,000	50,000	50,000	50,000	50,000	50,000
TRPVI (VND)									113,097	524,859	707,587	1,355,087
Subtotal - Pipeline					**140,166**	**464,612**	**717,431**	**1,011,428**	**1,163,690**	**1,177,865**	**1,252,963**	**1,471,400**
TOTAL GROSS SALES - MARKETED & PIPELINE	**2,971,161**	**3,004,905**	**2,821,354**	**3,043,783**	**3,034,249**	**3,288,287**	**3,346,707**	**3,441,379**	**3,621,668**	**3,620,640**	**1,528,569**	**1,637,782**
Gross to Net Sales Deduction	(748,666)	(806,438)	(714,147)	(1,157,226)	(1,181,440)	(1,277,712)	(1,436,887)	(1,403,379)	(1,380,316)	(1,318,384)	(426,522)	(568,640)
TOTAL NET SALES - MARKETED & PIPELINE	**2,222,495**	**2,198,467**	**2,107,207**	**1,886,557**	**1,852,809**	**2,010,575**	**1,909,820**	**2,038,000**	**2,241,352**	**2,302,256**	**1,102,047**	**1,069,142**

Summary of Product Gross Sales (Risk-Adjusted)

Products (Gross Sales)	Probability	2011A	2012A	2013F	2014	2015	2016	2017	2018	2019	2020	2021	2022
Marketed Products	100%	2,971,161	3,004,905	2,821,354	3,043,783	2,894,083	2,823,675	2,629,276	2,429,951	2,457,978	2,442,775	275,606	166,381
Tanganiq (ONU) - Pain→OIC	80%	-	-	-	-	33,004	130,809	212,908	344,521	361,841	36,120	23,709	16,948
Hydrocodone QD (HYD)	80%	-	-	-	-	71,129	216,880	321,037	424,622	438,633	446,285	372,592	35,302
Oxycodone ADIR (OCI)	90%	-	-	-	-	9,000	27,000	45,000	45,000	45,000	45,000	45,000	45,000
TRPVI (VND)	15%	-	-	-	-	-	-	-	-	16,965	78,729	105,138	203,413
Subtotal - Pipeline		-	-	-	-	113,133	374,690	578,944	814,143	862,439	606,134	547,439	300,664
TOTAL GROSS SALES - MARKETED & PIPELINE (RA)		**2,971,161**	**3,004,905**	**2,821,354**	**3,043,783**	**3,007,216**	**3,198,365**	**3,208,221**	**3,244,093**	**3,320,417**	**3,048,909**	**823,045**	**467,045**
Gross to Net Sales Deduction		(748,666)	(806,438)	(714,147)	(1,157,226)	(1,172,900)	(1,252,132)	(1,397,671)	(1,342,429)	(1,288,489)	(1,152,308)	(190,504)	(106,118)
TOTAL NET SALES - MARKETED & PIPELINE (RA)		**2,222,495**	**2,198,467**	**2,107,207**	**1,886,557**	**1,834,316**	**1,946,233**	**1,810,549**	**1,901,664**	**2,031,928**	**1,896,600**	**632,541**	**360,927**

Metrics	2011A	2012A	2013F	2014	2015	2016	2017	2018	2019	2020	2021	2022
Non-Risk Adjusted												
OxyContin as %of total gross sales	94%	92%	90%	90%	84%	74%	69%	67%	65%	64%	11%	4%
Marketed products as %of total gross sales	100%	100%	100%	100%	95%	86%	79%	71%	68%	67%	18%	10%
Pipeline products as %of total gross sales	0%	0%	0%	0%	5%	14%	21%	29%	32%	33%	82%	90%
BUP+ONU+HYD as %of total gross sales	2%	4%	6%	7%	12%	22%	27%	29%	28%	17%	33%	5%
Risk-Adjusted												
Risk-adjusted sales as %of non-risk adjusted gross sales	100%	100%	100%	100%	99%	97%	96%	94%	92%	84%	54%	29%

Confidential 44

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2012 vs 2013 10-Year Plan: Gross Sales (Total)

NON-RISK ADJUSTED

$000s

Marketed Products - Gross Sales	2011A	2012A	2013F	2014	2015	2016	2017	2018	2019	2020	2012-2020
10-Year Plan, presented in 2012	2,971,161	3,167,870	3,086,723	3,195,713	3,440,259	3,566,067	3,069,521	888,889	795,886	301,892	21,512,820
10-Year Plan, presented in 2013	2,971,161	3,004,905	2,821,354	3,043,783	2,894,083	2,823,675	2,629,276	2,429,951	2,457,978	2,442,775	24,547,780
Variance - Higher/(Lower)		(162,965)	(265,369)	(151,930)	(546,176)	(742,392)	(440,245)	1,541,061	1,662,092	2,140,883	3,034,960
Components of Variance											
OxyContin		(1,133,297)	(42,308)	271,257	133,663	52,241	180,770	2,376,711	2,195,366	2,232,263	6,735,193
Butrans [1st Gen (5-20mg)]		22,522	271,284	1,138,854	234,859	247,133	180,422	5,557	4,218	4,352	523,034
Intermezzo		32,529	142,574	337,130	438,036	540,135	531,414	523,338	519,986	377,137	3,139,249
Others		7,113	9,203	7,253	6,943	7,397	8,483	8,620	8,973	9,913	73,917
Total Variance		(162,965)	(265,369)	(151,930)	(546,176)	(742,392)	(440,245)	1,541,061	1,662,092	2,140,883	3,034,960

Pipeline Products - Gross Sales	2011A	2012A	2013F	2014	2015	2016	2017	2018	2019	2020	2012-2020
10-Year Plan, presented in 2012	-	-	-	46,043	297,737	729,407	1,470,875	1,916,246	2,474,057	2,034,694	8,969,057
10-Year Plan, presented in 2013	-	-	-	-	140,166	464,612	717,431	1,011,428	1,163,690	1,177,865	4,675,193
Variance - Higher/(Lower)	-	-	-	(46,043)	(157,572)	(264,794)	(753,444)	(904,818)	(1,310,366)	(856,829)	(4,293,865)
Components of Variance											
Butrans [2nd Gen]	-	-	-	-	-	-	(567,035)	(618,442)	(664,116)	(43,857)	(1,893,455)
Tanezumab (ONJ)	-	-	-	(46,043)	(138,419)	(290,362)	(338,196)	(291,039)	(338,374)	(33,755)	(1,455,738)
Hydrocodone (QD, HYD)	-	-	-	-	20,847	13,832	101,737	118,630	53,596	38,050	325,048
Oxycodone ADIR (OCD)	-	-	-	-	10,000	30,000	50,000	50,000	50,000	50,000	240,000
FAAH	-	-	-	-	-	-	-	-	(118,084)	(314,455)	(432,539)
TRPV1 (VND)	-	-	-	-	-	-	-	(193,861)	(293,382)	(352,657)	(840,305)
GRK-1	-	-	-	-	-	-	-	-	-	(193,814)	(193,814)
Total Variance	-	-	-	(46,043)	(157,572)	(264,794)	(753,444)	(904,818)	(1,310,366)	(856,829)	(4,293,865)

Total Products - Gross Sales	2011A	2012A	2013F	2014	2015	2016	2017	2018	2019	2020	2012-2020
10-Year Plan, presented in 2012	2,971,161	3,167,870	3,086,723	3,241,756	3,737,996	4,295,473	4,540,395	2,805,135	3,269,942	2,336,586	30,481,877
10-Year Plan, presented in 2013	2,971,161	3,004,905	2,821,354	3,043,783	3,034,249	3,288,287	3,346,707	3,441,379	3,621,668	3,620,640	29,222,972
Variance - Higher/(Lower)	-	(162,965)	(265,369)	(197,973)	(703,747)	(1,007,186)	(1,193,689)	636,244	351,726	1,284,054	(1,258,905)

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

OxyContin Settlements Impact to Net Sales

OxyContin Settlements Assumptions	*$ millions*	2014-2017	2018-2020	2014-2020
2012's 10-Year Plan		(1,100)	-	**(1,100)**
2013's 10-Year Plan		(1,312)	(841)	**(2,153)**
2013 Additional Settlements Over 2012		**(212)**	**(841)**	**(1,053)**

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Financial Schedules

NON-RISK ADJUSTED

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

10-Year Plan: Financial Highlights

Non-Risk Adjusted

($ millions)	2012 Actual	2013 Forecast	2014 Plan	2015 Plan	2016 Plan	2017 Plan	2018 Plan	2019 Plan	2020 Plan	2021 Plan	2022 Plan
Gross Branded Product Sales	3,004.9	2,821.4	3,043.8	3,034.2	3,288.3	3,346.7	3,441.4	3,621.7	3,620.6	1,528.6	1,637.8
OxyContin Settlements	-	-	(313.6)	(302.9)	(291.6)	(403.4)	(342.3)	(266.1)	(232.7)	-	-
Net Branded Sales	2,200.9	2,107.2	1,891.3	1,858.5	2,017.6	1,917.1	2,045.3	2,248.7	2,309.6	1,319.7	1,111.9
Operating Margin (before Incentive, Settlements & Other Items)	**1,037.8**	**952.6**	**748.5**	**667.4**	**835.4**	**713.9**	**824.6**	**947.2**	**970.4**	**539.4**	**308.9**
Operating Margin % Net Branded Sales	*47.2%*	*45.2%*	*39.6%*	*35.9%*	*41.4%*	*37.2%*	*40.3%*	*42.1%*	*42.0%*	*40.9%*	*27.8%*
Pre-Tax Profit / (Loss)	1,010.9	916.3	604.2	557.8	769.7	681.5	780.2	898.6	917.8	444.6	271.1
EBITDA	1,038.6	944.0	631.9	585.6	797.5	709.2	807.9	926.3	945.5	472.3	298.8
Tax Distributions	459.2	331.8	298.5	275.3	381.2	337.0	386.3	445.4	454.9	220.3	133.5
Total Equity (all Companies in Pharmaceutical Group reported to Management Revisions)	671.7	590.0	590.0	590.0	590.0	590.0	590.0	590.0	590.0	450.4	400.0
Unrestricted Cash	755.6	576.0	598.9	603.8	618.8	637.5	644.3	661.8	659.2	300.0	300.0

Product	Launch	Exclusivity Expiry
OxyContin	2010-Q3	2020-Q4
Butrans	2011-Q1	2017-Q3
Targiniq (ONU)	2015-Q1	2019-Q4
Hydrocodone QD (HYD)	2015-Q1	2021-Q4
TRPV1 (VND)	2019-Q1	2032-Q4

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014876

2013 10-Year Plan: Profit & Loss Statement

Non-Risk Adjusted

($000's)	2012 Actual	2013 Forecast	2014	2015	2016	2017	2018	2019	2020	2021	2022
Gross Branded Product Sales	$3,664,906	$2,821,387	$2,045,783	$3,024,249	$3,288,257	$3,346,797	$3,441,378	$3,621,665	$3,820,640	$1,626,669	$1,657,782
OxyContin Settlements	0	0	(310,648)	(302,939)	(291,578)	(403,400)	(342,293)	(286,121)	(232,980)	0	0
Fee for Service	(69,312)	(57,987)	(61,808)	(61,542)	(66,809)	(67,641)	(69,333)	(72,963)	(77,900)	(29,681)	(31,723)
Discounts and Allowances	(134,032)	(54,066)	(67,031)	(31,667)	(32,984)	(31,689)	(35,879)	(91,837)	(91,931)	(45,925)	(54,939)
Patient Savings Card Discounts	(26,104)	(41,334)	(31,499)	(37,441)	(55,239)	(66,533)	(74,793)	(80,292)	(71,194)	(54,919)	(55,233)
Additional Oxy Rebates on Final Proposed Rule	(60,383)	(73,892)	(44,238)	(43,897)	(41,977)	(39,480)	(39,609)	(40,240)	(39,837)	0	0
Rebates on Branded Sales	(517,606)	(488,582)	(639,001)	(663,963)	(733,357)	(779,144)	(791,472)	(828,513)	(816,832)	(286,997)	(428,746)
Rebates as % of Gross Branded Sales	19.2%	19.9%	26.0%	26.5%	26.8%	27.5%	25.5%	26.9%	26.1%	18.4%	25.1%
NET BRANDED REVENUES	**2,158,467**	**2,195,556**	**1,036,557**	**1,852,599**	**2,010,575**	**1,909,829**	**2,033,000**	**2,241,252**	**2,392,256**	**1,182,647**	**1,069,142**
AG Income	-	-	-	-	-	-	-	-	-	210,293	39,369
3rd Party Royalty Income	2,455	1,651	4,712	5,725	6,993	7,290	7,320	7,320	7,360	7,360	7,360
NET BRANDED REVENUES + AG & PROFIT SHARE INCOME	**2,200,922**	**2,197,207**	**1,891,269**	**1,858,534**	**2,017,568**	**1,917,169**	**2,045,319**	**2,248,571**	**2,399,616**	**1,319,700**	**1,111,867**
Cost of Goods Sold	(148,479)	(149,240)	(147,128)	(165,670)	(190,533)	(218,052)	(224,943)	(243,399)	(274,948)	(256,124)	(297,535)
COGS as % of Gross Branded Product Sales	4.2%	5.3%	5.4%	5.1%	5.8%	7.4%	7.2%	7.3%	5.1%	15.5%	15.2%
Royalty Expense	(120,268)	(122,339)	(122,278)	(125,841)	(133,278)	(131,577)	(131,940)	(140,399)	(166,283)	(71,364)	(79,661)
Shipping and Warehousing	(11,314)	(11,356)	(10,159)	(9,810)	(10,272)	(10,740)	(10,794)	(10,989)	(10,849)	(7,675)	(7,778)
GROSS PROFIT	**1,920,861**	**1,924,272**	**1,611,711**	**1,557,213**	**1,675,454**	**1,556,731**	**1,677,742**	**1,853,524**	**1,948,536**	**954,554**	**726,906**
G&A	(154,289)	(158,426)	(166,044)	(171,852)	(177,667)	(184,093)	(190,536)	(197,209)	(204,107)	(90,000)	(90,000)
G&A as % of Net Sales	7%	0%	9%	9%	9%	10%	9%	9%	9%	5%	5%
R&D - allocated to products	(312,613)	(327,247)	(304,314)	(284,352)	(222,910)	(179,844)	(150,348)	(101,084)	(108,358)	(37,258)	(37,058)
R&D - unallocated	-	-	-	-	(16,041)	(47,647)	(120,135)	(152,554)	(124,051)	(31,924)	(26,094)
R&D Other - Milestone and Alliances	(2,284)	(10,952)	(4,181)	(4,181)	(4,181)	(3,791)	171	171	171	56	56
R&D as % of Net Sales	14%	15%	15%	15%	12%	12%	11%	11%	10%	10%	10%
Sales and Promotion	(303,110)	(288,313)	(289,765)	(334,869)	(340,946)	(342,045)	(337,304)	(379,426)	(380,915)	(195,559)	(120,474)
S&P as % of Net Sales	14%	14%	15%	15%	17%	15%	17%	17%	17%	17%	17%
Health Care Reform Fee	(31,291)	(31,800)	(32,529)	(31,326)	(31,228)	(45,123)	(47,072)	(33,056)	(34,788)	(34,778)	(14,583)
Other - US	(17,933)	(439)	(12,123)	(4,121)	(4,107)	(4,036)	(4,031)	(4,026)	(4,026)	(4,020)	(4,014)
OPERATING EXPENSES	**(832,503)**	**(871,662)**	**(846,169)**	**(889,662)**	**(540,556)**	**(842,569)**	**(853,120)**	**(906,880)**	**(888,152)**	**(445,163)**	**(410,040)**
Operating Expenses as % of Net Sales	45.1%	47.4%	45.5%	45.7%	41.3%	44.1%	41.9%	40.5%	35.5%	42.4%	39.1%
OPERATING MARGIN BEFORE INCENTIVE & SETTLEMENTS											
Operating Margin as % of Net Sales	37.5%	35.2%	33.7%	33.0%	37.1%	37.4%	40.6%	42.0%	42.1%	35.0%	26.2%
Incentive Bonus	(34,285)	(35,618)	(36,330)	(37,057)	(37,798)	(38,554)	(39,325)	(40,112)	(40,914)	(20,457)	(20,868)
Insurance Income	3,520	3,558	390	-	-	-	-	-	-	-	-
Settlement Expense	(14,247)	(11,900)	-	-	-	-	-	-	-	-	-
TOTAL INCENTIVES AND SETTLEMENTS	**(45,012)**	**(43,960)**	**(35,940)**	**(37,057)**	**(37,798)**	**(38,554)**	**(39,325)**	**(40,112)**	**(40,914)**	**(20,457)**	**(20,868)**
OPERATING MARGIN AFTER INCENTIVES AND SETTLEMENTS	**692,750**	**618,680**	**712,685**	**620,294**	**787,601**	**676,309**	**756,297**	**907,092**	**920,440**	**618,924**	**237,999**
Other Items											
Royalty Income - ex US	53,961	40,692	39,031	37,664	37,777	37,855	34,721	31,429	28,387	25,662	23,214
Ex US Expenses	(65,083)	(164,309)	(144,477)	(107,075)	(62,489)	(23,398)	(36,385)	(36,385)	(36,385)	(36,385)	(36,385)
One Time Charges/Other Items	(2,148)	(2,966)	(3,021)	(3,196)	(3,314)	(3,437)	(3,565)	(3,698)	(3,836)	(63,744)	(3,894)
Gain on sale of infinity stock		124,591									
Interest (Expense) / Income	1,364	172	172	172	172	172	172	172	172	172	172
TOTAL OTHER ITEMS	**18,108**	**(2,400)**	**(108,369)**	**(72,444)**	**(27,854)**	**8,192**	**(6,058)**	**(8,480)**	**(11,863)**	**(74,295)**	**(16,893)**
PROFIT/LOSS BEFORE TAX	**$1,010,868**	**$918,280**	**$894,207**	**$867,560**	**$789,747**	**$851,691**	**$793,241**	**$899,806**	**$917,777**	**$444,628**	**$271,108**
Pre Tax Profit as % of Net Sales	46.0%	43.5%	32.0%	30.1%	35.3%	35.7%	35.2%	40.1%	38.2%	42.3%	25.4%

Confidential 49

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2013 10-Year Plan: Balance Sheet

Non-Risk Adjusted

Balance Sheet *Non-Risk Adjusted* ($000)	**2011** Actual	**2012** Actual	**2013** Forecast	**2014** Plan	**2015** Plan	**2016** Plan	**2017** Plan	**2018** Plan	**2019** Plan	**2020** Plan	**2021** Plan	**2022** Plan
Assets												
Current Assets:												
Cash and cash equivalents	$ 606,494	$ 755,593	$ 576,026	$ 598,892	$ 603,842	$ 618,794	$ 637,519	$ 644,257	$ 661,805	$ 659,193	$ 300,004	$ 300,004
Restricted Cash	16,000	23,927	4,800	-	-	-	-	-	-	-	-	-
Accounts and other receivable:												
Trade (net)	218,801	187,137	136,623	192,773	192,169	208,258	211,958	217,954	229,372	229,307	96,809	103,726
Associated companies	27,820	31,819	13,673	9,758	9,414	9,444	9,464	8,680	7,856	7,097	6,415	5,803
Other receivables	10,075	2,957	7,250	6,178	6,431	6,748	6,820	6,830	6,830	6,840	6,840	6,840
Total accounts and other receivable	256,696	221,913	157,545	208,709	208,014	224,451	228,242	233,464	244,059	243,244	110,065	116,370
Inventories	44,207	50,531	42,881	36,782	41,417	49,633	54,513	56,211	60,850	68,737	64,031	74,384
Prepaid expenses and other assets	32,658	22,144	23,670	23,670	23,670	23,670	23,670	23,670	23,670	23,670	23,670	23,670
Total current assets	956,055	1,074,208	804,923	868,052	876,943	916,547	943,944	957,602	990,383	994,844	497,770	514,427
Property, plant and equipment - net	143,163	149,483	159,119	210,619	220,028	222,958	221,428	221,143	221,938	223,675	226,237	229,527
Investments	19,787	7,871	69,111	69,111	69,111	69,111	69,111	69,111	69,111	69,111	69,111	69,111
Due from associated companies	3,250	3,000	3,250	3,250	3,250	3,250	3,250	3,250	3,250	3,250	3,250	3,250
Intangible assets, net	191,602	196,545	189,805	181,605	173,405	166,394	159,383	152,372	145,612	140,594	137,402	134,916
Other assets	90,454	231,856	38,672	38,672	38,672	38,672	38,672	38,672	38,672	38,672	38,672	38,672
Restricted cash	42,469	17,205	21,700	31,700	31,700	31,700	31,700	31,700	31,700	31,700	31,700	31,700
Total assets	$1,445,780	$1,680,268	$1,286,580	$1,403,009	$1,413,109	$1,448,632	$1,467,488	$1,473,851	$1,500,667	$1,501,846	$1,004,142	$1,021,603
Liabilities												
Current liabilities:												
Accounts payable	$ 87,361	$ 71,181	$ 81,600	$ 78,050	$ 81,038	$ 76,476	$ 75,559	$ 76,268	$ 83,412	$ 81,752	$ 38,867	$ 38,059
Accrued expenses and taxes	632,809	694,721	360,628	480,572	488,983	530,366	551,437	558,388	579,359	583,497	269,531	339,580
Due to associated companies	11,346	12,392	13,000	13,000	13,000	13,000	13,000	13,000	13,000	13,000	13,000	13,000
Total current liabilities	731,516	778,294	455,228	571,623	583,020	619,842	639,996	647,656	675,771	678,248	321,399	390,640
Other long-term obligations	223,628	230,249	241,382	241,382	240,084	238,786	237,488	236,190	234,892	233,594	232,296	230,998
Total liabilities	955,144	1,008,543	696,610	813,005	823,104	858,628	877,484	883,846	910,663	911,842	553,695	621,638
Equity:												
Capital stock-Common	9	9	9	9	9	9	9	9	9	9	9	9
Additional paid in capital	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982
Retained earnings and partners' capital	635,780	713,199	717,414	717,449	717,449	717,448	717,448	717,449	717,448	717,448	577,892	527,410
Minimum pension liability adjustment	(145,136)	(139,935)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)
Unrealized gain on Infinity Stock /FX Translation	-	97,469	-	-	-	-	-	-	-	-	-	-
Subscription Receivable	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)
Total stockholder's equity	491,636	671,725	589,970	590,005	590,005	590,004	590,004	590,005	590,004	590,004	450,448	399,966
Total liabilities and stockholder's equity	$1,445,780	$1,680,268	$1,286,580	$1,403,010	$1,413,109	$1,448,633	$1,467,489	$1,473,851	$1,500,667	$1,501,846	$1,004,142	$1,021,603

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2013 10-Year Plan: Statement of Cash Flows

Non-Risk Adjusted

Statement of Cash Flows *Non-Risk Adjusted* ($000)	2011 Actual	2012 Actual	2013 Forecast	2014 Plan	2015 Plan	2016 Plan	2017 Plan	2018 Plan	2019 Plan	2020 Plan	2021 Plan	2022 Plan
Operating activities												
Net income (loss) after tax before extraordinary item	$1,144,453	$1,008,308	$ 911,586	$ 597,067	$ 550,567	$ 762,319	$ 673,924	$ 772,512	$ 890,723	$ 909,736	$ 440,608	$ 267,005
Non-cash charges (credits) to net income:												
Depreciation	25,564	24,120	25,364	25,000	33,091	34,570	35,030	34,790	34,745	34,870	35,143	35,545
Amortization	2,740	4,939	6,840	8,200	8,200	7,011	7,011	7,011	6,760	5,018	3,192	2,486
Loss on equity investment companies	112,368	101,005	163,066	144,477	107,075	62,489	28,398	36,385	36,385	36,385	36,385	36,385
Working capital changes	162,044	88,604	(271,229)	67,416	7,113	12,200	11,502	(44)	12,057	(5,355)	(219,646)	51,972
Extraordinary Item Payout / Reduction in Infinity	(988)		189,500	-	-	-	-	-	-	-	-	-
Long-term assets and liabilities	29,846	(2,012)	(71,153)	-	(1,298)	(1,298)	(1,298)	(1,298)	(1,298)	(1,298)	(1,298)	(1,298)
Cash flow from operations	1,475,761	1,242,391	953,974	842,160	704,748	877,290	754,567	849,356	979,373	979,356	294,384	392,095
Investing activities												
Capital expenditure	(26,823)	(30,467)	(35,000)	(76,500)	(42,500)	(37,500)	(33,500)	(34,505)	(35,540)	(36,606)	(37,705)	(38,836)
Restricted Cash, net	12,944	17,337	14,632	(5,200)	-	-	-	-	-	-	-	-
Investments in JV and associates	(100,323)	(89,089)	(224,306)	(144,477)	(107,075)	(62,489)	(28,398)	(36,385)	(36,385)	(36,385)	(36,385)	(36,385)
Cash flow used by investing	(174,202)	(159,701)	(244,674)	(226,177)	(149,575)	(99,989)	(61,898)	(70,890)	(71,925)	(72,991)	(74,090)	(75,221)
Financing activities												
Proceeds from (to) associated companies, net	(3,823)	(2,703)	18,504	3,915	344	(31)	(20)	783	824	760	681	612
Distributions for Required Tax Payments	(553,393)	(459,245)	(331,772)	(298,534)	(275,283)	(381,159)	(336,962)	(386,256)	(445,362)	(454,868)	(220,304)	(133,502)
Distributions Non Tax	(575,246)	(471,643)	(575,600)	(298,498)	(275,284)	(381,160)	(336,962)	(386,256)	(445,362)	(454,868)	(359,860)	(183,985)
Cash flow provided by financing	(1,132,159)	(933,591)	(888,868)	(593,117)	(550,223)	(762,350)	(673,944)	(771,729)	(889,900)	(908,976)	(579,483)	(316,875)
Increase in cash and cash equivalents	169,400	149,099	(179,568)	22,867	4,950	14,952	18,726	6,738	17,548	(2,612)	(359,188)	(1)
Unrestricted Cash at beginning of period	437,094	606,494	755,593	576,025	598,892	603,842	618,794	637,519	644,257	661,805	659,193	300,004
Unrestricted Cash at end of period	**$ 606,494**	**$ 755,593**	**$ 576,025**	**$ 598,892**	**$ 603,842**	**$ 618,794**	**$ 637,519**	**$ 644,257**	**$ 661,805**	**$ 659,193**	**$ 300,004**	**$ 300,004**

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Headcount

Non-Risk Adjusted

10 Year Plan - Headcount	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
	Actual	Actual	Actual	Actual	Actual	10 Year Plan Outlook									
Sales and Marketing															
Sales Reps	346	397	474	508	487	517	517	517	517	517	517	517	517	385	385
DM	44	50	65	66	62	66	66	66	66	66	66	66	66	56	56
RM	6	7	9	9	11	11	11	11	11	11	11	11	11	8	8
Other	45	46	57	63	65	71	71	71	71	71	71	71	71	69	69
Subtotal - Field Sales	441	500	605	646	625	665	665	665	665	665	665	665	665	518	518
Marketing	35	40	44	45	48	55	55	57	57	57	57	57	57	57	57
Sales Support	17	21	18	23	29	32	32	32	32	32	32	32	32	32	32
Total: Sales & Marketing *	493	561	561	714	702	752	752	754	754	754	754	754	754	607	607
Manufacturing	309	262	262	263	262	279	292	331	370	380	384	384	391	387	387
G&A	325	336	343	357	368	384	384	384	384	384	384	384	384	170	170
R&D	237	252	270	299	334	360	360	360	360	360	360	360	360	283	283
President's Reserve					8	(24)									
Total Purdue Headcount	**1,364**	**1,411**	**1,436**	**1,633**	**1,674**	**1,751**	**1,788**	**1,829**	**1,868**	**1,878**	**1,882**	**1,882**	**1,889**	**1,447**	**1,447**

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

10-Year Plan: Non-Tax Distributions

Non-Risk Adjusted



	2012 A	2013F	2014	2015	2016	2017	2018	2019	2020	2021	2022
2012's 10-Year Plan	473	428	387	549	717	776	506	609	391		
2013's 10-Year Plan	472	576	298	275	381	337	386	445	455	360	184

	$ millions
Non-Tax Distributions	**2012-2020**
Presented in 2012 Plan	4,834
Presented in 2013 Plan	3,626
Change, 2013 vs 2012 Plan	**(1,208)**
Variance Analysis	
5% increase in tax rate (45% vs 50%)	(363)
Lower operating profits	(804)
Others	(42)
Total Change	**(1,208)**

Confidential 53

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Financial Schedules

RISK-ADJUSTED

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2013 10-Year Plan: Profit & Loss Statement

Risk-Adjusted

($000's)	2012 Actual	2012 Forecast	2014	2015	2016	2017	2018	2019	2020	2021	2022
Gross Branded Product Sales	$3,004,905	$2,821,387	$3,045,782	$3,007,219	$3,192,385	$3,208,221	$3,244,080	$3,220,417	$3,048,909	$825,046	$467,045
OxyContin Settlements	0	0	(313,648)	(302,939)	(291,573)	(403,400)	(342,292)	(256,121)	(232,660)	0	0
Fee for Service	(59,313)	(57,957)	(51,803)	(51,022)	(54,874)	(54,948)	(55,435)	(56,982)	(51,491)	(13,467)	(5,071)
Discounts and Allowances	(134,032)	(54,066)	(67,031)	(75,727)	(84,003)	(77,268)	(79,533)	(81,918)	(72,503)	(21,723)	(14,032)
Patient Savings Card Discounts	(25,104)	(41,334)	(31,498)	(36,000)	(50,276)	(57,666)	(62,861)	(63,150)	(45,937)	(26,960)	(11,286)
Additional Oxy Rebates on Final Proposed Rule	(50,383)	(73,892)	(44,238)	(43,897)	(41,977)	(39,480)	(39,609)	(40,240)	(33,837)	0	0
Rebates on Branded Sales	(517,606)	(455,882)	(539,001)	(550,314)	(719,419)	(754,908)	(753,001)	(770,069)	(705,880)	(129,355)	(74,728)
Rebates as % of Gross Branded Sales	19.2%	19.9%	22.4%	23.1%	23.5%	24.5%	24.4%	24.4%	24.3%	15.7%	15.0%
NET BRANDED REVENUES	2,198,467	2,105,556	1,886,557	1,834,316	1,946,233	1,810,549	1,901,664	2,031,928	1,896,600	632,541	360,927
AG Income	-	-	-	-	-	-	-	-	-	210,293	38,365
3rd Party Royalty Income	2,455	1,651	4,712	5,725	6,993	7,280	7,320	7,320	7,360	7,360	7,360
NET BRANDED REVENUES + AG & PROFIT SHARE INCOME	2,200,922	2,107,207	1,891,269	1,840,041	1,953,226	1,817,830	1,908,984	2,039,247	1,903,961	850,194	403,653
Cost of Goods Sold	(148,475)	(149,240)	(147,128)	(163,132)	(190,491)	(205,596)	(209,114)	(217,708)	(217,870)	(184,938)	(177,165)
COGS as % of Gross Branded Product Sales	4.9%	5.3%	5.4%	5.0%	5.6%	7.3%	7.2%	7.1%	7.7%	22.6%	37.9%
3rd Party Royalty Expense	(120,268)	(122,339)	(122,276)	(124,565)	(129,779)	(126,525)	(125,427)	(128,504)	(134,042)	(32,714)	(15,653)
Shipping and Warehousing	(11,814)	(11,356)	(10,151)	(9,742)	(10,092)	(10,466)	(10,449)	(10,578)	(10,312)	(7,010)	(5,761)
GROSS PROFIT	1,920,366	1,824,272	1,611,711	1,542,496	1,622,863	1,475,242	1,563,993	1,682,457	1,541,738	625,531	205,070
G&A (incl Legal Dept but excl Legal Fees)	(154,259)	(158,428)	(166,041)	(171,362)	(177,567)	(184,093)	(190,536)	(197,208)	(204,107)	(50,119)	(23,743)
G&A as % of Net Sales	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
R&D - allocated to projects	(312,519)	(327,247)	(304,314)	(295,292)	(222,618)	(173,981)	(110,346)	(101,078)	(104,589)	(65,518)	(61,861)
R&D - unallocated	-	-	-	-	(15,041)	(47,647)	(120,138)	(152,554)	(93,038)	-	-
R&D Other - Milestone and Alliances	(2,284)	(10,952)	(4,181)	(4,181)	(4,181)	(3,791)	171	171	171	56	56
R&D as % of Net Sales	14%	15%	15%	15%	12%	12%	12%	12%	10%	11%	17%
Sales and Promotion	(303,110)	(255,313)	(293,755)	(331,527)	(330,035)	(324,266)	(315,206)	(343,974)	(313,798)	(106,505)	(60,928)
S&P as % of Net Sales	14%	14%	15%	15%	17%	15%	17%	17%	17%	17%	17%
Pharmacy Fee (Health Reform)	(31,251)	(31,800)	(32,828)	(34,326)	(30,943)	(43,892)	(45,104)	(30,541)	(29,362)	(28,408)	(5,107)
Other - US	(17,933)	(439)	(12,182)	(4,181)	(4,107)	(4,036)	(4,031)	(4,026)	(4,026)	(4,020)	(4,014)
OPERATING EXPENSES	(862,602)	(871,662)	(863,198)	(886,620)	(828,566)	(822,669)	(828,663)	(866,710)	(784,627)	(279,214)	(183,558)
Operating Expenses as % of Net Sales	40.1%	41.4%	45.5%	48.3%	42.5%	45.5%	43.5%	42.5%	41.2%	44.1%	50.9%
OPERATING MARGIN BEFORE INCENTIVE & SETTLEMENTS	Redacted										
Incentive Bonus	(34,285)	(35,612)	(36,330)	(37,057)	(37,798)	(38,554)	(39,325)	(40,112)	(40,914)	(13,788)	(1,809)
Insurance Income	3,520	3,558	350	0	0	0	0	0	0	0	0
Settlement Expense	(14,247)	(1,900)	0	0	0	0	0	0	0	0	0
TOTAL INCENTIVES AND SETTLEMENTS	(45,012)	(33,960)	(35,980)	(37,057)	(37,798)	(38,554)	(39,325)	(40,112)	(40,914)	(13,788)	(1,809)
OPERATING MARGIN AFTER INCENTIVES AND SETTLEMENTS	992,760	918,660	712,662	618,919	756,166	612,829	696,116	773,832	716,166	332,529	19,702
Other Items											
Royalty Income - ex US	53,951	40,692	39,031	37,654	37,777	37,885	34,721	31,425	28,387	25,662	23,214
Ex US Expenses	(69,063)	(164,889)	(144,477)	(107,075)	(62,489)	(38,398)	(36,385)	(36,385)	(36,385)	(36,385)	(36,385)
One Time Charges	(2,146)	(2,956)	(3,081)	(3,196)	(3,314)	(3,437)	(3,566)	(3,698)	(3,836)	(127,459)	(3,894)
Gain on sale of Infinity stock		124,581									
Interest (Expense) / Income	1,354	172	172	172	172	172	172	172	172	172	172
TOTAL OTHER ITEMS	18,106	(2,400)	(108,356)	(72,444)	(27,854)	6,192	(5,056)	(8,486)	(11,662)	(138,010)	(16,892)
PROFIT & LOSS BEFORE TAX	$1,010,866	$916,260	$604,207	$546,475	$728,311	$619,022	$691,063	$765,147	$704,523	$194,489	$1,809
Pre Tax Profit as % of Net Sales	46.0%	43.5%	32.0%	29.7%	37.4%	34.0%	36.2%	37.7%	37.1%	30.7%	0.5%

Confidential 55

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2013 10-Year Plan: Balance Sheet

Risk-Adjusted

Risk-Adjusted ($000)	2011 Actual	2012 Actual	2013 Forecast	2014 Plan	2015 Plan	2016 Plan	2017 Plan	2018 Plan	2019 Plan	2020 Plan	2021 Plan	2022 Plan
Assets												
Current Assets:												
Cash and cash equivalents	$ 606,494	$ 755,593	$ 576,026	$ 644,158	$ 647,708	$ 659,239	$ 682,661	$ 681,926	$ 688,471	$ 663,853	$ 321,005	$ 300,004
Restricted Cash	16,000	23,927	4,800	-	-	-	-	-	-	-	-	-
Accounts and other receivable:												
Trade (net)	218,801	187,137	136,623	172,909	171,271	184,097	177,639	183,781	193,439	178,362	52,126	29,580
Associated companies	27,820	31,819	13,673	9,758	9,414	9,444	9,464	8,680	7,856	7,097	6,415	5,803
Other receivables	10,075	2,957	7,250	6,178	6,431	6,748	6,820	6,830	6,830	6,840	6,840	6,840
Total accounts and other receivable	256,696	221,913	157,545	188,844	187,116	200,289	193,922	199,291	208,125	192,299	65,382	42,223
Inventories	44,207	50,531	42,881	36,782	40,783	47,523	51,399	52,278	54,427	54,468	46,235	44,292
Prepaid expenses and other assets	32,658	22,144	23,670	23,670	23,670	23,670	23,670	23,670	23,670	23,670	23,670	23,670
Total current assets	956,055	1,074,208	804,923	893,454	899,277	930,820	951,653	957,166	974,693	934,290	456,291	410,189
Property, plant and equipment - net	143,163	149,483	159,119	210,619	220,028	222,958	221,428	221,143	221,938	223,675	226,237	229,527
Investments	19,787	7,871	69,111	69,111	69,111	69,111	69,111	69,111	69,111	69,111	69,111	69,111
Due from associated companies	3,250	3,000	3,250	3,250	3,250	3,250	3,250	3,250	3,250	3,250	3,250	3,250
Intangible assets, net	191,602	196,545	189,805	181,605	173,405	166,394	159,383	152,372	145,612	140,594	137,402	134,916
Other assets	90,454	231,856	38,672	38,672	38,672	38,672	38,672	38,672	38,672	38,672	38,672	38,672
Restricted cash	42,469	17,205	21,700	31,700	31,700	31,700	31,700	31,700	31,700	31,700	31,700	31,700
Total assets	$1,445,780	$1,580,268	$1,286,580	$1,428,411	$1,435,443	$1,462,905	$1,475,196	$1,473,414	$1,484,977	$1,441,292	$ 962,663	$ 917,366
Liabilities												
Current liabilities:												
Accounts payable	$ 87,361	$ 71,181	$ 81,600	$ 81,333	$ 83,836	$ 78,480	$ 78,171	$ 78,519	$ 82,921	$ 74,875	$ 25,751	$ 16,059
Accrued expenses and taxes	632,809	694,721	360,628	502,691	508,518	542,635	556,533	555,701	564,160	529,818	166,885	131,673
Due to associated companies	11,346	12,392	13,000	13,000	13,000	13,000	13,000	13,000	13,000	13,000	13,000	13,000
Total current liabilities	731,516	778,294	455,228	597,025	605,354	634,115	647,704	647,220	660,081	617,693	205,637	160,733
Other long-term obligations	223,628	230,249	241,382	241,382	240,084	238,786	237,488	236,190	234,892	233,594	232,296	230,998
Total liabilities	955,144	1,008,543	696,610	838,407	845,438	872,901	885,192	883,410	894,973	851,287	437,933	391,731
Equity:												
Capital stock-Common	9	9	9	9	9	9	9	9	9	9	9	9
Additional paid in capital	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982	1,982
Retained earnings and partners' capital	635,780	713,199	717,414	717,449	717,449	717,448	717,449	717,448	717,448	717,449	652,174	653,079
Minimum pension liability adjustment	(145,136)	(139,935)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)	(128,436)
Unrealized gain on Infinity Stock /FX Translation	-	97,469	-	-	-	-	-	-	-	-	-	-
Subscription Receivable	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)	(999)
Total stockholder's equity	491,636	671,725	589,970	590,005	590,005	590,004	590,005	590,004	590,004	590,005	524,730	525,635
Total liabilities and stockholder's equity	$1,445,780	$1,580,268	$1,286,580	$1,428,411	$1,435,443	$1,462,905	$1,475,197	$1,473,414	$1,484,977	$1,441,292	$ 962,663	$ 917,366

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2013 10-Year Plan: Statement of Cash Flows

Risk-Adjusted

Statement of Cash Flows *Risk-Adjusted* ($000)	2011 Actual	2012 Actual	2013 Forecast	2014 Plan	2015 Plan	2016 Plan	2017 Plan	2018 Plan	2019 Plan	2020 Plan	2021 Plan	2022 Plan
Operating activities												
Net income (loss) after tax before extraordinary item	$1,144,453	$1,008,308	$ 911,586	$ 604,207	$ 546,475	$ 728,311	$ 619,022	$ 691,058	$ 765,147	$ 704,533	$ 194,489	$ 1,809
Non-cash charges (credits) to net income:												
Depreciation	25,564	24,120	25,364	25,000	33,091	34,570	35,030	34,790	34,745	34,870	35,143	35,545
Amortization	2,740	4,939	6,840	8,200	8,200	7,011	7,011	7,011	6,760	5,018	3,192	2,486
Loss on equity investment companies	112,368	101,005	163,066	144,477	107,075	62,489	28,398	36,385	36,385	36,385	36,385	36,385
Working capital changes	162,044	88,604	(271,229)	112,682	5,713	8,779	16,198	(7,515)	1,054	(27,362)	(277,588)	(20,415)
Extraordinary Item Payout / Reduction in Infinity	(988)		189,500	-	-	-	-	-	-	-	-	-
Long-term assets and liabilities	29,846	(2,012)	(71,153)	-	(1,298)	(1,298)	(1,298)	(1,298)	(1,298)	(1,298)	(1,298)	(1,298)
Cash flow from operations	1,475,761	1,242,391	953,974	894,567	699,256	839,862	704,361	760,431	842,793	752,146	(9,675)	54,513
Investing activities												
Capital expenditure	(26,823)	(30,487)	(35,000)	(76,500)	(42,500)	(37,500)	(33,500)	(34,505)	(35,540)	(36,606)	(37,705)	(38,836)
Restricted Cash, net	12,944	17,337	14,632	(5,200)	-	-	-	-	-	-	-	-
Investments in JV and associates	(100,323)	(89,089)	(224,306)	(144,477)	(107,075)	(62,489)	(28,398)	(36,385)	(36,385)	(36,385)	(36,385)	(36,385)
Cash flow used by investing	(174,202)	(159,701)	(244,674)	(226,177)	(149,575)	(99,989)	(61,898)	(70,890)	(71,925)	(72,991)	(74,090)	(75,221)
Financing activities												
Proceeds from (to) associated companies, net	(3,823)	(2,703)	18,504	3,915	344	(31)	(20)	783	824	760	681	612
Distributions for Required Tax Payments	(553,393)	(459,245)	(331,772)	(302,104)	(273,237)	(364,156)	(309,511)	(345,529)	(382,573)	(352,266)	(97,245)	(904)
Distributions Non Tax	(575,246)	(471,643)	(575,600)	(302,068)	(273,238)	(364,156)	(309,510)	(345,530)	(382,574)	(352,266)	(162,519)	-
Cash flow provided by financing	(1,132,159)	(933,591)	(888,868)	(600,257)	(546,131)	(728,343)	(619,041)	(690,276)	(764,323)	(703,772)	(259,083)	(292)
Increase in cash and cash equivalents	169,400	149,099	(179,568)	68,133	3,550	11,530	23,422	(735)	6,545	(24,618)	(342,849)	(21,000)
Unrestricted Cash at beginning of period	437,094	606,494	755,593	576,025	644,158	647,708	659,239	682,661	681,926	688,471	663,853	321,005
Unrestricted Cash at end of period	**$ 606,494**	**$ 755,593**	**$ 576,025**	**$ 644,158**	**$ 647,708**	**$ 659,239**	**$ 682,661**	**$ 681,926**	**$ 688,471**	**$ 663,853**	**$ 321,005**	**$ 300,004**

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Non-Risk Adjusted versus Risk Adjusted Financials

10-Year Plan (2013-2022, Cumulative)	Non Risk-Adjusted $ millions	With Risk-Adjusted $ millions	Difference $ millions	Difference %
Net Branded Revenues	18,518	16,407	(2,111)	-11.4%
Pre-tax Net Profits	6,842	5,771	(1,071)	-15.6%

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00014886

Managed Care

June 6, 2013

Confidential. For Internal Discussion Only.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Managed Care Landscape

- Employers, Government, Patients:
  - Increasing pressure to reduce utilization of branded pharmaceuticals to reduce costs
    - Employers are seeking to reduce costs related to prescription benefit plans
    - Federal & State Government budgets are increasing as more patients move into government subsidized benefit plans
    - Patients are looking for ways to reduce medication costs
- Third-Party Payers (Managed Care):
  - Increasing implementation of strategies to minimize utilization of higher cost brands
    - Formulary "Tiers" with higher patient co-pays for branded products
    - Prior Authorization before an Rx is allowed
    - Step Edits/Algorithms to follow with a "generic first" approach
    - Drug Utilization Review/Counter-Detailing to Physicians by Pharm.D's.

2

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Managed Care Landscape

- Use of generic/therapeutic alternatives versus "AB-Rated" generics is commonplace
  - Same class of medication
  - Same indication
  - Same dosage form/schedule is preferable but not necessary
- Generic/therapeutic alternatives available in the Extended-Release Opioid category
  - Generic Duragesic (transdermal fentanyl)
  - Generic MS Contin (q12h morphine)
  - Generic Dolophine (methadone)
  - Generic Opana ER (q12h oxymorphone)

3

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY



4

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

10-Year Plan: Total Rebates as % of Gross Sales

= (Rebates on Branded Sales + Additional Oxy Rebates on Final Proposed Rule) ÷ (Gross Branded Product Sales – OxyContin Settlements)

Non-Risk Adjusted



	2013F	2014	2015	2016	2017	2018	2019	2020	2021	2022
2012's 10-Year Plan	20.2%	20.2%	19.7%	19.3%	20.0%	9.3%	12.6%	11.5%		
2013's 10-Year Plan	19.9%	25.0%	25.6%	25.9%	27.8%	26.8%	25.9%	25.1%	19.4%	26.1%

Confidential 5

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY



CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

OxyContin – Overview

- **Commercial Channel** **85% of lives on tier 2/preferred formulary position**
  - National market share 26.1%
    - Medco (30.2%), Express Scripts (28.2%), Caremark (27.4%), Prime (27.3%), United (26.8%), Regence (14.8%), Coventry (12.1%)
  - Rebate Ranges *(as of percentage of Wholesale Acquisition Cost [WAC])*
    - 10.0% to 19.75%
- **Medicare Part D Channel** **50% of lives on preferred tier formulary position**
  - National market share 20.5%
    - United (28.5%), Rx Solutions (28.2%), Silverscript (24%), MemberHealth (22.1%) Wellcare (5.2%), Humana (4.9%)
  - Rebate Ranges *(as of percentage of Wholesale Acquisition Cost [WAC])*
    - 24.5% to 38.0%
- **Medicaid Channel** **2.0% of lives on preferred drug list**
  - National market share 16.7%
    - Preferred Drug List States: Missouri, Nebraska, and Kansas

Confidential. For Internal Discussion Only.

7

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Butrans – Overview

- **Commercial Channel** **32% of lives on tier 2/preferred formulary position**
  - National market share 6.3%
    - Prime (8.2%), Express Scripts (7.7%), Medco (7.4%), Caremark (7.1%), Coventry (2.2%), Keystone (1.6%)
    - Aetna Butrans – 2nd tier: 34% increase in prescription in first 5 months
  - Rebate Ranges *(as of percentage of Wholesale Acquisition Cost [WAC])*
    - 12.5% to 23.0%
- **Medicare Part D Channel** **1% of lives on preferred tier formulary position**
  - National market share 2.1%
    - ESI (2.7%), United (1.9%), Coventry (1.7%), Humana (1.3%), Wellcare (1.2%)
  - Rebate Ranges *(as of percentage of Wholesale Acquisition Cost [WAC])*
    - 25% to 38%
- **Medicaid Channel** **3.0% of lives on preferred drug list**
  - National market share 2.6%
    - Preferred Drug List States: Wisconsin and Texas

Confidential. For Internal Discussion Only.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Payer – Challenges

- **Consolidation within payers** ⟶ Large payers are becoming larger
  - Increased negotiating power ⟶ Pharma companies must meet demands or products' formulary position compromised
    - Pressure for increased rebates in all channels to maintain or gain formulary position
      - 3rd Tier "Access" Rebates greater than 20% demanded
      - Brand Competitors offered 40-45% (preferred) in Commercial over 60% in Medicare Part D
    - Demands to accept payers' terms and conditions
      - Monthly rebate payments
      - Price protection/predictability
      - Longer term agreements with no cancellations clauses

- **Market Dynamics** decreasing opioid utilization/cost across all Channels
  - Pressure for increased utilization of therapeutic alternatives
    - Payer process challenges (step-edits and prior authorizations) to brands in category
  - Questions surrounding long-term use of opioids for specific patient populations
  - Initiatives to validate increased total daily doses – are having impact in the field
    - Centers for Medicaid and Medicare Services (CMS) 120mg./day Medicare guidance
    - PROP (Physicians for Responsible Opioid Prescribing) Initiatives
    - Washington State Initiative and its impact outside of Washington/Workers Comp

Confidential. For Internal Discussion Only.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Payers are able to rapidly erode sales



10

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Recent Formulary Changes for Purdue

Formulary Wins				
Date	*Account*	*Lives*	*Product*	*Est. Gross Sales*
Nov-12	Aetna Commercial	8.0mm	Butrans	$3,000,000
Jul-13	Coventry Med D	800K	Butrans	$450,000
Jan-14	Optum/United Med D	4.0mm	OxyContin	$200,000,000
Jan-14	Caremark Med D	3.5mm	OxyContin	$120,000,000
Jan-14	Cigna Med D	675K	OxyContin	$46,000,000
Jan-14	Medco Med D	3.5mm	Butrans	$1,100,000
Jan-14	Health Net Med D	200K	OxyContin	$5,000,000
Jan-14	Health Net Med D	200K	Butrans	$500,000

Formulary Losses				
Date	*Account*	*Lives*	*Product*	*Est. Gross Sales*
Jan-13	United MA-PD	2.5mm	OxyContin	$70,000,000
Jul-13	United Commercial	14.0mm	Butrans	$6,000,000

PURDUE

11

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Multiple customer segments shape the healthcare delivery system in the United States; complexity is the norm



PURDUE

12

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Strategies to Enhance Access in 2013 and Beyond

- Novel Access strategies
  - **Low Income Subsidy/Medicare Part D**
    - Offer aggressive rebates to accounts who have a disproportionate share of LIS
    - OxyContin shifted from Not Covered to preferred on Member Health/CCRx (87% increase in Trx from baseline)
  - **Unrestricted tier 3(non-preferred brand)**
    - Offer rebates to remove payer restriction(Prior Authorization or Step Edit)
    - Butrans shifted from a 3rd tier PA position to unrestricted on Blue Shield of CA
  - **Price Predictability**
    - Protects a customer at a contracted price and aides in setting payer fiscal budgets

Confidential. For Internal Discussion Only.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Strategies to Enhance Access Continued…

- **Pull through**
  - Standardizes the field sales communication process to HCPs
  - Enhances market share and increases revenue after a positive formulary shift
  - Customized physician target list is automatically generated to ensure managed care messaging is effectively delivered to the right audience
- **Educate internal and external stakeholders**
  - Clinical support/ Health outcomes/ Value added resources
- **Market Access Support Team**
  - Cross functional team designed to create compelling value propositions and generate evidence to achieve favorable formulary access

PURDUE

14

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Member Health Part D Pull Through Results



PURDUE

Confidential. For Internal Discussion Only.

15

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Market Access Support Team



Primary Objective: Clearly differentiate our current and emerging products to customers and develop research driven value propositions and evidence to gain favorable access

PURDUE

Confidential. For Internal Discussion Only.

16

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

ONU Payer Research

- **Payers do not consider opioid-related constipation as an unmet need requiring a new extended release opioid option.**
  - It will be necessary to establish, but not overstate, the need for ONU by providing evidence of the number and type of patients who fail existing extended release opioids due to constipation and the downstream health plan costs associated with this issue.
- **It will be critical to establish the relevance of constipation in vulnerable subgroups of chronic pain patients using extended release opioids, particularly the elderly.**
  - It will be necessary to establish unmet need in a clearly defined patient subgroup where the risks and consequences of constipation are greatest, and where a combination product provides a clinically meaningful improvement in that subgroup compared to a generic extended release opioid plus standard constipation products.
- **Payer research directionally indicates that while not ideal, we launch with a "pain-only" indication, with a promotional focus that communicates the effective reduction in side effects and describe/educate the role of naloxone**

Confidential. For Internal Discussion Only.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

HYD Payer Research

- **Payers do not understand the true risk and cost consequence of acetaminophen-related liver toxicity.**
  - Payers will not value a new hydrocodone product until they more fully understand the true incidence of opioid combination acetaminophen-related liver toxicity and the associated costs.
- **A specific role in the elderly population may be an opportunity for a place in therapy.**
  - Both 'simplification of care' and safety, based on elimination of acetaminophen, are value messages that will be especially compelling to Medicare and long-term care health plans.

Confidential. For Internal Discussion Only.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Affordable Care Act Timeline 2010 – 2015+

Health Reform Timeline

2010	2011	2012	2013	2014	2015+
Healthcare Reform Signed March 23, 2010	Manufacturers cover 50% of brand-prescription cost for patients in the Medicare Part D donut hole	Administrative Simplification rules required under Health Care Reform begin to phase in	Federal subsidies begin for brand-prescriptions for patients in the Medicare Part D donut hole (patient cost goal of 25% by 2020)	Deadline for state Health Insurance Exchanges and state Basic Health Plans expected to cover 24M patients	Comparative Effectiveness Review (CER) examines the cost effectiveness of individual medications, the comparative performance between therapies vs. procedures
Dependent child healthcare coverage up to age 26	State Health Insurance Exchange draft regulations and guidance open for public comment	Manufacturers required to report payments to physicians and teaching hospitals on a publically available website		Medicaid expansion to cover up to 133% of the federal poverty level (FPL); expansion estimated at 16M patients	Year 2020: Medicare Part D donut hole phased out; patients continue to pay 25% of their drug costs
Medicare Part D doctors utilizing Eprescribing obtain a 2% bonus; doctors not using e-prescribing will have their reimbursement rates reduced starting in 2012					

Source: Healthcare reform timeline 110111

Confidential. For Internal Discussion Only.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

The most far-reaching effects of the Affordable Care Act will come from: 1) expansion of coverage and 2) payment reforms

	What is it?	Implications?
Coverage Expansion	• Enrollment of the uninsured in health plans offered through state exchanges • Expansion of Medicaid	• Increased demand • Increased payer management • Lower profit margins
Payment Reforms	• Avoidable Readmission Penalties • Value-based Purchasing Program • ACO Shared Savings Program • Bundled payment pilots	• Emergence of integrated providers • Focus on cost and quality in all settings of care • Financial risk shifts from payers to providers

IDNS and ACOs will control product choice and utilization differently, which will present challenges to the pharma sales model.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

After 2014, 30+ million uninsured are expected to gain coverage through exchanges and Medicaid



Source: CBO, February 2013 Estimate of the Effects of the Affordable Care Act on Health Insurance Coverage

21

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Accountable Care Organizations

- CMS is implementing ACOs to overcome fragmentation and volume orientation of existing fee-for-service system.
- Goal is to align quality and safety initiatives, shares in savings and reduce overall cost of care.



PURDUE

Confidential. For Internal Discussion Only.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

In the evolving environment, real world evidence, compelling value propositions , and promotional mix must focus on stake-holders that control access to drugs across the care spectrum

Relevant Stakeholders

- Payers
- IDNs/ACOs
- Network P&T Committees
- Physicians

- *Challenges in this setting of care*
  - Sales Reps will face increasing barriers to access to prescribers
  - Prescribers face limited discretion under formularies and protocols
  - Payers will demand real world evidence in order for a product to achieve unencumbered access
- *Pharma must tailor its approach*
  - Clinical evidence must be developed against standard of care and tied to relevant outcomes and payment metrics
  - Manufacturer must show how new product will help provider achieve cost and quality objectives
  - In regions with large, integrated providers, promotion needs to evolve from sales reps to account managers and clinical liaisons

PURDUE

IDNS and ACOs will control product choice and utilization differently, which will present challenges to the pharma sales model.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Purdue US

Sales and Budget Update

June 2013

CONFIDENTIAL

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Agenda:

Opening Remarks	John Stewart
Sales Update	Russ Gasdia
	David Rosen
Budget Update	Edward Mahony

2

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Net Sales are forecasted to end 2013 $303.1 million and $93.7 million below budget and prior year, respectively. Details and corrective actions follow:

Product	2010 Actual	2011 Actual	2012 Actual	2013 Budget	2013 Forecast	$ Variance 2013 Budget vs 2013 Forecast
OxyContin - 10MG	$ 121.3	$ 146.8	$ 152.7	$ 157.0	$ 142.5	$ (14.5)
OxyContin - 15MG	23.6	27.1	34.0	37.8	35.8	(2.0)
OxyContin - 20MG	361.3	404.1	402.5	419.9	377.7	(42.2)
OxyContin - 30MG	161.0	171.7	205.3	237.4	214.5	(22.9)
OxyContin - 40MG	683.0	633.7	618.7	622.3	555.8	(66.5)
OxyContin - 60MG	315.7	300.7	340.7	388.8	338.3	(50.5)
OxyContin - 80MG	1,331.8	1,096.8	1,023.1	1,053.1	888.5	(164.6)
OxyContin	$ 2,997.8	$ 2,781.0	$ 2,777.1	$ 2,916.5	$ 2,553.1	$ (363.4)
Butrans	-	73.5	112.9	160.0	160.0	-
Intermezzo	-	-	16.6	57.6	13.9	(43.7)
Dilaudid	35.1	24.8	23.8	17.0	17.0	-
MS Contin	15.1	13.3	13.0	11.6	11.6	-
Laxatives	48.1	51.1	51.5	49.3	49.3	-
Betadine\Betasept	10.9	11.1	11.6	11.1	11.1	-
Slow Mag	4.6	5.4	5.6	5.3	5.3	-
Ryzolt	16.5	11.2	(6.9)	-	-	-
Uniphyl	(0.2)	(0.3)	(0.0)	-	-	-
All Other	(0.0)	(0.1)	(0.1)	-	-	-
					-	-
Total Gross Sales	**$ 3,127.9**	**$ 2,971.2**	**$ 3,004.9**	**$ 3,228.5**	**$ 2,821.4**	**$ (407.1)**
Fee for Service	$ (79.2)	$ (74.5)	$ (69.3)	$ (65.3)	$ (58.0)	$ 7.4
Sales Discounts & Allowances	(48.8)	(56.2)	(134.0)	(88.2)	(54.1)	34.1
Patient Savings Card Discounts	(15.7)	(15.6)	(25.1)	(34.5)	(41.3)	(6.8)
Rebates on Branded Sales	(621.6)	(545.9)	(517.6)	(554.9)	(488.6)	66.3
Proposed regulation adj for Medicaid rebates	(40.0)	(68.9)	(60.4)	(76.8)	(73.9)	2.9
Other	27.6	12.4	2.5	1.7	1.7	-
Total Rebates & Deductions $	**$ (777.8)**	**$ (748.7)**	**$ (804.0)**	**$ (818.1)**	**$ (714.2)**	**$ 103.9**
Rebates and Deductions %	24.9%	25.2%	26.8%	25.3%	25.3%	25.5%
Total Net Sales	**$ 2,350.1**	**$ 2,222.5**	**$ 2,200.9**	**$ 2,410.3**	**$ 2,107.2**	**$ (303.1)**

3

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

OxyContin® Sales Update

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Year to date April sales were below budget by $162 million:

- $61 million attributed to lower demand
  - $21 million due to lower numbers of tablets per prescription than assumed in budget
  - $11 million due to lower overall prescription volume than budgeted
  - $25 million due to higher strengths prescriptions declining more rapidly than lower strength prescriptions
- $101 million attributed to trade inventory changes

5

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Reconciliation of OxyContin sales from Budget to Forecast

	Year to Date April		Full Year Forecast vs. Budget	
	$ millions	%	$ millions	%
Budget	**$961**	**100%**	**$2,916**	**100%**
Number of Tablets per prescription lower than Budget	($21)	(2.2%)	($79)	(2.9%)
Lower total prescriptions than Budget	($11)	(1.2%)	($110)	(3.4%)
Impact of mix and in particular lower sales of higher strengths	($25)	(2.5%)	($79)	(2.8%)
Other	($4)	(0.5%)	$0	(0.1%)
Sub-total demand	**($61)**	**(6.4%)**	**($268)** (1)	**(9.2%)**
Impact of Trade Inventory Contraction	($101)	(10.5%)	($95)	(3.3%)
Total Variance to Budget	**($162)**	**(16.9%)**	**($363)**	**(12.4%)**
Actual / 2013 Forecast	**$799**	**83.1%**	**$2,553**	**87.6%**

(1) Includes the estimated demand impact of $65 million of losing formulary coverage on the United Healthcare AARP Medicare Advantage Prescription Drug program effective January 1st 2013.

6

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

In January there was a reduction in the number of tablets per prescription, which we project will continue.



7

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

The decline in tablets per prescription is also impacting major competitors.

Product	Jan 12 - Feb 13 Tab Per Rx Trend	Avg Tab Per Rx Jan - Feb 2012	Avg Tab Per Rx Jan - Feb 2013	Difference
OxyContin		69.4	66.8	-2.6
Generic 2x per day morphine		69.4	68.1	-1.2
Kadian + generics		59.1	58.9	-0.2
Avinza		44.2	44.4	0.2
Opana ER + generics		67.3	65.1	-2.2
Methadone		148.6	143.0	-5.7
Exalgo		46.0	43.5	-2.6
ERO Market (oral solids)		86.0	82.5	-3.4

Product	Jan 12 - Feb 13 Tab Per Rx Trend	Avg Tab Per Rx Jan - Feb 2012	Avg Tab Per Rx Jan - Feb 2013	Difference
IR oxycodone		106.3	101.4	-4.8
oxycodone combos		63.4	63.7	0.3
hydrocodone combos		57.0	58.3	1.3

8

IMS NPA

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

The decline in tablets per prescription is projected to reduce 2013 gross sales by $78.8 million vs. budget.

	Tablets per Prescription			Variance Budget versus Forecast			
		Full Year					
	YTD April	Budget	Forecast	Tablets	%	Millions	%
10mg	50.7	53.6	50.2	-3.4	-6.3%	$ (8.9)	-6.3%
15mg	57.4	59.2	56.5	-2.6	-4.5%	(1.7)	-4.5%
20mg	63.3	65.3	63.0	-2.3	-3.5%	(13.5)	-3.4%
30mg	64.4	66.1	63.8	-2.2	-3.4%	(7.7)	-3.2%
40mg	73.5	75.5	72.9	-2.6	-3.5%	(20.5)	-3.4%
60mg	72.4	73.3	71.7	-1.6	-2.2%	(7.8)	-2.0%
80mg	90.1	91.6	89.7	-1.8	-2.0%	(18.6)	-1.8%
Total*	66.6	69.0	66.1	-2.9	-4.2%	$(78.8)	-2.8%

*Tablets per prescription total is a weighted average.

9

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Causes of the decline in tablets per prescription are being researched to quantify impact and identify corrective actions.

- Potential increased and more aggressive enforcement of quantity limits by managed care organizations.
- Potential impact of PROP's messaging and other factors discouraging use of opioids.
- Medicare Part D opioid drug utilization review program for 120mg morphine equivalent prescriptions.
- Increased DEA/law enforcement scrutiny of physicians, pharmacies and wholesalers.
- Impact of Walgreens pharmacists calls to physicians to verify C2 prescription details.

10

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Year to date prescriptions are 1.2% behind budget. By the end of the year prescriptions are forecast to be 3.9% behind budget. At the budgeted average value per prescription, this is projected to result in a $110 million shortfall from budget.

	Year to Date April 2013			Full Year				
	Actual	Budget	Variance	2011 Actual	2012 Actual	2013 Budget	2013 Forecast	Variance Budget vs Forecast
Prescriptions	1,978,294	2,001,958	(23,664) -1.2%	6,481,879	6,197,937	6,037,235	5,804,624	(232,611) -3.9%
Budget price per prescription			$468.70					$472.89
Variance Due to Lower prescriptions			$ (11,091,451)			Note 1		$ (109,998,419)

(1) Includes the estimated demand impact of $65 million of losing formulary coverage on the United Healthcare AARP Medicare Advantage Prescription Drug program effective January 1st 2013.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Prescriptions of the higher strengths are declining most rapidly. This is changing the mix of prescriptions by strength, and is projected to result in an additional $79 million shortfall from budget.



12

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Potential Causes of the decline in prescriptions --- especially the higher strengths

- Direct switches from other products to the 80mg strength (in particular) are declining (6 months ended Feb 2013 versus previous 6 months showed a decline of 30.8%).
- Titration up to higher strengths, especially to the 40mg and 80mg strengths is declining.
- Potential causes which are being researched:
  - State and Medicare mg equivalent limits
  - Increased coinsurance/higher deductibles for employees
  - Increased DEA/law enforcement scrutiny of physicians, pharmacies and wholesalers
  - OxyContin primary sales calls below budget. This is likely impacting prescriptions, because calls have a positive impact. For example,
    - The loss in higher strengths in called on physicians is 33% lower than those not called on.
    - High dose prescribing grew in physicians we began calling over the last year.

13

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Planned Analyses

- Potential impact of reducing number of calls/quarter on highest prescribing physicians, and initiation calls on physicians not currently reached.
- Analysis to determine what physician characteristics are associated with lower tabs/prescription and lower strength prescriptions.
- Health Plan analysis to determine the extent to which individual plans are driving changes in number of tablets/prescription, lower prescriptions, strength mix.
- Impact of generic Opana ER
- How lack of patient access to pain medications impacts healthcare costs. For example, reports of an increase in ER visits.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Planned Actions

- Ensure the sales force delivers the budget number of primary OxyContin sales calls.
- Implement Marketing Initiatives
  - "Individualize the Dose" campaign
  - Titration – via iPad case studies
  - Reiterate patient savings programs/managed care formulary messaging
- Continue publishing information on the impact of the abuse deterrent formulation.
- Actions will be implemented where analyses indicate.

15

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Trade Inventory contraction in 2013 is now estimated at $131 million versus budgeted contraction of $36 million

- We estimate that wholesaler inventory will return to 28 days by the end of 2013. The result is a reduction from $296 million at end of 2012 to $250 million at end of 2013 (inventory at the end of April was $246 million).
- Pharmacy inventory is expected to reduce from $239 million (31 days) at the end of 2012 to $154 million (20 days) at the end of 2013. Inventory at end of April 2013 was $192 million. Reductions are due to:
  - CVS and Walgreens have made public announcements targeting inventory reductions.
  - Walgreens switch to ABC to improve store service levels. As a result, Walgreens closed their Perrysburg distribution center. ABC is moving Walgreens pharmacies from a 3 times to a 6 times a week delivery schedule.
  - Like Walgreens other chains are increasing their reliance on wholesaler just in time deliveries to reduce carrying costs.
  - Fewer stores are purchasing / stocking OxyContin -- in 2011, 2012 and YTD 2013 -- 28,817, 24,744 and 22,823 stores, respectively, purchased OxyContin.
  - Consultants have reported other clients having similar levels of inventory contraction.

16

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Intermezzo Sales Update

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Intermezzo sales are forecasted to be $14 million based on latest prescription trends and decisions to significantly decrease S&P.



Prescription Budget	295,870
Prescription 2013 Forecast	71,721
% of Budget	24%
Budgeted Gross Sales	$57.6 million
2013 Forecast Gross Sales	$13.9 million

18

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Purdue US

Budget Update

June 2013

19

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Net sales are forecasted to end 2013 $303.1 million and $93.7 million below budget and prior year, respectively.

($ MM)

Product	2010 Actual	2011 Actual	2012 Actual	2013 Budget	2013 Forecast	$ Variance 2013 Budget vs 2013 Forecast
OxyContin - 10MG	$ 121.3	$ 146.8	$ 152.7	$ 157.0	$ 142.5	$ (14.5)
OxyContin - 15MG	23.6	27.1	34.0	37.8	35.8	(2.0)
OxyContin - 20MG	361.3	404.1	402.5	419.9	377.7	(42.2)
OxyContin - 30MG	161.0	171.7	205.3	237.4	214.5	(22.9)
OxyContin - 40MG	683.0	633.7	618.7	622.3	555.8	(66.5)
OxyContin - 60MG	315.7	300.7	340.7	388.8	338.3	(50.5)
OxyContin - 80MG	1,331.8	1,096.8	1,023.1	1,053.1	888.5	(164.6)
OxyContin	$ 2,997.8	$ 2,781.0	$ 2,777.1	$ 2,916.5	$ 2,553.1	$ (363.4)
Butrans	-	73.5	112.9	160.0	160.0	-
Intermezzo	-	-	16.6	57.6	13.9	(43.7)
Dilaudid	35.1	24.8	23.8	17.0	17.0	-
MS Contin	15.1	13.3	13.0	11.6	11.6	-
Laxatives	48.1	51.1	51.5	49.3	49.3	-
Betadine\Betasept	10.9	11.1	11.6	11.1	11.1	-
Slow Mag	4.6	5.4	5.6	5.3	5.3	-
Ryzolt	16.5	11.2	(6.9)	-	-	-
Uniphyl	(0.2)	(0.3)	(0.0)	-	-	-
All Other	(0.0)	(0.1)	(0.1)	-	-	-
					-	-
Total Gross Sales	**$ 3,127.9**	**$ 2,971.2**	**$ 3,004.9**	**$ 3,228.5**	**$ 2,821.4**	**$ (407.1)**
Fee for Service	$ (79.2)	$ (74.5)	$ (69.3)	$ (65.3)	$ (58.0)	$ 7.4
Sales Discounts & Allowances	(48.8)	(56.2)	(134.0)	(88.2)	(54.1)	34.1
Patient Savings Card Discounts	(15.7)	(15.6)	(25.1)	(34.5)	(41.3)	(6.8)
Rebates on Branded Sales	(621.6)	(545.9)	(517.6)	(554.9)	(488.6)	66.3
Proposed regulation adj for Medicaid rebates	(40.0)	(68.9)	(60.4)	(76.8)	(73.9)	2.9
Other	27.6	12.4	2.5	1.7	1.7	-
Total Rebates & Deductions $	**$ (777.8)**	**$ (748.7)**	**$ (804.0)**	**$ (818.1)**	**$ (714.2)**	**$ 103.9**
Rebates and Deductions %	24.9%	25.2%	26.8%	25.3%	25.3%	25.5%
Total Net Sales	**$ 2,350.1**	**$ 2,222.5**	**$ 2,200.9**	**$ 2,410.3**	**$ 2,107.2**	**$ (303.1)**

20

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Pre-tax profit is forecasted to end 2013 $118.7 million and $94.6 million below budget and prior year, respectively.

($000's)	2010 Actual	2011 Actual	2012 Actual	2013 Budget	2013 Forecast	2013 Budget vs 2013 Forecast
Gross Branded Product Sales	$3,127,873	$2,971,161	$3,004,903	$3,228,472	$2,821,387	($407,085)
Fee for Service	(79,257)	(74,507)	(69,513)	(65,555)	(57,957)	7,551
Discounts and Allowances	(45,792)	(35,222)	(154,051)	(55,195)	(34,088)	34,152
Patient Savings Card Discounts	(15,691)	(15,572)	(25,104)	(54,557)	(41,554)	(6,797)
Rebates on Branded Sales	(821,555)	(545,591)	(517,805)	(554,595)	(455,552)	55,514
Proposed regulation adj for Medicaid rebates	(40,041)	(65,554)	(60,555)	(75,505)	(75,592)	2,915
Other	27,611	12,550	2,455	1,651	1,551	0
Rebates as % of Gross Branded Product Sales	23.2%	20.7%	19.2%	19.6%	19.9%	
NET REVENUE	2,550,090	2,222,495	2,200,924	2,410,349	2,107,207	(303,142)
Cost of Goods Sold	(161,090)	(168,570)	(145,475)	(152,211)	(149,240)	12,971
COGS as % of Gross Branded Product Sales	5.2%	5.6%	4.9%	5.0%	5.3%	
Royalty Expense	(55,542)	(115,272)	(120,259)	(151,575)	(122,559)	9,155
Shipping and Warehousing	(11,152)	(11,551)	(11,514)	(10,507)	(11,558)	(549)
GROSS PROFIT	2,124,476	1,928,522	1,920,566	2,105,756	1,824,272	(281,484)
G&A (incl. Legal Department but excl. Legal Fees)	(157,551)	(148,557)	(154,259)	(150,425)	(155,425)	2,000
G&A as % of Net Revenues	5.9%	6.6%	7.0%	6.2%	7.5%	
Legal Fees	(50,557)	(56,952)	(61,255)	(50,975)	(54,475)	(3,500)
R&D	(164,754)	(269,957)	(512,515)	(377,347)	(327,247)	50,100
R&D Other - Milestone and Alliances	(5,599)	(604)	(2,254)	(6,692)	(10,952)	(4,260)
R&D as % of Net Revenues	7.4%	12.2%	14.5%	15.8%	18.0%	0
Sales and Promotion	(194,755)	(229,537)	(505,110)	(509,915)	(288,515)	21,600
S&P as % of Net Revenues	5.5%	10.5%	15.5%	12.9%	13.7%	0
Health Care Reform Fee	0	(26,545)	(51,251)	(51,500)	(51,500)	-
Other - US	15,544	(5,055)	(17,553)	(4,552)	(432)	4,120
OPERATING EXPENSES	(540,272)	(733,245)	(862,603)	(942,092)	(871,652)	70,440
Operating Expenses as % of Net Revenues	15.0%	55.0%	40.1%	59.1%	41.4%	
OPERATING MARGIN BEFORE INCENTIVE & SETTLEMENTS	1,584,203	1,195,277	1,037,763	1,163,664	952,620	(211,044)
Operating margin as % of Net Revenues	57.4%	55.5%	47.2%	45.5%	45.2%	
Incentive Bonus	(55,744)	(55,054)	(54,255)	(42,615)	(55,615)	7,000
Insurance Income	15,555	50,659	5,520	5,555	5,555	-
Settlement Expense	(17,455)	(5,775)	(14,247)	-	(1,900)	(1,900)
TOTAL INCENTIVES AND SETTLEMENTS	(40,316)	(9,168)	(45,012)	(39,060)	(53,960)	5,100
OPERATING MARGIN AFTER INCENTIVES AND SETTLEMENTS	1,543,888	1,186,089	992,751	1,124,604	918,660	(205,944)
Operating margin as % of Net Revenues	55.7%	55.4%	45.1%	46.7%	45.6%	
Other Items						
Royalty Income - ex US	54,759	91,557	55,951	40,592	40,592	-
Ex US Expenses	(152,645)	(129,508)	(65,055)	(127,500)	(164,559)	(37,259)
One Time Charges/Other Items	(24,477)	(2,452)	(2,145)	(2,955)	(2,955)	-
Gain on Infinity stock	-	-	-	-	124,551	124,551
Interest Income / (Expense), net	555	556	1,554	172	172	-
TOTAL OTHER ITEMS	(71,803)	(40,265)	18,106	(89,692)	(2,400)	87,292
PROFIT/LOSS BEFORE TAX	$1,472,087	$1,145,824	1,010,857	1,034,912	916,260	(118,652)

21

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Pre-tax profit is forecasted to end 2013 $118.7 million below budget due to:

($ MM)

2013 Budget Profit Before Tax		**$ 1,034.9**
Gross margin impact of lower OxyContin and Intermezzo sales	(281.5)	
Reduced S&P spend as a result of termination of Intermezzo contract sales force	11.6	
Reduced R&D expense - discontinuation of Butrans higher strength program ($13.3 million), lower enrollment in the pain plus OIC efficacy studies ($40.2 million), offset by a reduction in the underspend estimate ($6.9 million) and all other ($6.1 million)	40.1	
R&D Milestones - Recently approved upfront payment to Grunenthal for MS Contin TR formulation ($7.3 million) and removal of budgeted payment to convert McGinity patent for HYD to exclusive ($3 million).	(4.3)	
Targeted reductions (across R&D, S&P, G&A, annual bonus and other US)	30.5	
Other	(2.4)	
Sub-Total Purdue Operations		(205.9)
Gain on Infinity stock, not budgeted		124.6
Higher than budget ex-USA funding		(37.3)
2013 Forecast Profit Before Tax		**$ 916.3**

22

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Distributions are forecasted to be $575.6 million -- $37.5 million higher than budget.

	Infinity Stock	Cash	To Reinvest	Total
Budgeted Distributions	**$ -**	**$ 508.1**	**$ 30.0 (1)**	**$ 538.1**
Distribution of Infinity Shares **(2)**	216.7	(216.7)		-
Reinvestment in Japan and Thailand	-	-	4.2	4.2
Purdue Operations - after tax impact of lower profit of $205.9 million **(3)**		(97.0)		(97.0)
Other - primarily higher ex-USA and Infinity price appreciation		15.1		15.1
Reduction in equity from $705 million to $590 million		115.2		115.2
Change	**216.7**	**(183.4)**	**4.2**	**37.5**
Forecast Distributions	**$ 216.7**	**$ 324.7**	**$ 34.2**	**$ 575.6**

(1) $14 million for Rhodes Pharmaceuticals and $16 million for Rhodes Tech.
(2) 5.42 million shares distributed at $40 per share = $216.7 million.
(3) Net impact of lower profitability on Purdue operations ($205.9 million) and other book/tax favorability ($20 million).

Abbott covenant- Purdue is in negotiations with Abbott to have the equity covenant removed - If the covenant is removed, Purdue would be able to pay approximately $50 million of additional distributions while still maintaining 3 months of net sales in cash.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Balance Sheet

($ MMs)	2010 Actual	2011 Actual	2012 Actual	2013 Budget	2013 Forecast	2013 Budget vs Forecast
ASSETS						
CURRENT ASSETS						
Cash and cash equivalents	$ 437.1	$ 606.5	$ 755.6	$ 600.0	$ 576.0	($ 23.9) (1)
Accounts receivable	212.9	218.8	187.1	150.6	136.6	(14.0) (2)
Due from associated companies	24.7	27.8	31.8	13.7	13.7	0.0
Other receivables	26.5	10.1	3.0	8.4	7.3	(1.1)
Inventories	57.3	44.2	50.6	42.9	42.9	0.0
Prepaid expenses and other assets	39.2	32.7	22.1	28.7	23.7	(5.0) (3)
Restricted cash - current	52.9	16.0	23.9	0.0	4.8	4.8 (4)
TOTAL CURRENT ASSETS	**850.7**	**956.1**	**1,074.2**	**844.1**	**804.9**	**(39.2)**
Property and equipment, net	140.2	143.2	149.5	163.4	159.1	(4.3)
Investments in associated companies	31.8	19.8	7.9	14.9	69.1	54.2 (5)
Due from associated companies	3.4	3.3	3.0	3.3	3.3	0.0
Restricted cash - long term	18.5	42.5	17.2	21.7	21.7	0.0
Goodwill	23.4	23.4	23.4	23.4	23.4	0.0
Product rights, trademarks and other intangibles	166.7	168.2	173.2	166.0	166.4	0.4
Other assets	24.0	73.3	22.5	21.2	21.2	0.0
Investment in Infinity stock	0.0	0.0	189.5	138.8	0.0	(138.8) (6)
Deferred income taxes	12.9	17.2	19.8	17.4	17.4	0.0
TOTAL ASSETS	**$ 1,271.5**	**$ 1,446.8**	**$ 1,680.3**	**$ 1,414.3**	**$ 1,286.6**	**$ (127.7)**
LIABILITIES AND EQUITY						
CURRENT LIABILITIES						
Accounts payable	$ 63.9	$ 87.4	$ 71.2	$ 94.1	$ 81.6	($ 12.5) (7)
Accrued expenses and taxes payable	485.4	632.8	694.7	360.6	360.6	0.0
Due to associated companies	12.1	11.3	12.4	13.0	13.0	0.0
Long-term debt - associated companies	0.0	0.0	0.0	0.0	0.0	0.0
TOTAL CURRENT LIABILITIES	**561.4**	**731.5**	**778.3**	**467.7**	**455.2**	**(12.5)**
Other long-term liabilities	133.0	223.6	230.2	241.4	241.4	0.0
TOTAL LIABILITIES	**694.4**	**955.1**	**1,008.5**	**709.1**	**696.6**	**(12.5)**
EQUITY						
Capital stock - common	0.0	0.0	0.0	0.0	0.0	0.0
Additional paid in capital	2.0	2.0	2.0	2.0	2.0	0.0
Subscription receivable	(1.0)	(1.0)	(1.0)	(1.0)	(1.0)	0.0
Accumulated other comprehensive income	(83.7)	(145.1)	(139.9)	(128.4)	(128.4)	0.0 (8)
Unrealized gain / loss on Infinity stock	0.0	0.0	97.5	60.2	0.0	(60.2) (6)
Retained earnings and partners' capital	659.7	635.8	713.2	772.4	717.4	(55.0) (9)
TOTAL EQUITY	**577.0**	**491.6**	**671.7**	**705.2**	**590.0**	**(115.2)**
TOTAL LIABILITIES AND EQUITY	**$ 1,271.5**	**$ 1,446.8**	**$ 1,680.3**	**$ 1,414.3**	**$ 1,286.6**	**$ (127.7)**

See next slide for explanation of footnotes

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Balance Sheet Update – footnote explanations

(1) Forecasted cash balance of $576 million is $50 million higher than 3 months net sales in order to achieve equity target.
(2) Trade Accounts Receivable - decrease primarily due to lower sales.
(3) Decrease of prepaid expenses is due to lower forecasted payments of clinical study upfront payments.
(4) Restricted Cash - assumes that $19.1 million of the balance remaining in the qualified settlement trust is returned in 2013 and the $4.8 million balance is returned in 2014.
(5) Investments - increase primarily due to the purchase of $50 million of stock of Pearl Therapeutics.
(6) Infinity Investment / Unrealized Gain - decrease is due to the distribution of Infinity stock in April 2013.
(7) Decrease is due to lower forecasted expenses.
(8) Accumulated other comprehensive income represents the cumulative difference between actual returns on pension plan assets being lower than the assumed return of 7%, the impact of changes in discount rates on benefit plan liabilities and other changes in benefit plan assumptions.
(9) The equity target built into the 2013 budget was set to (1) allow Purdue to meet our three months net sales cash target, (2) ensure that the Abbott covenant is met and (3) carry the investment in Infinity stock. The 2013 forecast equity was set lower than budget because (1) the Infinity stock is no longer carried by Purdue, (2) less of a cushion is needed half way into the year to ensure the Abbott covenant it met and (3) less cash is needed to meet the 3 month of net sales cash target.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Cash Flow

($ MMs)	2010 Actual	2011 Actual	2012 Actual	2013 Budget	2013 Forecast	2013 Budget vs Forecast	
Operating activities							
Net income	$ 1,463.4	$ 1,144.5	$ 1,008.3	$ 1,030.2	$ 911.6	$ (118.7)	
Adjustments to reconcile net income to net cash provided by operating activities:							
Depreciation and amortization	33.6	28.3	29.1	32.1	32.2	0.1	
Impairment of intangible asset	0.0	4.0	20.0	0.0	0.0	0.0	
Deferred income taxes	(6.3)	(4.3)	(2.6)	0.0	2.4	2.4	
Loss on unconsolidated, associated companies	117.1	112.4	101.0	128.6	163.1	34.4	(1)
(Gain) loss on disposal of assets	0.3	0.1	0.0	0.0	0.0	0.0	
Changes to working capital	142.3	162.0	88.6	(212.3)	(271.2)	(58.9)	(2)
Long-term assets and liabilities	0.0	29.8	(2.0)	27.4	116.0	88.6	(3)
Changes to extraordinary item	(0.8)	(1.0)	0.0	0.0	0.0	0.0	
Total cash provided by operating activities	**1,749.5**	**1,475.8**	**1,242.4**	**1,006.1**	**954.0**	**(52.2)**	
Investing activities							
Capital expenditures	(30.4)	(26.8)	(30.5)	(35.0)	(35.0)	0.0	
Purchase of product marketing rights and other intangib	(10.1)	(10.0)	(30.0)	0.0	0.0	0.0	
Restricted cash, net	18.8	12.9	17.3	22.5	14.6	(7.8)	(4)
Investments in associated companies, net	(119.1)	(100.3)	(89.1)	(134.6)	(224.3)	(89.7)	(5)
Acquisition of Infinity common stock	0.0	0.0	(27.5)	0.0	0.0	0.0	
Funding of Infinity LOC	0.0	(50.0)	0.0	0.0	0.0	0.0	
Total cash used in investing activities	**(140.8)**	**(174.2)**	**(159.7)**	**(147.1)**	**(244.7)**	**(97.5)**	
Financing activities							
Payments (to) from associates, net	(9.1)	(3.8)	(2.7)	6.8	18.5	11.7	(6)
Capital contributions	4.1	0.3	0.0	0.0	0.0	0.0	
Distributions to partners for required tax payments	(651.4)	(553.4)	(459.2)	(444.0)	(331.8)	112.2	(7)
Distributions to partners non-tax	(889.8)	(575.2)	(471.6)	(538.1)	(575.6)	(37.5)	(8)
Total cash used in financing activities	**(1,546.2)**	**(1,132.2)**	**(933.6)**	**(975.3)**	**(888.9)**	**86.4**	
Increase in cash and cash equivalents	**62.5**	**169.4**	**149.1**	**(116.3)**	**(179.6)**	**(63.3)**	
Cash and cash equivalents:							
Unrestricted cash at the beginning of the period	374.6	437.1	606.5	716.3	755.6	39.3	
Unrestricted cash at the end of the period	**$ 437.1**	**$ 606.5**	**$ 755.6**	**$ 600.0**	**$ 576.0**	**$ (23.9)**	

See next slide for explanation of footnotes

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Cash flow statement – footnote explanations

(1) Increase is due to equity losses as a result of higher funding of the European start-ups for Pearl Therapeutics.
(2) Change in working capital is primarily due to the assumed payment of Medicaid "line extension" rebates in 2013.
(3) Change in long term assets is due to distribution of the Infinity stock.
(4) Change from budget is due to the actual 2012 year end balance being different from what was used in the budget and delay in the timing of the return of the QST.
(5) Increase in investments in associated companies due to stock purchase and funding of Pearl Therapeutics.
(6) Change from budget is due to timing of payments.
(7) Lower tax distributions are as a result of lower pretax profit
(8) See page 5.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Back-Up Slides

Budget
1. Assumptions
2. BBU P&Ls
3. R&D Details
4. Detailed rollforward schedule
5. Tax distribution reconciliation
6. April Year to Date 2013 Financial Statements
7. Associate Company Transactions
8. Ex USA Expenses
9. Headcount

Sales
10. Sales year-to-date April
11. Sales - kilograms and price
12. Extended release opioid market
13. Tablets per prescription
14. Mix/strength

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2013 Forecast - Key Assumptions

A. OxyContin Sales Update:

1. ERO market Rxs are forecasted at 26.0 mm in 2013 versus budget of 26.3 mm.
2. The OxyContin share of the ERO market is forecasted to be 22.3% (5.8 mm Rxs) in 2013 versus the budget assumptions of 23.0% (6.0 mm Rxs).
3. 2013 forecast assumes no Oxycodone generic competition (no change from budget).
4. OxyContin price increase of 5.5% in February 2013 (no change from budget).
5. Branded competition in 2013 includes Opana ER, Exalgo, and Nucynta ER. Embeda is not expected back on the market until after 2013. Remoxy launch is assumed delayed – filing in 2015 or later (budget assumed late 2013).
6. Major events/assumptions impacting the forecast include:
    1. 745,000 rep calls in 2013. 50:50 split between OxyContin and Butrans achieved by the end of Q2 2013.
    2. Nucynta ER – J&J has significantly reduced promotion.
    3. Impact of $65 million of losing formulary coverage on the United Healthcare AARP Medicare Advantage Prescription Drug program is included in forecast.
    4. TR formulations do not have a measurable impact on demand.
7. OxyContin sales by payer channel and rebate rates are assumed to be same as 2013 budget:

Rebate Eligible Sales (% of Xponent Retail Sales):	
Commercial (Tier 2)	45.2%
Commercial (Tier 3)	0.0%
Medicare Part D (Tier 2)	24.7%
Medicare Part D (Tier 3)	0.0%
Medicaid	9.9%
Tricare	2.4%
Cash / Non Rebated	17.8%
Total	100.0%

Rebate Rates	
Commercial (Tier 2)	17.7%
Commercial (Tier 3)	0.0%
Medicare Part D (Tier 2)	29.5%
Medicare Part D (Tier 3)	0.0%
Medicaid (1)	58.2%
Tricare	40.0%

(1) Continue to assume that the higher Medicaid Rebates on line extensions apply to OxyContin when CMS rules are finalized. A final rules rebate payment is forecasted to be in Q4 2013, however further delay is possible.

8. Trade inventory was forecasted to be $459.0 million at 12/31/2012 and $407.0 million at 12/31/2013 in the budget and $540 million and $393 million, respectively, in forecast.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2013 Forecast - Key Assumptions

B. Butrans Sales Update:

There are no changes to the assumptions used in the budget.

C. Intermezzo Sales Update:

Mid-Year update represents current trending of prescription demand:

Rx Budget	295,870
Rx Forecast	71,721
% of Budget	24%
Budgeted Gross Sales	$57.6 million
Forecast Gross Sales	$13.9 million

D. Fee For Service:

Fee For Service ("FFS") is forecasted to be $2.5 million favorable to budget due to wholesaler inventory appreciation passed back to Purdue.

E. Patient Savings Card Expense:

Expense is estimated based on average redemption rates and average redemption amount. Full year 2013 estimate of $41.3 million is projected based on actual experience year to date April 2013, which are significantly higher than budget of $34.5 million, primarily due to higher OxyContin e-voucher program redemptions. OxyContin projection estimates a redemption rate of 10.7% (vs. 7.1% budget rate) for e-voucher program and 2.7% (vs. 3.8% budget rate) for saving cards. The average redemption amounts were $37.43 (vs. $31.00 budget rate) for e-voucher program and $54.01 (vs. $46.50 budget rate) for saving cards.

F. Technical Operations:

1. Intermezzo inventory write-offs of $2.3 million are included in forecast due to lower sales.
2. Assumes a delay in Rhodes Pharma's Oxy APAP launch to late 2013, reducing Purdue's budgeted overhead recovery by $1.1 million.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2013 Forecast - Key Assumptions

G. S&P:

Reductions of $11.6 million relate to termination of contract sales force effective on May 14, 2013 of $8.0 million (includes two months of severance and fleet disposal costs) and reductions in promotional spend in light of reduced sales forecast of $6.0 million offset by a decrease in Transcept Contribution of $2.4 million.

H. R&D:

1. R&D Projects include: Butrans, HYD, OCI, ONU/Targiniq, ORF, VND, ORL1 (not in budget) and MS Contin tamper resistant formulation (not in budget). Clinical spend forecasted at $141.8 million, $49.3 million lower than budget.
2. Butrans change in registration strategy for higher strengths results in discontinuation of Phase 3 efficacy and open label safety studies and 2nd generation timing – $13.9 million lower than budget.
3. HYD includes 6 month extension to long-term, open label safety study of $2.5 million (not in budget) and carryover of $3.6 million.
4. Targiniq reflects changes to protocols in response to slower enrollment for Pain/OIC studies ($40.3 million lower than budget).
5. ORL1 reflects $1.5 million dental pain POC study not included in original budget.
6. Shionogi Collaboration includes $2 million milestone for IND filing (not in budget).

I. Licensing & Business Development:

1. Possible new product licenses or acquisitions have not been included. These will be presented to the Board for approval on a project-by-project basis, when the economics, timing and justification are known.
2. Forecast assumes $3 million payment to convert McGinity HYCR license for hydrocodone to exclusive in budget is not made.
3. Includes $7.3 million upfront payment to Grunenthal for MS Contin tamper resistant formulation (not in budget).

J. Ex USA:

Assumes additional funding for the purchase of $50 million of stock of Pearl Therapeutics plus additional funding of Pearl of $30.8 million.

K. Investment in Infinity:

Infinity stock was distributed in April 2013 (not in budget).

L. Tax and Distributions:

2013 tax distributions assumes $42 million tax write-off of Transcept milestone payments (initial $25 million plus $10 million for each orange book listing of patents less tax amortization taken to date). This assumes all Intermezzo assets (including rights to tail royalties) are returned to Transcept by 12/31/2013.

2013 tax distribution assumes that $11.5 million of milestone payments made prior to 2010 to Abbott-McGinity for Hydromorphone, Oxymorphone and Morphine will not be written off even though no plans for development exist at this time. In order to write-off these tax assets, Purdue would have to relinquish its rights back to McGinity.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

OxyContin P&L

($MMs)	2013 Forecast	% Sales	2013 Budget	% Sales	Variance	Growth	2012 Actual	% Sales	2011 Actual	% Sales
Gross Sales[1]	**$2,553.1**		**$2,916.5**		***($363.4)***		**$2,777.1**		**$2,781.0**	
Fee for Service	*(53.4)*		*(59.9)*		*6.5*		*(65.6)*		*(71.0)*	
Sales Disc. & Allowances/Savings Cards Disc.	*(76.6)*	*26%*	*(95.5)*	*26%*	*18.8*		*(134.8)*	*28%*	*(69.9)*	*27%*
Rebates	*(471.6)*		*(547.9)*		*76.3*		*(509.6)*		*(540.4)*	
Proposed regulation adj for Medicaid Rebates	*(73.9)*		*(65.6)*		*(8.3)*		*(60.4)*		*(68.9)*	
Net Sales	**$1,877.6**		**$2,147.6**		***($270.0)***	-13%	**$2,006.7**		**$2,030.9**	
COGS	**($177.0)**	**9.4%**	**($190.0)**	**8.8%**	***$13.0***		**($183.8)**	**9.2%**	**($192.5)**	**9.5%**
COGS/Shipping & Warehousing	*(68.7)*		*(77.4)*		*8.8*		*(74.5)*		*(81.7)*	
Royalty Expense/Amort. of Milestone Pymts.	*(108.4)*		*(112.6)*		*4.2*		*(109.3)*		*(110.8)*	
Gross Profit	**$1,700.6**		**$1,957.6**		***($257.0)***		**$1,822.9**		**$1,838.4**	
Product Spending	**($100.4)**	**5.3%**	**($100.4)**	**4.7%**	***$0.0***	0%	**($62.0)**	**3.1%**	**($50.8)**	**2.5%**
Marketing Expense	*(23.6)*		*(23.6)*		-		*(14.4)*		*(15.1)*	
Sales Force Expense [2]	*(76.8)*		*(76.8)*		-		*(47.7)*		*(35.7)*	
Other Expenses					***0.0%***					
G & A Allocation [3]	*(79.2)*		*(80.2)*		*1.0*		*(77.1)*		*(73.1)*	
Legal Fees [4]	*(25.2)*		*(22.8)*		*(2.4)*		*(30.7)*		*(21.0)*	
R&D Market Support [5]	*(52.9)*		*(52.9)*		*0.0*		*(48.8)*		*(86.3)*	
Insurance Income/Settlement Expense	*0.8*		*0.8*		*0.0*		*4.3*		*30.0*	
Health Care Reform Fee	*(30.1)*		*(30.1)*		-		*(30.0)*		*(23.3)*	
Product Contribution	**$1,413.5**	**75.3%**	**$1,671.9**	**77.8%**	***($258.4)***	-15%	**$1,578.5**	**78.7%**	**$1,613.9**	**79.5%**

Notes:

(1) Includes price increase of 5.5% on February 1, 2013.

(2) Sales force allocation based on call position/cost per call (2011 includes a shift from primary position to secondary call position due to Butrans launch, 2012 Actual includes 18% primary calls, 2013 Budget includes 50% primary calls). Year to date April OxyContin primary sales calls were running 40% behind budget. The above P&L assumes that the number of primary sales calls is at budget by year end. That assumption will be updated in the fall following more months of actual sales call reporting.

(3) 50% of consolidated G&A allocated to OxyP&L.

(4) $2.4 million increase is due to the Depomed patent infringement complaint received in February which was not anticipated in the budget.

(5) $52.9 million includes cost of pediatric studies ($14.7 million), health outcomes studies in support of payor initiatives ($0.5 million), OxyContin Risk Management Plan ($2.8 million), PDUFA fees ($1.8 million), product complaints/adverse events ($3.4 million), allocated non-branded Medical Education, RADARS etc ($16.2 million), and allocated people costs ($11.5 million).

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Butrans P&L

($MMs)

	2013 Forecast	% Sales	2013 Budget	% Sales	Variance	Growth	2012 Actual	% Sales	2011 Actual	% Sales
Gross Sales	*$160.0*		*$160.0*		*$0.0*		*$112.9*		$73.5	
Fee for Service	(3.4)		(3.4)		-		(2.7)		(1.8)	
Sales Discounts & Allowances/Savings Cards Discounts [1]	(15.2)	21%	(15.4)	21%	0.2		(19.9)	24%	(12.6)	24%
Rebates	(14.3)		(14.3)		-		(6.1)		(3.1)	
Net Sales	*$127.0*		*$126.9*		*$0.2*	0.1%	*$84.1*		$55.9	
COGS	*($13.2)*	*10.4%*	*($15.0)*	*11.8%*	*$1.8*		*($13.1)*	*15.5%*	($10.2)	*18.3%*
COGS/Shipping & Warehousing [2]	(5.9)		(7.7)		1.8		(8.5)		(6.9)	
Royalty Expense/Amortization of Milestone Payments	(7.3)		(7.3)		-		(4.5)		(3.4)	
Gross Profit	*$113.8*		*$111.9*		*$2.0*		*$71.1*		$45.7	
Product Spending	*($100.5)*	*79.1%*	*($100.5)*	*79.2%*	*$0.0*	0%	*($105.9)*	*125.9%*	($120.5)	*215.5%*
Marketing Expense	(23.8)		(23.8)		-		(20.4)		(28.1)	
Sales Force Expense [3]	(76.7)		(76.7)		-		(85.5)		(92.4)	
Other Expenses										
G & A Allocation [4]	(7.6)		(7.6)		-		(5.1)		(3.4)	
Legal Fees [5]	(1.3)		(2.4)		1.2		(0.9)		(0.7)	
R&D Market Support [6]	(24.7)		(24.7)		(0.0)		(17.1)		(22.2)	
Health Care Reform Fee	(1.7)		(1.7)		-		(1.2)		-	
Product Contribution	*($21.9)*	-17.2%	*($25.0)*	-19.7%	*$3.1*	-12%	($59.2)	-70.3%	($101.1)	-180.8%

Notes:

(1) Includes an accrual for returns of 10% of gross sales for 2011 and 2012 and 8% for 2013. Forecast includes lower saving card discount due to lower redemptions.

(2) Includes standard cost of goods, inventory adjustments and product stability expenses. 2012 also includes inventory reserves for specification issues with batches manufactured by LTS in West Caldwell ($2.3 million) and expiring batches due to lower than expected demand ($1.0 million). Forecast includes estimated LTS reimbursement ($2.3 million) for the value of 2012 batches with specification issues, manufactured by LTS in West Caldwell.

(3) Sales force allocation based on call position/cost per call and 82% of primary calls in 2012 and 50% in 2013 Budget. In Q1 2013, actual experience has been closer to 70%. The above P&L assumes that the number of primary sales calls is at budget by year end. That assumption will be updated in the fall following more months of actual sales call reporting.

(4) G&A allocated to Butrans P/L @ 6% of net sales.

(5) Legal fees cover pre-litigation activities, responses to paragraph 4 letter challenges, document collection and review costs. Forecast includes a reduction due to non-receipt of paragraph 4 patent challenge and the lower estimate is expected to cover the 2013 remainder costs.

(6) R&D includes cost of supporting existing strengths, product complaints/adverse events, allocated non-branded Medical Education, RADARS etc.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Laxatives P&L

($MMs)

	2013 Forecast	% Sales	2013 Budget	% Sales	Variance	Growth	2012 Actual	% Sales	2011 Actual	% Sales
Gross Sales	$49.3		$49.3		$0.0		$51.5		$51.1	
Sales Discounts & Allowances/Savings Cards Discounts [1]	(0.6)	1%	(0.6)	1%	-		(2.6)	5%	(1.1)	2%
Net Sales	$48.6		$48.6		$0.0	0%	$48.8		$50.0	
COGS	($11.4)	23.4%	($11.4)	23.4%	$0.0		($11.3)	23.1%	($12.8)	25.6%
COGS/Shipping & Warehousing [2]	(11.4)		(11.4)		-		(11.3)		(12.8)	
Gross Profit	$37.2		$37.2		$0.0		$37.6		$37.2	
Product Spending	($15.6)	32.2%	($15.6)	32.2%	$0.0	0%	($19.0)	38.8%	($17.7)	35.4%
Marketing Expense [3]	(15.0)		(15.0)		-		(14.3)		(13.8)	
Sales Force Expense [4]	(0.7)		(0.7)		-		(4.6)		(3.9)	
Other Expenses										
R&D Market Support [5]	(1.3)		(1.3)		-		(1.3)		(1.3)	
Health Care Reform Fee	-		-		-		-		-	
Product Contribution	$20.3	41.7%	$20.3	41.7%	$0.0	0%	$17.3	35.4%	$18.3	36.5%

Notes:

(1) Laxatives includes Senokot®, Senokot-S®, Colace®, and Peri-Colace brands. The gross sales impact of product diversion for 2012 actual and 2013 budget is ($1.0 million) and ($2.8 million), respectively.

(2) Cost of goods reflects units at standard cost, inventory adjustments and other costs (eg. annual product stability). 2012 actual and 2013 budget reflect production in Canada.

(3) Marketing expenses include consumer advertising, coop advertising, advertising & agency fees, samples and coupons.
(4) Sales force allocation includes cost of sales agents.
(5) Includes estimated R&D support across Medical Services, Drug Safety, Regulatory and other support functions.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Intermezzo P&L

($MMs)	2013 Budget	Q1 2013 Actual	Q2 2013 Estimate	1ST HALF 2013	Q3 2013 Estimate	Q4 2013 Estimate	2ND HALF 2013	2013 Forecast	Inception to Date	Variance to Budget
Gross Sales (Note 1)	$ 57.6	$ 3.7	$ 4.0	$ 7.7	$ 3.2	$ 2.9	$ 6.2	$ 13.9	$ 20.4	$ (43.8)
Fee for Service	(1.1)	(0.1)	(0.1)	(0.2)	(0.1)	(0.1)	(0.1)	(0.3)	(0.7)	0.9
Sales Disc & Allow - 2% Discount and 10% Returns Reserve	(5.9)	(0.4)	(0.1)	(0.5)	(0.1)	(0.1)	(0.1)	(0.6)	(10.6)	5.3
Savings Cards Discounts	(3.2)	(0.3)	(0.4)	(0.7)	(0.3)	(0.3)	(0.6)	(1.3)	(1.9)	1.9
Rebates	(2.4)	(0.4)	(0.1)	(0.5)	(0.1)	(0.1)	(0.2)	(0.7)	(0.9)	1.5
Net Sales	44.9	2.5	3.3	5.8	2.7	2.4	5.1	10.9	16.5	(33.1)
COGS	(10.7)	(1.1)	(2.3)	(3.5)	(0.7)	(0.5)	(1.2)	(5.1)	(8.5)	5.8
COGS/Shipping & Warehousing (Note 2)	(4.1)	(0.6)	(2.3)	(2.9)	(0.3)	(0.3)	(0.6)	(3.5)	(5.9)	0.6
Royalty Expense	(6.6)	(0.4)	(0.5)	(0.9)	(0.4)	(0.3)	(0.7)	(1.6)	(2.3)	5.1
Gross Profit	33.3	1.4	0.5	2.0	2.1	1.8	3.9	5.8	8.2	(27.5)
Product Spending (excludes ASF allocation)	(57.5)	(26.0)	(7.3)	(33.3)	(2.0)	(2.0)	(4.0)	(40.7)	(120.8)	16.8
Marketing Expense	(35.5)	(23.3)	(4.1)	(27.4)	(1.5)	(1.5)	(3.2)	(30.6)	(55.5)	5.0
Sales Force Expense - ISF (Note 3)	(20.0)	(5.7)	(3.7)	(9.4)	(0.4)	(0.4)	(0.8)	(10.1)	(65.2)	10.5
Legal Fees (Note 4)	(0.6)	(0.1)	(0.3)	(0.5)	(0.5)	(0.5)	(1.0)	(1.5)	(1.5)	(1.0)
R&D Market Support (Note 5)	(0.4)	(0.2)	(0.1)	(0.3)	(0.1)	(0.3)	(0.4)	(0.7)	(2.4)	(0.3)
Product Contribution Before Allocations	$ (25.0)	$ (27.3)	$ (7.7)	$ (35.0)	$ (0.5)	$ (1.0)	$ (1.5)	$ (37.1)	$ (120.9)	$ (12.1)
Allocated Expenses and Discontinued ISF Sales Force										
Sales Force Expense - ASF Allocation (Note 6)	(3.7)	(1.0)	(0.9)	(1.9)	(0.9)	(0.9)	(1.8)	(3.7)	(3.7)	0.0
G & A Allocation	(1.3)	(0.6)	(0.5)	(1.3)	(0.0)	0.0	(0.0)	(1.3)	(1.6)	(0.0)
ISF Discontinuation Expenses (Note 7)	-	-	(2.5)	(2.5)	-	-	0.0	(2.5)	(2.5)	(2.5)
Transcept Contribution	10.0	7.6	-	7.6	-	-	-	7.6	7.6	(2.4)
Product Contribution	$ (20.0)	$ (21.7)	$ (12.2)	$ (33.9)	$ (1.5)	$ (1.9)	$ (3.3)	$ (37.2)	$ (121.2)	$ (17.3)
									S&P	$ 11.6

Note 1 - Accounting rules requires recording sales based on demand.

Note 2 - Q1 included costs of stability charges and inventory reserves. Q2 to Q4 is projected at budgeted COGS as a % of sales and includes additional inventory reserves / write offs of $2.3 million as a result of lower demand projections recorded in Q2.

Note 3 - ISF sales force has 90 reps, 10 DMs and 2 Other. ISF is eliminated effective May14th, 2013. Accrue 2 months of termination (salary rate and bonus) in Q2 on 100% of contract field force, including $0.5MM estimated for lease and disposal costs of fleet. Assumes we retain IMS Data purchased by Sales Operations through end of year and 4 S&P Support Headcount (2 Purdue RMs, 1 Sales Operations Analyst, 1 Sales Trainer) are redeployed to open Purdue positions or leave Purdue by the end Q2 and therefore are not allocated to Intermezzo P&L.

Note 4 - Legal fees in 2013 is estimated at $2.5 million, before Transcepts contribution of lower of 40% or $1 million per year - so net cost to Purdue is $1.5 million. Purdue is required to pay their proportionate share of patent defense costs for 180 days following notice of termination of agreement.

Note 5 - No work will commence on the pediatric studies due to recent FDA determination that the previously required work is not necessary.

Note 6 - Assumes only Tertiary calls from ASF from May14th 2013.

Note 7 - Two months of discontinuance expense for Intermezzo contract field force terminated on May14th 2013.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

2013 Tax and Non-Tax Distribution

($ millions)

2013 Forecast	2013 Payments Proposal			
Calculated Payment	**To Beacon & Rosebay**	**To Reinvest**	**Non-Tax Distribution Total**	**Tax Distribution**
Q1: Jan-Mar	127.0 (3a)		$ 127.0	$ 9.3
Q2: Apr-Jun - Infinity shares	216.7 (3b)		216.7	
- cash	42.0	10.0 (3c)	52.0	167.7
Q3: Jul-Sep (projected)	77.9	4.2 (3d)	82.1	77.2
Q4: Oct (projected)		10.0 (3c)	10.0	
Q4: Nov-Dec (projected)	77.9	10.0 (3c)	87.9	77.6
Total - Shareholders:	**$ 541.4**	**$ 34.2**	**$ 575.6**	**$ 331.8**

(3a) included $543K payments for the annual equity distributions guaranteed to Varus, Jibwind, and Connecticut Ave Realty under their amended partnership agreements.

(3b) Distribution of 5,416,565 Infinity shares at a value of $40.00 per share.

(3c) $14 million for Rhodes Pharmaceuticals were deferred from 2012 to 2013. In late November, Rhodes Pharma received Board approval to fund an additional $16 million in 2013. Therefore, this brings the total to Rhodes Pharma at $30 million.

(3d) Reinvestment of $0.9 million to Japan and $3.3 million to Thailand.

Non-Tax distributions are calculated to obtain bank equity of $550 million which is lower than our historical target of $600 million. Prior to making Q4 distributions we will ensure that we comfortably exceeded our $500 million equity requirement / cash target, and depending on the outcome of this review, we could require some or all of the Q4 distribution to be deferred until Q1 of the following year.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

P&L Rollforward - Detail

$000s		2013 Pre-Tax
2013 Budget		**$1,034,912**
Sales		
Latest estimate of Intermezzo reduces gross sales from $57.6 million to $14.0 million	(43,722)	
Latest estimate of OxyContin reduces gross sales from $2,916 million to $2,553 million as a result of lower demand ($265 million) and trade inventory contraction ($95 million)	(363,363)	
		(407,085)
Fee for Service		
Impact of lower Intermezzo sales	878	
Impact of lower OxyContin Sales	7,177	
Adjustment to 2012 Fee for Service recorded in 2013 but not accrued in 2012	(674)	
		7,381
Discounts and Allowances		
Impact of lower Intermezzo sales on early payment discounts	874	
Impact of lower OxyContin sales (on early payment discounts, GPO admin fees, returns etc)	10,854	
Offset for OxyContin returns included in gross sales	15,164	
Remove Intermezzo returns reserve included in budget since gross sales is budgeted based on demand only with no trade stocking assumption.	4,701	
Reduction in Fee for Service for price increase not included in Budget	2,539	
		34,132
Patient Savings Card Discounts		
Impact of lower Intermezzo sales	1,730	
Impact of higher redemptions on OxyContin and Butrans and higher card limits (Note 1)	(8,527)	
Note 1: Further investigation is currently being made into the higher redemption rate. If possible data errors on part of the vendor are confirmed, this number may be adjusted at a later date.		**(6,797)**
Rebates		
Impact of lower Intermezzo sales	1,793	
Impact of lower OxyContin sales	64,521	
		66,314

37

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

P&L Rollforward – Detail (continued)

Proposed regulation adj for Medicaid rebates		
Impact of lower OxyContin sales	2,913	
		2,913
COGS		
Higher Intermezzo inventory reserve.	(2,323)	
Lower manufacturing overhead recovery due to potential launch delay of Rhodes Pharma's Oxy APAP.	(1,099)	
Impact of lower sales of OxyContin and Intermezzo.	12,424	
Reversal of 2012 inventory reserve for West Caldwell 7.5 mg validation batches deemed LTS responsibility.	2,328	
Labor and overhead spending reduction.	1,641	
		12,971
3rd Party Royalty Income		
		0
Royalty Expense		
Impact of lower OxyContin sales on McGinity royalties ($5.9 million) , partially offset by change in budgeted exchange rate resulting in higher Grunenthal royalties ($1.6 million) which are paid at the maximum of EURO 50 million.	4,186	
Impact of lower Intermezzo sales	5,050	
		9,236
Shipping and Warehousing		
Estimated 2013 impact of Walgreens sales shifting from Cardinal to ABC in September.	(300)	
Higher than budget OTC freight rates offset by lower variable costs due to lower sales volume.	(129)	
Higher Butrans inbound freight cost from Germany due to West Caldwell investigation.	(120)	
		(549)

38

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

P&L Rollforward – Detail (continued)

Legal Fees		
Intermezzo patent defense costs in 2nd half of 2013 not in budget net of Transcept 40% contribution	(1,050)	
Depomed patent litigation	(2,400)	
Chicago Investigation	(1,000)	
FDA/Exclusivity Actions	(1,000)	
Asia - Patent litigation lower activities	500	
Australia - Patent litigation for Spirit close to final	300	
BuTrans - Patent litigation - paragraph 4 letter not received to date	1,150	
		(3,500)
G&A		
Targeted reduction	2,000	
		2,000
R&D US		
Discontinuance and close out of Butrans higher strength program	13,900	
Enrollment delays in ONU pain/OIC studies	34,500	
Increase in HYD driven by carryover and 6 month extension to open label safety study	(8,200)	
Reduction in Finance underspend estimate	(6,900)	
All Other driven by Butrans 2nd Generation Tech Transfer shift to 2014 and Shionogi collaboration milestone	6,800	
Targeted reductions	10,000	
		50,100
R&D Other - Milestone and Alliances		
McGinity convert to exclusive milestone payment, now not expected to be paid in 2013.	3,000	
Upfront (€5.5 million) milestone payment to Grunenthal for MS Contin tamper resistant formulation.	(7,260)	
		(4,260)
S&P		
Targeted reduction - Intermezzo	11,600	
Targeted reduction - Other	10,000	
		21,600

39

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

P&L Rollforward – Detail (continued)

Health Care Reform Fee		
		0
Other - US		
Targeted reduction of Presidents reserve (from $5.9 million to $2.9 million).	3,000	
Targeted reduction of headcount 20-25 positions	1,500	
		4,500
Insurance Income		
		0
Incentive Bonus		
Targeted reduction	7,000	
		7,000
Settlement Expenses		
Varum Patent Litigation settlement estimate	(1,900)	
		(1,900)
Royalty Income - ex. US		
		0
Ex US Expenses		
Funding of Pearl Therapeutics	(30,800)	
Higher losses in Germany	(10,670)	
Funding of Northlake R&D	(2,844)	
Lower funding of Spain	5,765	
Other	1,260	
		(37,289)

40

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

P&L Rollforward – Detail (continued)

Other Items		
Gain on sale of Infinity stock.	124,581	
		124,581
		0
Interest Income/(Expense)		
		0
		(118,652)
2013 Forecast		**$916,260**

Impact on pre-tax income:		
Lower OxyContin sales	$	(258.5)
Lower Intermezzo sales		(20.5)
Sale of Infinity stock		124.5
Targeted reductions		30.5
Other		5.3
Total	$	(118.7)

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Tax distribution reconciliation

Lower Purdue operating profit	$ 205,944	
Extension of 50% bonus depreciation after budget	7,819	
Pension pointed to 2013 after budget	6,378	
All other Schedule M updates	186	
$4.8 million of QST reversionary income pointed to 2014 after budget	4,800	
Total changes	225,127	(108,961)
Tax benefit (48.4%)	(108,961)	
Ex-US	37,289	
Nondeductible milestones and other Schedule M updates	(7,605)	
Total changes	29,684	(14,367)
Tax benefit (48.4%)	(14,367)	
Total decrease in 2013 tax		(123,329)
Increase in 2012 tax		11,100
Total decrease in 2013 tax distributions from budget		$(112,229)

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

R&D Update - Detail

($ MM)

BUP - Change in registration strategy for higher strengths resulted in discontinuation of Phase 3 efficacy and open label safety studies. Change in timing of BUP 2nd Generation program results in deferral of costs to later years.	$	(13.9)
HYD - Carryover spend from 2012 plus 6 month extension to long-term, open label safety study offset by phase 3b neuropathic pain study removal.		6.1
ONU - Slower enrollment in Pain/OIC efficacy studies (3704/3705) required protocol changes and a shift in both clinical study spend and associated ISS/ISE spend to later years.		(40.2)
VND - Shift in Burn Pain POC study pending outcome of OA and neuropathic pain POC study results.		(3.1)
ORL1 - Dental Pain POC study.		1.5
Clinical Supplies - Carryover spend from 2012 for HYD and ONU and an increase in packaging and distribution costs for ONU.		7.1
Tech Transfer - Delay in Tech Transfer for BUP 2nd Generation development.		(4.0)
Shionogi Collaboration - Milestone for IND filing for TRPV1 backup.		(3.0)
Underspend Estimate - Reduction in estimate from $25.8 million to $18.9 million - this is the estimate of spend that will slip from 2013 to 2014 or be cancelled. The underspend estimate is based on historical underspend experienced at Purdue and Industry success rates.		6.9
Targeted reductions		(10.0)
All Other, net		2.5
Total Decrease in Budget	**$**	**(50.1)**

43

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY